Methods of treating pancreatic cancer
Through the targeted binding of multi-chain chimeric polypeptides to TGF-β receptor II, the problems of poor tolerance and short survival of unresectable pancreatic cancer treatment were solved, and the therapeutic effect was significantly improved, including remission rate and survival.
Patent Information
- Application Number
- CN202380036635.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-02
- Filing Date
- 2023-03-02
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to effectively treat unresectable advanced or metastatic pancreatic cancer, especially in cases where the tolerance to traditional therapies and short survival periods are poor.
Using a multi-chain chimeric polypeptide, including a target binding domain, a soluble tissue factor domain and affinity domain, is used to treat unresectable advanced or metastatic pancreatic cancer, and improves the Objective remission rate, progression-free survival, progression time and overall survival.
It significantly improves the objective response rate, progression-free survival, progression time and overall survival in patients with unresectable pancreatic cancer, and provides a more effective treatment plan for patients with poor tolerability and ineffective frontline therapy.
Smart Images

Figure CN119095611A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Patent Application Serial No. 63 / 315,820 filed on March 2, 2022 and U.S. Provisional Patent Application Serial No. 63 / 315,840 filed on March 2, 2022; the entire contents of which are incorporated herein by reference.
[0003] Sequence Listing
[0004] This application contains a sequence listing, which has been submitted electronically as an XML file named 47039-0030WO1.xml. This XML file was created on February 23, 2023, and is 96,770 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety. Technical Field
[0005] The present disclosure relates to the field of biotechnology, and more particularly, to methods of treating pancreatic cancer in a subject using multi-chain chimeric polypeptides. Background Art
[0006] Tissue factor (TF) is a 263-amino acid integral membrane glycoprotein with a molecular weight of approximately 46 kDa and a triggering protein of the extrinsic coagulation pathway. It is the primary initiator of coagulation in vivo. Tissue factor is normally isolated from circulating blood but initiates the coagulation cascade upon exposure to circulating coagulation serine proteases. Vascular injury exposes subendothelial cells expressing tissue factor, leading to the formation of a calcium-dependent, high-affinity complex with pre-existing plasma factor VIIa (FVIIa). Binding of the serine protease FVIIa to tissue factor promotes the rapid cleavage of FX to FXa and FIX to FIXa. The resulting proteolytic activity and active membrane surface area of FXa subsequently prevent the efficient conversion of small amounts of prothrombin to thrombin. Thrombin generated by FXa initiates platelet activation and activates trace amounts of pro-cofactors (factor V (FV) and factor VIII (FVIII)) into active cofactors (factor Va (FVa) and factor VIIIa (FVIIIa)). FIXa complexes with FVIIIa on the platelet surface to form an intrinsic tenase complex, leading to the rapid generation of FXa. FXa complexes with FVa to form a prothrombinase complex on the surface of activated platelets, leading to the rapid cleavage of prothrombin into thrombin.
[0007] In addition to the tissue factor-FVIIa complex, a recent study demonstrated that the tissue factor-FVIIa-FXa complex can activate FVIII, thereby providing additional levels of FVIIIa during the initial phase. The extrinsic pathway is crucial in initiating coagulation by activating a limited amount of thrombin, while the intrinsic pathway maintains coagulation through a dramatic amplification of the initial signal.
[0008] Many tissue factors expressed on the cell surface are "encrypted" and must be "decrypted" to fully participate in coagulation. At present, the mechanism of "decryption" of tissue factors on the cell surface is still unclear, but the exposure of anionic phospholipids plays an important role in this process. Healthy cells actively sequester anionic phospholipids (such as phosphatidylserine (PS)) to the inner leaflet of the plasma membrane. Cell damage, activation or cytosolic Ca 2+ Upon increased levels, this bilayer asymmetry disappears, leading to increased exposure of PS on the outer leaflet and, consequently, increased specific activity of the tissue factor-FVIIa complex at the cell surface. While PS exposure is known to reduce the apparent Km for activation of FIX and FX by the tissue factor-FVIIa complex, other mechanisms may include conformational rearrangements of tissue factor or tissue factor-FVIIa and subsequent exposure of substrate binding sites.
[0009] It is estimated that more than 62,000 Americans will be diagnosed with pancreatic cancer by 2022 (see the Pancreatic Cancer Action Network website). Effective treatments for pancreatic cancer are needed. Summary of the Invention
[0010] The present invention is based on the discovery that a multi-chain chimeric polypeptide comprising (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; and (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair, and the first target binding domain specifically binds a ligand of TGF-β receptor II (TGF-βRII) and the second target binding domain specifically binds a ligand of TGF-βRII can provide treatment for pancreatic cancer in a subject.
[0011] Provided herein are methods for treating unresectable advanced / metastatic pancreatic cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds a ligand for TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand for TGF-βRII.
[0012] Also provided herein are methods of improving the objective response rate in a subject with unresectable advanced / metastatic pancreatic cancer, the method comprising administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds a ligand for TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand for TGF-βRII.
[0013] Also provided herein are methods of increasing progression-free survival or progression-free survival in a subject or a population of subjects with unresectable advanced / metastatic pancreatic cancer, the methods comprising administering to one or more subjects a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds a ligand for TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand for TGF-βRII.
[0014] Also provided herein are methods of increasing time to progression in a subject or a population of subjects with unresectable advanced / metastatic pancreatic cancer, the methods comprising administering to one or more subjects a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds a ligand for TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand for TGF-βRII.
[0015] Also provided herein are methods of increasing the duration of remission in a subject or a population of subjects with unresectable advanced / metastatic pancreatic cancer, the methods comprising administering to one or more subjects a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds a ligand for TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand for TGF-βRII.
[0016] Also provided herein are methods of increasing overall survival in a population of subjects with unresectable advanced / metastatic pancreatic cancer, the method comprising administering to each subject in the population a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds a ligand for TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand for TGF-βRII.
[0017] In some embodiments of any of the methods described herein, one or more subjects are 18 years of age or older. In some embodiments of any of the methods described herein, one or more subjects have received prior treatment with standard first-line systemic therapy for pancreatic cancer, and the pancreatic cancer of one or more subjects has progressed with and / or is intolerant to the prior treatment. In some embodiments of any of the methods described herein, one or more subjects have received prior treatment with standard first-line systemic therapy for pancreatic cancer, and one or more subjects are intolerant to the first-line systemic therapy. In some embodiments of any of the methods described herein, the standard first-line systemic therapy includes one or more of the following: FOLFIRINOX, modified FOLFINIROX, gemcitabine, albumin-bound paclitaxel, cisplatin, erlotinib, capecitabine, docetaxel, a fluoropyrimidine, and oxaliplatin. In some embodiments of any of the methods described herein, the first-line systemic therapy comprises one of the following: (i) FOLFIRINOX; (ii) modified FOLFIRINOX; (iii) gemcitabine and nab-paclitaxel; (iv) gemcitabine and erlotinib; (v) gemcitabine; (vi) gemcitabine and capecitabine; (vii) gemcitabine, docetaxel, and capecitabine; and (viii) a fluoropyrimidine and oxaliplatin. In some embodiments of any of the methods described herein, one or more subjects have previously been identified as having a BRCA1, BRCA2, or PALB2 mutation, and the first-line systemic therapy comprises one of the following: (i) FOLFIRINOX; (ii) modified FOLFIRINOX; and (iii) gemcitabine and cisplatin.
[0018] In some embodiments of any of the methods described herein, one or more subjects have received prior treatment with second-line or later-line systemic therapy for pancreatic cancer, and the pancreatic cancer of one or more subjects has progressed with and / or is intolerant to the prior treatment. In some embodiments of any of the methods described herein, second-line or later-line systemic therapy includes one or more of the following: a different first-line systemic therapy, 5-fluorouracil, folinic acid, liposomal irinotecan, irinotecan, FOLFIRINOX, modified FOLFIRINOX, oxaliplatin, FOLFOX, capecitabine, gemcitabine, albumin-bound paclitaxel, cisplatin, erlotinib, pembrolizumab, larotrectinib, and entrectinib. In some embodiments of any of the methods described herein, second-line or later-line systemic therapy is a different first-line systemic therapy. In some embodiments of any of the methods described herein, second-line or subsequent systemic therapy comprises one of the following: (i) 5-fluorouracil, leucovorin, and liposomal irinotecan; (ii) 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI); (iii) FOLFIRINOX or modified FOLFIRINOX; (iv) oxaliplatin, 5-fluorouracil, and leucovorin (OFF); (v) FOLFOX; (vi) capecitabine and oxaliplatin; (vii) capecitabine; and (viii) continuous infusion of 5-fluorouracil. In some embodiments of any of the methods described herein, one or more subjects have previously been treated with a fluoropyrimidine-based therapy, and second-line or subsequent systemic therapy comprises one of the following: (i) gemcitabine; (ii) gemcitabine and nab-paclitaxel; and (iii) gemcitabine with erlotinib. In some embodiments of any of the methods described herein, one or more subjects have been previously treated with a fluoropyrimidine-based therapy and have been previously identified as having a BRCA1, BRCA2, or PALB2 mutation, and second-line or later-line systemic therapy includes gemcitabine and cisplatin. In some embodiments of any of the methods described herein, one or more subjects have been previously treated with a fluoropyrimidine-based therapy and have not received prior treatment with irinotecan, and second-line or later-line systemic therapy includes 5-fluorouracil, folinic acid, and liposomal irinotecan. In some embodiments of any of the methods described herein, one or more subjects have been previously identified as having an MSI-H or dMMR tumor, and second-line or later-line systemic therapy includes pembrolizumab. In some embodiments of any of the methods described herein, one or more subjects have been previously identified as having an NTRK gene fusion, and second-line or later-line systemic therapy includes larotrectinib or entrectinib.
[0019] In some embodiments of any of the methods described herein, one or more subjects suffer from distant metastatic disease. In some embodiments of any of the methods described herein, one or more subjects have adequate heart, lung, liver, and kidney function. In some embodiments of any of the methods described herein, one or more subjects have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. In some embodiments of any of the methods described herein, one or more subjects have a life expectancy of at least 12 weeks prior to the administering step.
[0020] In some embodiments of any of the methods described herein, prior to the administering step, one or more subjects have been determined to have measurable disease as assessed by imaging studies. In some embodiments of any of the methods described herein, one or more subjects have received prior radiation therapy at least four weeks prior to the administering step. In some embodiments of any of the methods described herein, prior to the administering step, any acute effects of any prior therapy in one or more subjects have been reduced to baseline or to a grade less than or equal to that of the NCI CTCAE v5.0.
[0021] In some embodiments of any of the methods described herein, one or more subjects have: an absolute neutrophil count greater than or equal to 1,500 / microliter; a platelet count greater than or equal to 100,000 / microliter; a hemoglobin level greater than or equal to 9 g / dL; a glomerular filtration rate (GFR) greater than 40 mL / min or a serum creatinine level less than or equal to 1.5 x upper limit of normal (ULN); a total bilirubin level less than or equal to 2.0 x ULN, or for subjects with Gilbert's syndrome, a total bilirubin level less than or equal to 3.0 x ULN; and aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) levels less than or equal to 2.5 x ULN, or less than or equal to 5.0 x ULN if liver metastases are present. In some embodiments of any of the methods described herein, if there are symptoms or previously known injuries, one or more subjects have a pulmonary function test (PFT) level greater than 50% of forced expiratory volume (FEV1).
[0022] In some embodiments of any of the methods described herein, the one or more subjects are female and the one or more females have had a negative pregnancy test within 14 days prior to the administering step. In some embodiments of any of the methods described herein, the one or more females have been on birth control for at least 14 days prior to and during the administering step, or have been surgically sterilized.
[0023] In some embodiments of any of the methods described herein, one or more subjects is male, and one or more subjects uses a barrier method of contraception during the administering step and for at least 28 days after the administering step.
[0024] In some embodiments of any method described herein, one or more subjects do not have a history of clinically significant vascular disease. In some embodiments of any method described herein, one or more subjects do not have a corrected QT interval (QTc) greater than or equal to 470 milliseconds according to Fridericia correction. In some embodiments of any method described herein, one or more subjects do not have untreated CNS metastases. In some embodiments of any method described herein, one or more subjects have received prior treatment for CNS metastases and one or more subjects were neurologically stable for at least two weeks before the administering step. In some embodiments of any method described herein, one or more subjects are not receiving corticosteroids during the administering step. In some embodiments of any method described herein, one or more subjects are receiving a stable dose or decreasing dose of corticosteroids less than or equal to 10 mg per day during the administering step.
[0025] In some embodiments of any of the methods described herein, the one or more subjects have not received surgery, radiation therapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days prior to the administering step. In some embodiments of any of the methods described herein, the one or more subjects do not have any other prior malignancies except for adequately treated basal cell or squamous cell skin cancer, cervical cancer in situ, adequately treated stage I or II cancer for which the one or more subjects is currently in complete remission, or any other cancer for which the one or more subjects are disease-free within 3 years of surgical treatment.
[0026] In some embodiments of any of the methods described herein, one or more subjects do not have a known history of hypersensitivity or allergic reaction to compounds having a similar chemical or biological composition to the multi-chain chimeric polypeptide. In some embodiments of any of the methods described herein, one or more subjects have not previously received treatment with a TGF-β antagonist or IL-15 or an analog thereof.
[0027] In some embodiments of any of the methods described herein, one or more subjects are not receiving concurrent herbal or unconventional therapies. In some embodiments of any of the methods described herein, one or more subjects do not have an autoimmune disease requiring active treatment. In some embodiments of any of the methods described herein, one or more subjects do not have a condition requiring systemic treatment with corticosteroids or immunosuppressive therapy within 14 days of the administering step. In some embodiments of any of the methods described herein, one or more subjects do not have an active autoimmune disease and have received an inhaled or topical steroid or adrenal replacement steroid dose equal to or less than 10 mg daily prednisone equivalents.
[0028] In some embodiments of any of the methods described herein, one or more subjects do not have an active systemic infection requiring parenteral antibiotic therapy. In some embodiments of any of the methods described herein, one or more subjects have not previously received an organ allograft or allogeneic transplant. In some embodiments of any of the methods described herein, one or more subjects have not been identified or diagnosed as HIV positive or suffering from AIDS. In some embodiments of any of the methods described herein, one or more subjects are female and the one or more females are not pregnant or breastfeeding.
[0029] In some embodiments of any of the methods described herein, one or more subjects do not have any ongoing toxicity from prior treatment. In some embodiments of any of the methods described herein, the ongoing toxicity is greater than Grade 1 (using NCICTCAE v5.0) or greater than baseline. In some embodiments of any of the methods described herein, the ongoing toxicity does not include peripheral neuropathy, alopecia, and fatigue. In some embodiments of any of the methods described herein, one or more subjects do not suffer from a psychiatric disorder.
[0030] In some embodiments of any of the methods described herein, the first target binding domain and the soluble tissue factor domain are directly adjacent to each other in the first chimeric polypeptide. In some embodiments of any of the methods described herein, the first chimeric polypeptide further comprises a linker sequence between the first target binding domain and the soluble tissue factor domain in the first chimeric polypeptide. In some embodiments of any of the methods described herein, the soluble tissue factor domain and the first domain of the affinity domain pair are directly adjacent to each other in the first chimeric polypeptide. In some embodiments of any of the methods described herein, the first chimeric polypeptide further comprises a linker sequence between the soluble tissue factor domain and the first domain of the affinity domain pair in the first chimeric polypeptide.
[0031] In some embodiments of any of the methods described herein, the second domain of the affinity domain pair and the second target binding domain are directly adjacent to each other in the second chimeric polypeptide. In some embodiments of any of the methods described herein, the second chimeric polypeptide further comprises a linker sequence between the second domain of the affinity domain pair and the second target binding domain in the second chimeric polypeptide.
[0032] In some embodiments of any of the methods described herein, one or both of the first target binding domain and the second target binding domain are antigen binding domains. In some embodiments of any of the methods described herein, one or both of the first target binding domain and the second target binding domain are soluble interleukin or cytokine receptors. In some embodiments of any of the methods described herein, the first chimeric polypeptide further comprises one or more additional target binding domains. In some embodiments of any of the methods described herein, the second chimeric polypeptide further comprises one or more additional target binding domains.
[0033] In some embodiments of any of the methods described herein, the soluble tissue factor domain is a soluble human tissue factor domain. In some embodiments of any of the methods described herein, the soluble human tissue factor domain comprises a sequence having at least 80% identity to SEQ ID NO: 1. In some embodiments of any of the methods described herein, the affinity domain pair is a sushi domain from the alpha chain of the human IL-15 receptor (IL-15Rα) and soluble IL-15.
[0034] In some embodiments of any of the methods described herein, the first target binding domain comprises soluble TGF-βRII. In some embodiments of any of the methods described herein, the first target binding domain comprises a first sequence that is at least 80% identical to SEQ ID NO: 66 and a second sequence that is at least 80% identical to SEQ ID NO: 66, wherein the first sequence and the second sequence are separated by a linker. In some embodiments of any of the methods described herein, the first target binding domain comprises a first sequence that is at least 90% identical to SEQ ID NO: 66 and a second sequence that is at least 90% identical to SEQ ID NO: 66. In some embodiments of any of the methods described herein, the first target binding domain comprises a first sequence that is at least 80% identical to SEQ ID NO: 66 and a second sequence that is at least 80% identical to SEQ ID NO: 66.
[0035] In some embodiments of any of the methods described herein, the linker comprises the sequence of SEQ ID NO:7.
[0036] In some embodiments of any of the methods described herein, the first target binding domain comprises a sequence that is at least 80% identical to SEQ ID NO: 69. In some embodiments of any of the methods described herein, the first target binding domain comprises a sequence that is at least 90% identical to SEQ ID NO: 69. In some embodiments of any of the methods described herein, the first target binding domain comprises the sequence of SEQ ID NO: 69.
[0037] In some embodiments of any of the methods described herein, the first chimeric polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 70. In some embodiments of any of the methods described herein, the first chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 70. In some embodiments of any of the methods described herein, the first chimeric polypeptide comprises the sequence of SEQ ID NO: 70. In some embodiments of any of the methods described herein, the first chimeric polypeptide comprises the sequence of SEQ ID NO: 72.
[0038] In some embodiments of any of the methods described herein, the second target binding domain comprises soluble TGF-βRII. In some embodiments of any of the methods described herein, the second target binding domain comprises a first sequence that is at least 80% identical to SEQ ID NO: 66 and a second sequence that is at least 80% identical to SEQ ID NO: 66, wherein the first sequence and the second sequence are separated by a linker. In some embodiments of any of the methods described herein, the second target binding domain comprises a first sequence that is at least 90% identical to SEQ ID NO: 66 and a second sequence that is at least 90% identical to SEQ ID NO: 66. In some embodiments of any of the methods described herein, the second target binding domain comprises a first sequence that is at least 80% identical to SEQ ID NO: 66 and a second sequence that is at least 80% identical to SEQ ID NO: 66.
[0039] In some embodiments of any of the methods described herein, the linker comprises the sequence of SEQ ID NO:7.
[0040] In some embodiments of any of the methods described herein, the second target binding domain comprises a sequence that is at least 80% identical to SEQ ID NO: 69. In some embodiments of any of the methods described herein, the second target binding domain comprises a sequence that is at least 90% identical to SEQ ID NO: 69. In some embodiments of any of the methods described herein, the second target binding domain comprises the sequence of SEQ ID NO: 69.
[0041] In some embodiments of any of the methods described herein, the second chimeric polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 74. In some embodiments of any of the methods described herein, the first chimeric polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 70. In some embodiments of any of the methods described herein, the second chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 74. In some embodiments of any of the methods described herein, the first chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 70. In some embodiments of any of the methods described herein, the second chimeric polypeptide comprises the sequence of SEQ ID NO: 74. In some embodiments of any of the methods described herein, the first chimeric polypeptide comprises the sequence of SEQ ID NO: 70.
[0042] In some embodiments of any of the methods described herein, the multi-chain chimeric polypeptide is administered subcutaneously to one or more subjects. In other embodiments of any of the methods described herein, the multi-chain chimeric polypeptide is administered intravenously, intraperitoneally, intramuscularly, intratumorally, or subcutaneously to one or more subjects. In some embodiments of any of the methods described herein, a single dose of the multi-chain chimeric polypeptide is administered to one or more subjects. In some embodiments of any of the methods described herein, the single dose is 0.1 mg of the multi-chain chimeric polypeptide / kg of subject body weight (mg / kg). In some embodiments of any of the methods described herein, the single dose is 0.25 mg / kg. In some embodiments of any of the methods described herein, the single dose is 0.5 mg / kg. In some embodiments of any of the methods described herein, the single dose is 0.8 mg / kg. In some embodiments of any of the methods described herein, the single dose is 1.2 mg / kg.
[0043] In some embodiments of any of the methods described herein, two or more doses of the multi-chain chimeric polypeptide are administered to one or more subjects during the treatment period. In some embodiments of any of the methods described herein, at least one of the two or more doses is 0.1 mg of the multi-chain chimeric polypeptide / kg of subject body weight (mg / kg). In some embodiments of any of the methods described herein, at least one of the two or more doses is 0.25 mg / kg. In some embodiments of any of the methods described herein, at least one of the two or more doses is 0.5 mg / kg. In some embodiments of any of the methods described herein, at least one of the two or more doses is 0.8 mg / kg. In some embodiments of any of the methods described herein, at least one of the two or more doses is 1.2 mg / kg. In some embodiments of any of the methods described herein, the treatment period is about 4 weeks.
[0044] As used herein, the term "chimeric" refers to a polypeptide that includes an amino acid sequence (e.g., domain) originally derived from two different sources (e.g., two different naturally occurring proteins, e.g., from the same or different species). For example, a chimeric polypeptide can include domains from at least two different naturally occurring human proteins. In some instances, a chimeric polypeptide can include a domain (e.g., scFv) that is a synthetic sequence and a domain derived from a naturally occurring protein (e.g., a naturally occurring human protein). In some embodiments, a chimeric polypeptide can include at least two different domains (e.g., two different scFvs) that are synthetic sequences.
[0045] An "antigen binding domain" is one or more protein domains (e.g., formed from amino acids from a single polypeptide, or formed from amino acids from two or more polypeptides (e.g., the same or different polypeptides)) that can specifically bind to one or more different antigens. In some examples, the antigen binding domain can bind to an antigen or epitope with a specificity and affinity similar to that of a naturally occurring antibody. In some embodiments, the antigen binding domain can be an antibody or fragment thereof. In some embodiments, the antigen binding domain can include an alternative scaffold. Non-limiting examples of antigen binding domains are described herein. Additional examples of antigen binding domains are known in the art.
[0046] A "soluble tissue factor domain" refers to a polypeptide that is at least 70% identical (e.g., at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 99% identical, or 100% identical) to a segment of a wild-type mammalian tissue factor protein (e.g., a wild-type human tissue factor protein) that lacks the transmembrane domain and the intracellular domain. Non-limiting examples of soluble tissue factor domains are described herein.
[0047] The term "soluble interleukin receptor" is used herein in the broadest sense to refer to a polypeptide lacking a transmembrane domain (and optionally an intracellular domain) that is capable of binding to one or more of its natural ligands (e.g., under physiological conditions, e.g., in phosphate-buffered saline at room temperature). For example, a soluble interleukin receptor can include a sequence that has at least 70% identity (e.g., at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, at least 99% identity, or 100% identity) to the extracellular domain of a wild-type interleukin receptor and retains its ability to specifically bind to one or more of its natural ligands but lacks its transmembrane domain (and optionally, further lacks its intracellular domain). Non-limiting examples of soluble interleukin receptors are described herein.
[0048] The term "soluble cytokine receptor" is used herein in the broadest sense to refer to a polypeptide that lacks a transmembrane domain (and optionally an intracellular domain) that is capable of binding to one or more of its natural ligands (e.g., under physiological conditions, e.g., in phosphate-buffered saline at room temperature). For example, a soluble cytokine receptor can include a sequence that is at least 70% identical (e.g., at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 99% identical, or 100% identical) to the extracellular domain of a wild-type cytokine receptor and retains its ability to specifically bind to one or more of its natural ligands but lacks its transmembrane domain (and, optionally, further lacks its intracellular domain). Non-limiting examples of soluble cytokine receptors are described herein.
[0049] The term "antibody" is used herein in its broadest sense and includes certain types of immunoglobulin molecules that include one or more antigen binding domains that specifically bind to an antigen or epitope. Antibodies specifically include, for example, complete antibodies (e.g., complete immunoglobulins), antibody fragments, and multispecific antibodies. An example of an antigen binding domain is an antigen binding domain formed by a VH-VL dimer. Other examples of antibodies are described herein. Additional examples of antibodies are known in the art.
[0050] "Affinity" refers to the total strength of non-covalent interactions between an antigen binding site and its binding partner (e.g., an antigen or epitope). Unless otherwise indicated, "affinity" as used herein refers to intrinsic binding affinity, which reflects a 1:1 interaction between a member of an antigen binding domain and an antigen or epitope. The affinity of a molecule X for its partner Y can be expressed in terms of the dissociation equilibrium constant (K D ) is represented. The kinetic components that contribute to the dissociation equilibrium constant are described in more detail below. Affinity can be measured by common methods known in the art, including those described herein. For example, surface plasmon resonance (SPR) techniques (e.g., ) or biolayer interferometry (e.g. Other methods for determining the affinity of an antigen binding domain and its corresponding antigen or epitope are known in the art.
[0051] As used herein, a "multi-chain polypeptide" refers to a polypeptide comprising two or more (e.g., three, four, five, six, seven, eight, nine, or ten) protein chains (e.g., at least a first chimeric polypeptide and a second polypeptide), wherein the two or more protein chains are associated by non-covalent bonds to form a quaternary structure.
[0052] The term "affinity domain pair" refers to two different protein domains that bind specifically to each other with a K D Less than 1x10 -7 M (e.g., less than 1x 10 -8 M, less than 1x 10 -9 M, less than 1x 10 -10 M, or less than 1x 10 -11 M). In some instances, the affinity domain pair can be a pair of naturally occurring proteins. In some embodiments, the affinity domain pair can be a pair of synthetic proteins. Non-limiting examples of affinity domain pairs are described herein.
[0053] The term "epitope" refers to a portion of an antigen that specifically binds to an antigen-binding domain. An epitope can, for example, be composed of surface-accessible amino acid residues and / or sugar side chains and can have specific three-dimensional structural characteristics as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that binding to the former may be lost in the presence of denaturing solvents, but binding to the latter may not be lost. An epitope can include amino acid residues that are directly involved in binding and other amino acid residues that are not directly involved in binding. Methods for identifying epitopes bound by antigen-binding domains are known in the art.
[0054] The term "treatment" means improving at least one symptom of an obstacle. In some instances, the condition being treated is cancer and improving at least one symptom of cancer includes, for example, reducing abnormal proliferation, gene expression, signal transduction, translation and / or secretion of a factor. In some embodiments, the treatment of cancer can include, for example, reducing the cancer progression rate in a subject and / or the metastasis development rate in a subject (for example, compared to the cancer progression rate and / or metastasis development rate in similar subjects who are not receiving treatment or receiving different treatments). In general, methods of treatment include administering a therapeutically effective amount of a composition to a subject who is in need or has been determined to need such treatment, and the composition alleviates at least one symptom of the obstacle.
[0055] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Methods and materials for use in the present invention are described herein; other suitable methods and materials known in the art may also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification (including definitions) will prevail.
[0056] Other features and advantages of the invention will be apparent from the following detailed description and drawings, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Figure 1 A schematic diagram of the TGFRt15-TGFR construct is shown.
[0058] Figure 2 Additional schematics of the TGFRt15-TGFR construct are shown.
[0059] Figure 3 Results showing inhibition of TGFβ1 by TGFRt15-TGFR and TGFR-Fc.
[0060] Figure 4 Shows the results of a 32D β-cell proliferation assay using TGFRt15-TGFR or recombinant IL-15
[0061] Figure 5A and 5B Shown are the results of detecting IL-15 and TGF□RII in TGFRt15-TGFR using ELISA with corresponding antibodies.
[0062] Figure 6 The line graph shows the chromatographic profile of cell culture supernatant containing TGFRt15-TGFR protein after binding and elution on anti-TF antibody resin.
[0063] Figure 7 The analytical SEC profile of TGFRt15-TGFR is shown.
[0064] Figure 8 Shown are TGFRt15-TGFR before and after deglycosylation analyzed by reducing SDS-PAGE.
[0065] Figure 9A and 9B Shown are spleen weights and percentages of immune cell types in TGFRt15-TGFR-treated and control-treated mice. Figure 9A Shown are spleen weights of mice treated with TGFRt15-TGFR compared to PBS controls. Figure 9B Shows the CD4 + T cells, CD8 + The percentages of T cells and NK cells.
[0066] Figure 10A and 10B Shown are spleen weights and immune stimulation over 92 hours in mice treated with TGFRt15-TGFR. Figure 10A Shown are the spleen weights of mice treated with TGFRt15-TGFR at 16, 24, 48, 72, and 92 hours after treatment. Figure 10BShown are the percentages of immune cells in mice treated with TGFRt15-TGFR at 16, 24, 48, 72, and 92 hours after treatment.
[0067] Figure 11A and 11B Shown are the expressions of Ki67 and granzyme B over time in mice treated with TGFRt15-TGFR.
[0068] Figure 12 The enhanced cytotoxicity of TGFRt15-TGFR on splenocytes in C57BL / 6 mice was shown.
[0069] Figure 13 Shown are changes in tumor size in response to treatment with PBS, chemotherapy alone, TGFRt15-TGFR alone, or a combination of chemotherapy and TGFRt15-TGFR in a pancreatic cancer mouse model.
[0070] Figure 14 The cytotoxicity of NK cells isolated from mice treated with TGFRt15-TGFR is shown.
[0071] Figures 15A-15B Shown are the immunostimulatory results of exemplary multi-chain polypeptides in C57BL / 6 mice. Figure 15A Shown are spleen weights of mice treated with increasing doses of exemplary multi-chain polypeptides compared to mice treated with control solution. Figure 15B Shown are the percentages of immune cell types present in the spleens of mice treated with increasing doses of an exemplary multi-chain polypeptide compared to mice treated with a control solution.
[0072] Figures 16A-16B The duration of immune stimulation of exemplary multi-chain polypeptides in C57BL / 6 mice is shown. Figure 16A Shown are spleen weights over 92 hours for mice treated with 3 mg / kg of an exemplary multi-chain polypeptide. Figure 16B Shown are the percentages of immune cell types present in the spleen over 92 hours in mice treated with 3 mg / kg of an exemplary multi-chain polypeptide.
[0073] Figures 17A-17B The exemplary multi-chain polypeptides induce the expression of Ki67 and granzyme B in immune cells. Figure 17A The CD4 + T cells, CD8 + T cells, natural killer (NK) cells, and CD19 + Ki67 expression in B cells. Figure 17B The CD4 +T cells, CD8 + T cells, natural killer (NK) cells, and CD19 + Granzyme B expression in B cells.
[0074] Figure 18 Shown are the tumor inhibitory effects of splenocytes prepared from mice treated with exemplary multi-chain polypeptides at various time points after treatment.
[0075] Figure 19A and Figure 19B Shown are B6.129P2-ApoE fed a control diet, a high-fat diet, and no treatment. tm1Unc CD4 T cells in the blood of TGFR / J mice (purchased from Jackson Laboratory) and mice fed a high-fat diet and treated with TGFRt15-TGFR, 2t2, or 21t15-TGFR + T cells, CD8 + T cells, natural killer (NK) cells, and CD19 + The percentage and proliferation rate of B cells. Figure 19A The percentages of different cell types in each control and experimental group are shown. Figure 19B The proliferation rates of different cell types in each control and experimental group are shown.
[0076] Figures 20A-20E Shown are exemplary physical appearances of mice fed a control or high-fat diet and untreated or treated with TGFRt15-TGFR, 2t2, or 21t15-TGFR.
[0077] Figure 21 Shown are fasting body weights of mice fed a control or high-fat diet and left untreated or treated with TGFRt15-TGFR, 2t2, or 21t15-TGFR.
[0078] Figure 22 Shown are fasting blood glucose levels of mice fed a control or high-fat diet and left untreated or treated with TGFRt15-TGFR, 2t2, or 21t15-TGFR.
[0079] Figures 23A-23F Figure 23A shows chemotherapy-induced senescent B16F10 cells and expression of senescent genes. Figure 23B-23F shows chemotherapy-induced senescent B16F10 cells observed using SAβ-gal staining. CIP1 , IL6, DPP4, RATE1E and ULBP1 expression over time.
[0080] Figures 24A-24F show the colony formation and expression of stem cell markers of chemotherapy-induced senescent B16F10 cells. Figure 24A shows the colony formation of chemotherapy-induced senescent B16F10 cells. Figures 24B and 24C show the expression of Oct4 mRNA and Notch4 mRNA in chemotherapy-induced senescent B16F10 cells compared to control B16F10 cells. Figures 24D-24F Shown are the percentages of chemotherapy-induced senescent B16F10 cells that are doubly positive for two of three stem cell markers, including CD44, CD24, and CD133.
[0081] Figures 25A-25C show the migration and invasion properties of chemotherapy-induced senescent B16F10 cells. Figure 25A shows the results of a migration assay comparing chemotherapy-induced senescent cells with stem cell properties (B16F10-SNC-CSC) with control B16F10 cells. Figures 25B and 25C show the results of an invasion assay comparing chemotherapy-induced senescent cells with stem cell properties (B16F10-SNC-CSC) with control B16F10 cells.
[0082] Figure 26 A and 26B show the NK cells of in vitro expansion and the cytotoxicity thereof for the senescent cells (B16F10-SNC-CSC) or control B16F10 cells with stem cell properties induced by chemotherapy. Figure 26 A shows the exemplary schematic diagram of the process of obtaining the NK cells of in vitro expansion. Figure 26 B shows the cytotoxicity of the NK cells of expansion for the senescent cells (B16F10-SNC-CSC) or control B16F10 cells induced by chemotherapy with stem cell properties.
[0083] Figures 27A-27C Results of combination therapy using a mouse melanoma model are shown. Figure 27A shows an exemplary schematic diagram of treating melanoma in a mouse model. Figures 27B and 27C show changes in tumor volume over time when treated with a combination including TGFRt15-TGFR compared to chemotherapy or TA99 treatment alone.
[0084] Figures 28A-28C The set of figures shows immune stimulation in C57BL / 6 mice after treatment with 2t2.
[0085] Figure 29A and 29B The set of figures shows immune stimulation in C57BL / 6 mice after treatment with TGFRt15-TGFR.
[0086] Figures 30A-30C A set of figures shows ApoE mice fed a Western diet and treated with TGFRt15-TGFR or 2t2 - / -Treg, NK cells and CD8 in mice + In vivo stimulation of T cells.
[0087] Figure 31A and 31B The figure shows that 2t2 induces splenocyte proliferation in C57BL / 6 mice.
[0088] Figures 32A-32C The set of figures shows immune stimulation in C57BL / 6 mice after treatment with TGFRt15-TGFR.
[0089] Figure 33A and 33B The following figures show that ApoE - / - In vivo induction of NK cells and CD8 + T cell proliferation.
[0090] Figure 34 Schematic set of figures showing the persistence of 7t15-21s- and anti-TF antibody-expanded NK cells in NSG mice after treatment with 7t15-21, TGFRt15-TGFR, or 2t2.
[0091] Figure 35A and 35B The figure shows that NK cell cytotoxicity is enhanced after NK cells are treated with TGFRt15-TGFR.
[0092] Figure 36A and 36B The figure shows that ADCC activity of NK cells is enhanced after treatment of NK cells with TGFRt15-TGFR.
[0093] Figure 37 This figure shows that TGFRt15-TGFR / 2t2-activated mouse NK cells kill senescent B16F10 melanoma cells in vitro.
[0094] Figures 38A-38H The figure shows the anti-tumor activity of TGFRt15-TGFR plus anti-TRP1 antibody (TA99) in combination with chemotherapy in a melanoma mouse model.
[0095] Figures 39A-39C A set of figures shows that 2t2 improves ApoE - / - Western diet-induced hyperglycemia in mice.
[0096] Figure 40Shows upregulation of CD44 memory T cells. The upper panel shows upregulation of CD44 memory T cells after treatment with TGFRt15-TGFR. The lower panel shows upregulation of CD44 memory T cells after 2T2 treatment.
[0097] Figure 41 The set of graphs shows the immunophenotype and cell proliferation after treatment with IL-15 based agents on day 3 post-treatment.
[0098] Figures 42A-42C The figures show that TGFRt15-TGFR treatment reduces the expression of aging-related genes in C57BL / 6 mice. These figures show the expression of p21 in lung tissue (42A and 42B), respectively. CIP1 Expression of p21 and CD26 and p21 in liver (42C) tissue CIP1 Expression of p21.
[0099] Figure 43 A set of figures shows CD4 + 、CD8 + and Treg cell percentage and proliferation.
[0100] Figure 44 A set of figures shows NK, CD19 + and monocyte percentage and proliferation.
[0101] Figures 45A-45C Figure 2 shows the expression of the senescence marker p21 in lung and liver tissues. CIP1 Evaluation of p21 and CD26. Figures 208A and 208B show lung p21 CIP1 p21 (45A) and lung CD26 (45B) are senescence markers. Figure 45C Liver p21 CIP1 p21 senescence marker.
[0102] Figure 46 The panel shows the immunophenotype from peripheral blood analysis 4 days after a single dose of treatment with TGFRt15-TGFR.
[0103] Figure 47 The panel shows the immunophenotype from peripheral blood analysis 4 days after a single dose of treatment with TGFRt15-TGFR.
[0104] Figure 48 The graph shows β-Gal staining analysis by FACS seven days after the second administration of TGFRt15-TGFR.
[0105] Figure 49The panel shows the levels of senescence markers in liver tissue measured using qPCR 7 days after the second administration of TGFRt15-TGFR.
[0106] Figure 50 The panel shows the levels of senescence markers in kidney tissue measured using qPCR 7 days after the second administration of TGFRt15-TGFR.
[0107] Figure 51 The set of graphs shows the levels of aging markers in skin tissue measured using qPCR 7 days after the second administration of TGFRt15-TGFR.
[0108] Figure 52 The panel shows the levels of senescence markers in lung tissue measured using qPCR 7 days after the second administration of TGFRt15-TGFR.
[0109] Figure 53 A set of histological images shows β-Gal staining on kidney tissue 7 days after the second treatment with TGFRt15-TGFR.
[0110] Figure 54 A schematic diagram showing the interaction between exemplary TGFβRII / IL-15RαSu and TGFβRII / TF / IL-15Mut proteins to generate the TGFRt15*-TGFR complex is shown.
[0111] Figure 55 A schematic diagram of the interaction between exemplary TGFβRII / IL-15RαSu and TGFβRII / TF / IL-15Mut proteins is shown.
[0112] Figure 56 Graph A shows the binding activity of TGFRt15-TGFR to TGF-β1 and LAP.
[0113] Figure 56 Panel B shows the binding activity of TGFRII / Fc to TGF-β1 and LAP.
[0114] Figure 56 Graph C shows the binding activity of TGFRt15-TGFR to TGF-β1 and LAP.
[0115] Figure 56 The graph in D shows the binding activity of TGFRt15*-TGFR to TGF-β1 and LAP.
[0116] Figure 56 Graph E shows the binding activity of TGFRt15-TGFR, TGFRt15*-TGFR, and 7t15-21s to CTLL-2 cells.
[0117] Figure 57 A is a graph showing the TGF-β1 blocking activity of TGFRt15-TGFR and TGFRt15*-TGFR.
[0118] Figure 57 B is a graph showing the IL-15 bioactivity of TGFRt15-TGFR and TGFRt15*-TGFR.
[0119] Figure 57 Panel C shows that TGF-β1, TGF-β2, and TGF-β3 each similarly inhibit IL-4-induced CTLL-2 growth in the absence of TGFRt15*-TGFR.
[0120] Figure 57 Graph D shows that TGFRt15*-TGFR significantly reversed the inhibition of IL-4-induced CTLL-2 cell growth by TGF-β1 and TGF-β3.
[0121] Figure 58 A shows no significant damage to the IL-15 domain of TGFRt15-TGFR after 10 days of incubation at 4°C, 25°C, or 37°C.
[0122] Figure 58 B shows no significant damage to the TGFβ-RII domain of TGFRt15-TGFR after 10 days of incubation at 4°C, 25°C, or 37°C.
[0123] Figure 58 Graph C shows the TGF-β1 neutralizing activity of TGFRt15-TGFR after incubation in human serum at 4°C, 25°C, or 37°C for 10 days.
[0124] Figure 58 Graph D shows IL-15 activity of TGFRt15-TGFR after incubation in human serum for 10 days at 4°C, 25°C, or 37°C.
[0125] Figure 59 Panel A shows cell-mediated cytotoxicity in assays using NK cells and the indicated constructs.
[0126] Figure 59 Panel B shows cell-mediated cytotoxicity in assays using PMBCs and the indicated constructs.
[0127] Figure 59 Panel C shows intracellular granzyme B production in an assay using NK cells and the indicated constructs.
[0128] Figure 59Panel D shows intracellular granzyme B production in assays using PBMCs and the indicated constructs.
[0129] Figure 59 Panel E shows interferon-γ production in assays using NK cells and the indicated constructs.
[0130] Figure 59 Panel F shows interferon-γ production in assays using PMBCs and the indicated constructs.
[0131] Figure 60 The graph shows the pharmacokinetics (half-life, t) of TGFRt15-TGFR evaluated in female C57BL / 6 mice. 1 / 2 ).
[0132] Figure 61 The figure shows the toxicity of TGFRt15-TGFR in C57BL / 6 mice.
[0133] Figure 62 The figure shows the antitumor activity of TGFRt15-TGFR in a C57BL / 6 mouse melanoma model.
[0134] Figure 63 The activity of TGFRt15-TGFR in nine-week-old C57BL6 / j male mice is shown, in which the mice were given 50 μl of bleomycin (2.5 mg / kg, single dose) by the oropharyngeal route and then TGFRt15-TGFR (3 mg / kg) was administered subcutaneously on day 17 after bleomycin treatment.
[0135] Figure 64 Shown are fasting plasma glucose levels of db / db mice 4 days after treatment with TGFRt15-TGFR or TGFRt15*-TGFR.
[0136] Figures 65A-65C Shown are the levels of TGFβ1-3 in db / db mice after 4 days of treatment with TGFRt15-TGFR or TGFRt15*-TGFR: TGFβ1 ( Figure 65A )、TGFβ2( Figure 65B ) and TGFβ3( Figure 65C ).
[0137] Figure 66 A-66E shows lymphocyte subsets in db / db mice 4 days after treatment with TGFRt15-TGFR or TGFRt15*-TGFR: blood NK cells ( Figure 66 A) Blood Ki67 + NK cells ( Figure 66 B) Blood granzyme B +(GzmB + )( Figure 66 C) Blood CD8 + ( Figure 66 D) and blood CD8 + Ki67 + T cells ( Figure 66 E).
[0138] Figure 67 A shows the interaction of TGFRt15*-TGFR or TGFRt15-TGFR with latent TGFβ1 (SLC) or with CD39 (control).
[0139] Figure 67 B shows the interaction of TGFRt15*-TGFR and TGFRII-Fc with latent TGFβ1.
[0140] Figure 68 This is a graph showing the coagulation time of Innovin in the PT assay.
[0141] Figure 69 This is a graph showing the coagulation time of TGFRt15-TGFR in the PT assay.
[0142] Figure 70 The first set of graphs shows gene expression of aging markers PAI-1, IL-1α, IL6, and IL-1β in the kidney and compares short-term and long-term follow-up of young mice with PBS or TGFRt15-TGFR treated old mice.
[0143] Figure 71 The panel shows gene expression of the senescence markers IL-1α and IL6 in the liver.
[0144] Figure 72 Shown is the protein expression of the senescence marker PAI-1 in the kidney.
[0145] Figure 73 The following figure shows the expression of CD3 mediated by IL15SA (positive control) or TGFRt15*-TGFRs+IL15SA in blood. + CD8 + 、CD3 - NK1.1 + , and CD3 + CD45 + The percentages of immune cells increased, whereas TGFRt15*-TGFR treatment had little effect on the percentages of these cell populations.
[0146] Figure 74The following figure shows the expression of CD3 Tgf15*-TGFRs+IL15SA in the spleen. + CD8 + 、CD3 - NK1.1 + , and CD3 + CD45 + The percentages of immune cells increased, whereas TGFRt15*-TGFR treatment had little effect on the percentages of these cell populations.
[0147] Figure 75A Shown is the gene expression of the senescence marker p21 in kidney and liver tissues after test article treatment.
[0148] Figure 75B Shown is the gene expression of the senescence marker PAI1 in kidney and liver tissues after study treatment.
[0149] Figure 75C Shown is the gene expression of the senescence marker IL-1α in kidney and liver tissues after study treatment.
[0150] Figure 75D Shown is the gene expression of the senescence marker IL-6 in kidney and liver tissues after study treatment.
[0151] Figure 76A CD4 + 、CD8 + and Treg cell percentage and proliferation.
[0152] Figure 76B NK, CD19, and NK cells after treatment with the indicated agents are shown. + and monocyte percentage and proliferation.
[0153] Figure 77A Shown is the evaluation of gene expression of the senescence marker p21 in mouse lung tissue following chemotherapy and treatment with the indicated agents.
[0154] Figure 77B Shown is the evaluation of gene expression of the senescence marker CD26 in mouse lung tissue following chemotherapy and treatment with the indicated agents.
[0155] Figure 77C Shown are assessments of gene expression of the senescence marker p21 in mouse liver tissue following chemotherapy and treatment with the indicated agents.
[0156] Figure 78A and 78B The figure shows that TGFRt15-TGFR treatment enhances the proliferation, expansion, and activation of immune cells in the peripheral blood of B16F10 tumor-bearing mice.
[0157] Figure 79 The figure shows that TGFRt15-TGFR treatment reduces TGFβ levels in the plasma of B16F10 tumor-bearing mice.
[0158] Figure 80 A set of figures shows that TGFRt15-TGFR treatment reduces the levels of proinflammatory cytokines in the plasma of B16F10 tumor-bearing mice.
[0159] Figure 81 We show that TGFRt15-TGFR treatment enhances NK and CD8 expansion in the spleens of B16F10 tumor-bearing mice.
[0160] Figure 82A and 82B showed that TGFRt15-TGFR treatment enhanced the glycolytic activity of splenocytes in B16F10 tumor-bearing mice.
[0161] Figure 83A and 83B We show that TGFRt15-TGFR treatment enhances mitochondrial respiration in splenocytes of B16F10 tumor-bearing mice.
[0162] Figure 84A and 84B We showed that TGFRt15-TGFR treatment enhanced NK and CD8 immune cell infiltration (TIL) into tumors in B16F10 tumor-bearing mice.
[0163] Figure 85 Figure 3 shows histopathological analysis of tumors after TGFRt15-TGFR treatment, where tumors treated with TGFRt15-TGFR plus TA99 antibody exhibited less mitotic and necrotic activity. The mitotic index correlates with dividing cells, while the presence of necrosis is a measure of more aggressive features and poor prognosis.
[0164] Figure 86 The figure shows the combination of anti-PD-L1 antibody with TGFRt15-TGFR+TA99 antibody and chemotherapy in the B16F10 melanoma mouse model.
[0165] Figure 87 Figure 2 shows that the anti-tumor efficacy of TGFRt15-TGFR in the B16F10 melanoma mouse model is dependent on NK and CD8 T cells.
[0166] Figure 88A and 88B The figure shows the gene expression of senescence markers p21, IL-1α, and IL6 in liver and lung tissues of tumor-bearing mice after chemotherapy.
[0167] Figure 89The graph shows that docetaxel treatment of B16F10 GFP cells induces gene expression of senescence markers p21, IL6, H2AX, and NK cell ligands Rae1e and ULBP1.
[0168] Figure 90 Shown are tumor-infiltrating lymphocytes / day in tumor-bearing mice 4 days after treatment.
[0169] Figure 91A and Figure 91B Figure 5 shows flow cytometric analysis of tumor cells, demonstrating that mice treated with immunotherapy displayed lower numbers of GFP-positive senescent tumor cells after 4 and 10 days of treatment compared to the PBS control group. Figure 91A ), and tumor cells plated in 24-well plates were evaluated by fluorescence microscopy ( Figure 91B ).
[0170] Figure 92 Shown are TGFβ levels in the kidneys of mice after induction of renal injury with cisplatin and treatment with TGFRt15-TGFR.
[0171] Figures 93A-93C The toxicological effects of repeated subcutaneous administration of TGFR15-TGFR in C57BL / 6 mice are shown. Body weight changes are shown by SD21 ( Figure 93A ). Spleen weights of indicated mice at SD7 after one dose of TGFRt15-TGFR and at SD21 after two doses of TGFRt15-TGFR ( Figure 93B ) and blood cell count and differential ( Figure 93C ).
[0172] Figure 94 Shown are plasma levels of TGF-β isoforms in mice following in vivo treatment with PBS, TGFRt15-TGFR (3 mg / kg), or TGFRt15*-TGFR (3 mg / kg).
[0173] Figure 95A and Figure 95B Shown is the glycolytic capacity (ECAR) in mouse splenocytes after in vivo treatment with PBS, TGFRt15-TGFR, TGFRt15*-TGFR, or IL15SA ( Figure 95A ) and mitochondrial respiratory capacity (OCR) ( Figure 95B ) rate of change.
[0174] Figure 96A and Figure 96B Shown is the glycolytic capacity (ECAR) in mouse splenocytes after in vitro treatment with PBS, TGFRt15-TGFR, or TGFRt15*-TGFR ( Figure 96A) and mitochondrial respiratory capacity (OCR) ( Figure 96B ) rate of change.
[0175] Figures 97A-97E Shown are changes in tumor growth and survival of B16F10 melanoma tumors in C57BL / 6 mice after in vitro treatment with PBS, TGFRt15-TGFR, or TGFRt15*-TGFR. Tumor volume ( Figure 97A ) and mouse survival (based on tumor volume <4000mm 3 )( Figure 97B ).like Figure 97A As shown, mice were treated with anti-CD8, anti-NK, or anti-CD8 and anti-NK Abs intraperitoneally for 1 week before injection of B16F10 melanoma tumor cells to deplete immune cells. Tumor-bearing mice were then treated with PBS or 20 mg / kg TGFRt15-TGFR on days 1 and 4 after tumor cell inoculation. The tumor volume of the animals was assessed ( Figure 97C ) and mouse survival ( Figure 97D Mice bearing B16F10 tumors were treated with PBS or 20 mg / kg TGFRt15-TGFR on days 1 and 7 after tumor inoculation ( Figure 97E On day 11 after tumor inoculation, tumors were collected and analyzed by flow cytometry for tumor-infiltrating NK1.1 + cells and CD8 + T cells were quantified.
[0176] Figure 98A Shown are the fold changes in gene expression levels in the pancreas of db / db mice receiving TGFRt15-TGFR compared to PBS controls.
[0177] Figures 98B-98D Shown are the mean fold changes in pancreatic expression levels of genes for SASP, senescence, and beta cell index, respectively, for db / db mice receiving TGFRt15-TGFR compared to PBS controls.
[0178] Figure 99A and 99B Shown are the results from treatment with PBS (control) ( Figure 99A ) or TGFRt15-TGFR( Figure 99B Multispectral imaging of pancreatic tissue sections of db / db mice treated with PBS ( Figure 99A ) compared with the TGRt15-TGFR treatment group ( Figure 99B ) + Pancreatic beta cells (as OPAL-520), insulin + p21 +Beta cells (as OPAL-570) (grayscale images are seen as white blood cells) are reduced.
[0179] Figure 99C and Figure 99D Shown are islet insulin levels in pancreatic tissue sections from db / db mice treated with PBS (control) or TGFRt15-TGFR + ( Figure 99C ) and pancreatic insulin + p21 + ( Figure 99D ) cellular level.
[0180] Figures 100A-100C Shown are the effects of treatment on the percentages of blood immune cell subsets in db / db mice receiving PBS (control) or TGFRt15-TGFR.
[0181] Figure 101 Shown are the percentages of Ki67-positive immune cells induced in the blood of cynomolgus monkeys after subcutaneous treatment with TGFRt15-TGFR compared to PBS (vehicle).
[0182] Figure 102 Shown are the extracellular acidification rates (ECARs) representing the glycolytic function of splenocytes isolated from young (6 weeks old) and old (72 weeks old) mice 4 days after in vivo treatment with PBS, TGFRt15-TGFR (3 mg), or TGFRt15*-TGFR (3 mg / kg).
[0183] Figure 103 Shown are oxygen consumption rates (OCR) representing mitochondrial respiration in splenocytes isolated from young (6 weeks old) and old (72 weeks old) mice 4 days after in vivo treatment with PBS, TGFRt15-TGFR (3 mg), or TGFRt15*-TGFR (3 mg / kg).
[0184] Figure 104 Shown are the percentages of immune cell subsets in the blood of young (6 weeks old) and old (72 weeks old) mice 4 days after in vivo treatment with PBS, TGFRt15-TGFR (3 mg / kg), or TGFRt15*-TGFR (3 mg / kg).
[0185] Figure 105 Shown are the percentages of immune cell subsets in the spleens of young (6 weeks old) and old (72 weeks old) mice 4 days after in vivo treatment with PBS, TGFRt15-TGFR, or TGFRt15*-TGFR.
[0186] Figure 106Shown are the gene expression levels of IL1-α, IL1-β, IL-6, p21, and PAI-1 in the liver of aged mice after treatment with one or two doses of TGFRt15-TGFR.
[0187] Figure 107 Shown are the inflammation scores of liver tissues from aged mice after treatment with one or two doses of TGFRt15-TGFR.
[0188] Figure 108 Shown are the expression levels of IL1-α, IL1-β, IL-6, IL-8, TGF-β, PAI-1, collagen, and fibronectin in the liver of aged mice after treatment with one or two doses of TGFRt15-TGFR.
[0189] Figure 109 Shown are the levels of β-galactosidase in liver tissue of aged mice 4 days after in vivo treatment with PBS or TGFRt15-TGFR.
[0190] Figure 110 Shown are survival curves of 72-week-old C57BL / 6 mice treated subcutaneously with PBS or one dose of TGFRt15-TGFR (3 mg / kg).
[0191] Figure 111 Shown are the protein levels of SASP factors in the liver of B16F10 tumor-bearing mice after chemotherapy and TGFRt15-TGFR+TA99 therapy.
[0192] Figure 112A and Figure 112B Shown are CD8 in mouse tumors after chemotherapy and TGFRt15-TGFR+TA99 therapy + T cell (dpCD8) and NK cell (dpNK) antibody depletion of TIS B16F10-GFP cells ( Figure 112A ) and NK and CD8 + T cells ( Figure 112B ) level.
[0193] Figures 113A-113E The antitumor activity and mechanism of action of TGFRt15-TGFR+TA99 in combination with immune checkpoint inhibitors in B16F10 tumor-bearing mice were shown. Figure 113A An exemplary schematic for treating B16F10 melanoma in a mouse model is shown. Figure 113B Shown are changes in tumor volume over time and at day 18 following combination treatment including TGFRt15-TGFR+TA99+anti-PD-L1 antibody after docetaxel compared to PBS or chemotherapy treatment alone. Figure 113C and 113DShows the expression of tumor-infiltrating CD28 on day 18 + CD8 + T cells and splenic IFNγ + CD8 + The percentage of T cells was analyzed for treatment effect. Figure 113E The results show that the tumor infiltrating CD8 + and CD8 + CD44 hi Treatment effects on NKG2D levels (MFI) of T cells.
[0194] Figures 114A-114D Shown are changes in tumor growth and survival of SW1990 human pancreatic tumors in C57BL / 6 scid mice following in vitro treatment with PBS, gemcitabine and nab-paclitaxel chemotherapy, TGFRt15-TGFR, or TGFRt15-TGFR+chemotherapy. Figure 114A An exemplary scheme for treating SW1990 human pancreatic tumors in a xenograft mouse model is shown. Figure 114B and 114C Shown are the changes in tumor volume over time and at day 38 following combination treatment including TGFRt15-TGFR+chemotherapy compared to PBS or chemotherapy treatment alone, respectively. Figure 114D Therapeutic effects on the survival of mice bearing SW1990 human pancreatic tumors are shown.
[0195] Figures 115A-115C The panel shows gene expression levels of aging markers (IL-1α, IL-6, and PAI-1, respectively) in tissues of aged mice after treatment with: PBS; TGFRt15-TGFR; 2t2; a first dose of TGFRt15-TGFR on day 0 and a second dose of 2t2 on day 60; or a first dose of 2t2 on day 0 and a second dose of TGFRt15-TGFR on day 60.
[0196] Figure 116 is an exemplary schematic diagram of the experimental design using a melanoma mouse model.
[0197] Figures 117A-117H The graph shows the effect of administration of TGFRt15-TGFR on the proliferation, expansion, and activation of NK / T cells in the blood of a melanoma mouse model.
[0198] Figures 118A-118C The figure shows the effect of TGFRt15-TGFR treatment on plasma levels of TGF-β1, TGF-β2, and TGF-β3 in a melanoma mouse model.
[0199] Figures 119A-119EThe graph shows the effect of dexamethasone or the combination of TGFRt15-TGFR and dexamethasone treatment on IL-2, IL-1β, IL-6 and GM-CSF plasma levels in a melanoma mouse model.
[0200] Figure 120A and 120B The figure shows the effects of dexamethasone or the combination of TGFRt15-TGFR and dexamethasone on NK cells and CD8 in the spleen of a melanoma mouse model. + Effects on T cell levels.
[0201] Figures 121A-121C The panel shows the effect of treatment with saline (black line), dexamethasone (dark grey line), or a combination of dexamethasone, TGFRt15-TGFR, and TA99 (light grey line) on splenocyte glycolytic activity.
[0202] Figures 122A-122L The set of graphs shows the effect of treatment with saline, dexamethasone, or a combination of dexamethasone, TGFRt15-TGFR, and TA99 on glycolytic activity (glycolysis, glycolytic capacity, glycolytic reserve, and non-glycolytic acidification) of splenocytes from a melanoma mouse model.
[0203] Figures 123A-123C The set of graphs shows the effect of treatment with PBS, dexamethasone, or a combination of dexamethasone, TGFRt15-TGFR, and TA99 on mitochondrial respiration in splenocytes from a melanoma mouse model.
[0204] Figures 124A-124L The set of graphs shows the effect of treatment with PBS, dexamethasone, or a combination of dexamethasone, TGFRt15-TGFR, and TA99 on mitochondrial respiration (basal respiration, maximal respiration, spare respiratory capacity, and ATP production) in splenocytes from a mouse melanoma model.
[0205] Figures 125A-125H The set of figures shows the effects of treatment with PBS, dexamethasone, or a combination of dexamethasone, TGFRt15-TGFR, and TA99 on the infiltration of NK / Ki67 cells, CD8 / Ki67 cells, NK cells, CD8 cells, NK / CD25 cells, NK / granzyme B cells, CD8 / CD25 cells, and CD8 / granzyme B cells into melanoma tumors in a melanoma mouse model.
[0206] Figure 126A Schematic diagram of the experimental design for therapy-induced senescence in B16F10 tumors in a melanoma mouse model.
[0207] Figures 126B-126EThe figure shows the effect of DTX treatment on the expression of senescence-related genes (DPP4, IL-6, p16 and p21) in mouse B16F10 tumor cells.
[0208] Figure 127A Schematic diagram of the experimental design for therapy-induced senescence in B16F10 tumors in a melanoma mouse model.
[0209] Figure 127B and Figure 127C The graph shows the effects of treatment with saline, dexamethasone, or a combination of dexamethasone, TGFRt15-TGFR, and TA99 on p21 and IL-6 expression, respectively, in B16F10 tumors in a melanoma tumor model.
[0210] Figures 128A-128D The panel shows protein expression levels of aging markers (PAI1, IL-1α, CXCL1, and IL-2, respectively) in the plasma of aged mice after treatment with: PBS; TGFRt15-TGFR; 2t2; a first dose of TGFRt15-TGFR on day 0 and a second dose of 2t2 on day 60; or a first dose of 2t2 on day 0 and a second dose of TGFRt15-TGFR on day 60.
[0211] Figure 129 RNA-seq analysis of differentially expressed genes between PBS (control group) or TGFRt15-TGFR (TGFRt15-TGFR group) in the liver of db / db mice is shown.
[0212] Figure 130 RNA-seq analysis of differentially expressed genes between PBS (control group) or TGFRt15-TGFR (TGFRt15-TGFR group) in the liver of aged mice is shown. DETAILED DESCRIPTION
[0213] Provided herein are methods for treating unresectable advanced / metastatic pancreatic cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds a ligand for TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand for TGF-βRII.
[0214] Also provided herein are methods of improving the objective response rate in a subject with unresectable advanced / metastatic pancreatic cancer, the method comprising administering to the subject a therapeutically effective amount of any of the multi-chain chimeric polypeptides described herein.
[0215] Also provided herein are methods of increasing progression-free survival or progression-free survival in a subject or population of subjects with unresectable advanced / metastatic pancreatic cancer, comprising administering to one or more subjects a therapeutically effective amount of any of the multi-chain chimeric polypeptides described herein.
[0216] Also provided herein are methods of increasing the time to progression in a subject or population of subjects with unresectable advanced / metastatic pancreatic cancer, the methods comprising administering to one or more subjects a therapeutically effective amount of any of the multi-chain chimeric polypeptides described herein.
[0217] Also provided herein are methods of increasing the duration of remission in a subject or population of subjects with unresectable advanced / metastatic pancreatic cancer, the methods comprising administering to one or more subjects a therapeutically effective amount of any of the multi-chain chimeric polypeptides described herein.
[0218] Also provided herein are methods of increasing overall survival in a population of subjects with unresectable advanced / metastatic pancreatic cancer, comprising administering to these subjects a therapeutically effective amount of any of the multi-chain chimeric polypeptides described herein.
[0219] In some examples of any of the multi-chain chimeric polypeptides described herein, the total length of the first chimeric polypeptide and / or the second chimeric polypeptide can each independently be about 50 amino acids to about 3000 amino acids, about 50 amino acids to about 2500 amino acids, about 50 amino acids to about 2000 amino acids, about 50 amino acids to about 1500 amino acids, about 50 amino acids to about 1000 amino acids, about 50 amino acids to about 800 amino acids, about 50 amino acids to about 600 amino acids, about 50 amino acids to about 500 amino acids, about 50 amino acids to about 450 amino acids, about 50 amino acids to about 400 amino acids, about 50 amino acids to about 350 amino acids, about 50 amino acids to about 500 amino acids, or about 50 amino acids to about 600 amino acids. to about 300 amino acids, about 50 amino acids to about 250 amino acids, about 50 amino acids to about 200 amino acids, about 50 amino acids to about 150 amino acids, about 50 amino acids to about 100 amino acids, about 100 amino acids to about 3000 amino acids, about 100 amino acids to about 2500 amino acids, about 100 amino acids to about 2000 amino acids, about 100 amino acids to about 1500 amino acids, about 100 amino acids to about 1000 amino acids, about 100 amino acids to about 800 amino acids, about 100 amino acids to about 600 amino acids, about 100 amino acids to about 500 amino acids, about 100 amino acids to about 450 amino acids, about 1 00 amino acids to about 400 amino acids, about 100 amino acids to about 350 amino acids, about 100 amino acids to about 300 amino acids, about 100 amino acids to about 250 amino acids, about 100 amino acids to about 200 amino acids, about 100 amino acids to about 150 amino acids, about 150 amino acids to about 3000 amino acids, about 150 amino acids to about 2500 amino acids, about 150 amino acids to about 2000 amino acids, about 150 amino acids to about 1500 amino acids, about 150 amino acids to about 1000 amino acids, about 150 amino acids to about 800 amino acids, about 150 amino acids to about 600 amino acids, about 150 amino acids to about from about 150 amino acids to about 400 amino acids, from about 150 amino acids to about 350 amino acids, from about 150 amino acids to about 300 amino acids, from about 150 amino acids to about 250 amino acids, from about 150 amino acids to about 200 amino acids, from about 200 amino acids to about 3000 amino acids, from about 200 amino acids to about 2500 amino acids, from about 200 amino acids to about 2000 amino acids, from about 200 amino acids to about 1500 amino acids, from about 200 amino acids to about 1000 amino acids, from about 200 amino acids to about 800 amino acids, from about 200 amino acids to about 600 amino acids,about 200 amino acids to about 500 amino acids, about 200 amino acids to about 450 amino acids, about 200 amino acids to about 400 amino acids, about 200 amino acids to about 350 amino acids, about 200 amino acids to about 300 amino acids, about 200 amino acids to about 250 amino acids, about 250 amino acids to about 3000 amino acids, about 250 amino acids to about 2500 amino acids, about 250 amino acids to about 2000 amino acids, about 250 amino acids to about 1500 amino acids, about 250 amino acids to about 1000 amino acids, about 250 amino acids to about 800 amino acids, about 250 amino acids to about 600 amino acids, about 250 amino acids to about 500 amino acids, about 250 amino acids to about 450 amino acids, about 250 amino acids to about 400 amino acids, about 250 amino acids to about 350 amino acids, about 250 amino acids to about 300 amino acids, about 300 amino acids to about 3000 amino acids, about 300 amino acids to about 2500 amino acids, about 300 amino acids to about 2000 amino acids, about 300 amino acids to about 1500 amino acids, about 300 amino acids to about 1000 amino acids, about 300 amino acids to about 800 amino acids, about 300 amino acids to about 600 amino acids, about 300 amino acids to about 500 amino acids, about 300 amino acids to about 450 amino acids, about 3 00 amino acids to about 400 amino acids, about 300 amino acids to about 350 amino acids, about 350 amino acids to about 3000 amino acids, about 350 amino acids to about 2500 amino acids, about 350 amino acids to about 2000 amino acids, about 350 amino acids to about 1500 amino acids, about 350 amino acids to about 1000 amino acids, about 350 amino acids to about 800 amino acids, about 350 amino acids to about 600 amino acids, about 350 amino acids to about 500 amino acids, about 350 amino acids to about 450 amino acids, about 350 amino acids to about 400 amino acids, about 400 amino acids to about 3000 amino acids, about 400 amino acids to about 2 about 400 amino acids to about 3000 amino acids, about 450 amino acids to about 2500 amino acids, about 450 amino acids to about 2000 amino acids, about 400 amino acids to about 1500 amino acids, about 400 amino acids to about 1000 amino acids, about 400 amino acids to about 800 amino acids, about 400 amino acids to about 600 amino acids, about 400 amino acids to about 500 amino acids, about 400 amino acids to about 450 amino acids, about 450 amino acids to about 3000 amino acids, about 450 amino acids to about 2500 amino acids, about 450 amino acids to about 2000 amino acids, about 450 amino acids to about 1500 amino acids, about 450 amino acids to about 1000 amino acids, about 450 amino acids to about 800 amino acids,about 450 amino acids to about 600 amino acids, about 450 amino acids to about 500 amino acids, about 500 amino acids to about 3000 amino acids, about 500 amino acids to about 2500 amino acids, about 500 amino acids to about 2000 amino acids, about 500 amino acids to about 1500 amino acids, about 500 amino acids to about 1000 amino acids, about 500 amino acids to about 800 amino acids, about 500 amino acids to about 600 amino acids, about 600 amino acids to about 3000 amino acids, about 600 amino acids to about 2500 amino acids, about 600 amino acids to about 2000 amino acids, about 600 amino acids to about 1500 amino acids, about 600 amino acids to about 1000 amino acids, about 600 amino acids to about 800 amino acids, about 800 amino acids to about 3000 amino acids, about 800 amino acids to about 2500 amino acids, about 800 amino acids to about 2000 amino acids, about 800 amino acids to about 1500 amino acids, about 800 amino acids to about 1000 amino acids, about 1000 amino acids to about 3000 amino acids, about 1000 amino acids to about 2500 amino acids, about 1000 amino acids to about 2000 amino acids, about 1000 amino acids to about 1500 amino acids, about 1500 amino acids to about 3000 amino acids, about 1500 amino acids to about 2500 amino acids, about 1500 amino acids to about 2000 amino acids, about 2000 amino acids to about 3000 amino acids, about 2000 amino acids to about 2500 amino acids, or about 2500 amino acids to about 3000 amino acids.
[0220] In some embodiments of any of the multi-chain chimeric polypeptides described herein, the first target binding domain (e.g., any first target binding domain described herein) and the soluble tissue factor domain (e.g., any exemplary soluble tissue factor domain described herein) are directly adjacent to each other in the first chimeric polypeptide. In some embodiments of any of the multi-chain chimeric polypeptides described herein, the first chimeric polypeptide further comprises a linker sequence (e.g., any exemplary linker sequence described herein or known in the art) between the first target binding domain (e.g., any exemplary first target binding domain described herein) and the soluble tissue factor domain (e.g., any exemplary soluble tissue factor domain described herein) in the first chimeric polypeptide.
[0221] In some embodiments of any of the multi-chain chimeric polypeptides described herein, the soluble tissue factor domain (e.g., any exemplary soluble tissue factor domain described herein) and the first domain of the affinity domain pair (e.g., any exemplary first domain of any exemplary affinity domain pair described herein) are directly adjacent to each other in the first chimeric polypeptide. In some embodiments of any of the multi-chain chimeric polypeptides described herein, the first chimeric polypeptide further comprises a linker sequence (e.g., any exemplary linker sequence described herein or known in the art) between the soluble tissue factor domain (e.g., any exemplary soluble tissue factor domain described herein) and the first domain of the affinity domain pair (e.g., any exemplary first domain of any exemplary affinity domain pair described herein) in the first chimeric polypeptide.
[0222] In some embodiments of any of the multi-chain chimeric polypeptides described herein, the second domain of the affinity domain pair (e.g., any exemplary second domain of any exemplary affinity domain pair described herein) and the second target binding domain (e.g., any exemplary second target binding domain described herein) are directly adjacent to each other in the second chimeric polypeptide. In some embodiments of any of the multi-chain chimeric polypeptides described herein, the second chimeric polypeptide further comprises a linker sequence (e.g., any exemplary linker sequence described herein or known in the art) between the second domain of the affinity domain pair (e.g., any exemplary second domain of any exemplary affinity domain pair described herein) and the second target binding domain (e.g., any exemplary second target binding domain described herein) in the second chimeric polypeptide.
[0223] Non-limiting aspects of these chimeric polypeptides, nucleic acids, vectors, cells and methods are described below and can be used in any combination without limitation. Other aspects of these chimeric polypeptides, nucleic acids, vectors, cells and methods are known in the art.
[0224] Tissue Factor
[0225] Human tissue factor is a 263-amino acid transmembrane protein consisting of three domains: (1) a 219-amino acid N-terminal extracellular domain (residues 1-219); (2) a 22-amino acid transmembrane domain (residues 220-242); and (3) a 21-amino acid cytoplasmic C-terminal tail (residues 242-263) (UniProtKB identifier: P13726). The cytoplasmic tail contains two phosphorylation sites at Ser253 and Ser258, and an S-palmitoylation site at Cys245. Deletions or mutations in the cytoplasmic domain have not been found to affect the coagulation activity of tissue factor. Tissue factor has an S-palmitoylation site at Cys245 in its intracellular domain. Cys245 is located at the amino-terminal end of the intracellular domain and close to the membrane surface. The tissue factor transmembrane domain consists of a single-spanning α-helix.
[0226] The extracellular domain of tissue factor, composed of two type III fibronectin domains, is connected to the transmembrane domain by a six-amino acid linker. This linker provides conformational flexibility, decoupling the extracellular domain of tissue factor from its transmembrane and cytoplasmic domains. Each tissue factor fibronectin type III module consists of two overlapping β-sheets: the top sheet domain contains three antiparallel β-strands, and the bottom sheet domain contains four β-strands. The β-strands are connected by β-loops between strands βA and βB, βC and βD, and βE and βF, all of which are conformationally conserved in both modules. Three short α-helical segments connect the β-strands. A unique feature of tissue factor is the 17-amino acid β-hairpin between strands β10 and β11, which is not a common element in the fibronectin superfamily. The N-terminal domain also contains a 12-amino acid loop between β6F and β7G, which is not present in the C-terminal domain and is unique to tissue factor. This fibronectin type III domain structure is characteristic of the immunoglobulin-like protein fold family and is conserved in a variety of extracellular proteins.
[0227] Once zymogen FVII binds to tissue to form the active tissue factor-FVIIa complex, it is rapidly converted to FVIIa by limited proteolysis. FVIIa circulates as an enzyme at a concentration of approximately 0.1 nM (1% of plasma FVII) and can also bind directly to tissue factor. The allosteric interaction between tissue factor and FVIIa on the tissue factor-FVIIa complex greatly increases the enzymatic activity of FVIIa: the rate of hydrolysis of small chromogenic peptide substrates is increased by approximately 20-fold to 100-fold, and the rate of activation of the natural macromolecular substrates FIX and FX is increased by nearly a million-fold. Consistent with allosteric activation of the FVIIa active site upon tissue factor binding, formation of the tissue factor-FVIIa complex on the phospholipid bilayer (i.e., after exposure of phosphatidyl-L-serine on the membrane surface) increases the rate of activation of FIX or FX, as measured by Ca. 2+ The tissue factor-FVIIa-phospholipid complex resulted in an overall approximately million-fold increase in FX activation, a key regulatory point in the coagulation cascade, relative to free FVIIa.
[0228] FVII is a single-chain polypeptide of approximately 50 kDa, consisting of 406 amino acid residues, with an N-terminal γ-carboxyglutamic acid (GLA)-rich domain, two epidermal growth factor-like domains (EGF1 and EFG2), and a C-terminal serine protease domain. FVII is expressed through the Ile- 154 -Arg 152 FVIIa is activated by specific proteolytic cleavage of the Cys bond. This cleavage results in the light chain and heavy chain being separated by Cys 135 and Cys 262 FVIIa is held together by a single disulfide bond. 2+ The GLA domain binds to phospholipid membranes in a C-dependent manner. Immediately adjacent to the C-terminus of the GLA domain is an aromatic stack and two EGF domains. The aromatic stack connects GLA to the binding of a single Ca 2+ ion domain of EGF1. 2+ Occupancy of the binding site increases FVIIa amidolytic activity and tissue factor association. The catalytic triad consists of His 193 、Asp 242 and Ser 344 Composed of a single Ca 2+ The binding of ions is crucial for its catalytic activity. FVII is proteolytically activated to FVIIa, which is released at Ile 153 The newly formed amino terminus folds back and inserts into the activation pocket, where it binds to Asp 343The carboxylate salts of FVIIa form a salt bridge, generating an oxyanion pore. This salt bridge formation is crucial for FVIIa activity. However, upon proteolytic activation, oxyanion cavities do not form in free FVIIa. Consequently, FVIIa circulates in a zymogen-like state, which is poorly recognized by plasma protease inhibitors, resulting in a circulation half-life of approximately 90 minutes.
[0229] The tissue factor-mediated positioning of the FVIIa active site above the membrane surface is important for FVIIa to orient toward its cognate substrate. Free FVIIa adopts a stable extended structure when bound to the membrane, with its active site located approximately After FVIIa binds to tissue factor, the FVa active site is relocated closer to the membrane. This regulation may facilitate the correct alignment of the FVIIa catalytic triad with the target substrate cleavage site. Using FVIIa without the GLA domain, it has been shown that the active site remains located at a similar distance above the membrane, demonstrating that tissue factor is able to fully support FVIIa active site positioning even in the absence of FVIIa-membrane interactions. Other data suggest that tissue factor supports full FVIIa proteolytic activity as long as the tissue factor extracellular domain is somehow tethered to the membrane surface. However, raising the FVIIa active site above the membrane surface to greater than It significantly reduces the ability of the tissue factor-FVIIa complex to activate FX, but does not attenuate the tissue factor-FVIIa amidolytic activity.
[0230] Alanine scanning mutagenesis has been used to evaluate the role of specific amino acid side chains in the extracellular domain of tissue factor for interaction with FVIIa (Gibbs et al., Biochemistry 33(47):14003-14010, 1994; Schullek et al., J Biol Chem 269(30):19399-19403, 1994). Alanine substitution identified a limited number of residue positions at which alanine substitution resulted in a 5- to 10-fold decrease in FVIIa binding affinity. The majority of these residue side chains were found to be well exposed to solvent in the crystal structure, consistent with a macromolecular ligand interaction. The FVIIa ligand binding site is located in a broad region at the boundary between the two modules. In the C-module, the residue Arg located on the protruding BC loop is located in the C-module. 135 and Phe 140 Provides independent contact with FVIIa. 133 Located at the bottom of the finger structure and fills the gap between the two modules. 20 、Thr 60 、Asp 58and Ile 22 The main cluster of important binding residues provides continuity. 60 Only partially exposed to solvent, it may play a local structural role rather than making significant contacts with the ligand. The binding site extends to the concave side of the intermodule angle and involves Glu 24 and Gln 110 , and possibly the more distant residue Val 207 The binding region extends from Asp58 to the region bound by Lys 48 、Lys 46 、Gln 37 、Asp 44 and Trp 45 Trp 45 and Asp 44 does not interact independently with FVIIa, suggesting that the effect of mutation at Trp45 may reflect the effect of this side chain on the adjacent Asp 44 and Gln 37 The interaction region further includes two surface-exposed aromatic residues, Phe 76 and Tyr 78 , which form part of the hydrophobic cluster in the N-module.
[0231] The known physiological substrates of tissue factor-FVIIa are FVII, FIX and FX and certain protease-activated receptors. Mutational analysis has identified a number of residues that, when mutated, support intact FVIIa amidolytic activity towards small peptide substrates but lack the ability to support activation of macromolecular substrates (i.e., FVII, FIX and FX) (Ruf et al., J Biol Chem [Biochemistry] 267(31):22206-22210, 1992; Ruf et al., J Biol Chem [Biochemistry] 267(9):6375-6381, 1992; Huang et al., J Biol Chem [Biochemistry] 271(36):21752-21757, 1996; Kirchhofer et al., Biochemistry [Biochemistry] 39(25):7380-7387, 2000). The tissue factor loop region at residues 159-165, as well as residues within or adjacent to this flexible loop, has been shown to be critical for the proteolytic activity of the tissue factor-FVIIa complex. This defines a proposed substrate binding exosite region of tissue factor that is quite distant from the FVIIa active site. Substitution of glycine residues with slightly larger alanine residues significantly impairs tissue factor-FVIIa proteolytic activity. This suggests that the flexibility provided by glycine is crucial for the residues 159-165 loop to recognize macromolecular substrates of tissue factor.
[0232] Lys residue 165 and Lys 166 It has also been shown to be important for substrate recognition and binding. Mutation of any of these residues to alanine results in a significant reduction in tissue factor cofactor function. Lys 165 and Lys 166 With their backs to each other, Lys 165 In most tissue factor-FVIIa structures, it points toward FVIIa, while Lys 166 Pointing to the substrate binding exosite region in the crystal structure. Lys 165 and Gla 35 The putative salt bridge formation between them supports the view that tissue factor interacts with the GLA domain of FVIIa to regulate substrate recognition. These results suggest that the C-terminal portion of the tissue factor extracellular domain directly interacts with the GLA domains of FIX and FX (and possibly the adjacent EGF1 domain), and that the presence of the FVIIa GLA domain may directly or indirectly regulate these interactions.
[0233] Soluble tissue factor domain
[0234] In some embodiments of any polypeptide, composition, or method described herein, the soluble tissue factor domain can be a wild-type tissue factor polypeptide lacking a signal sequence, a transmembrane domain, and an intracellular domain. In some instances, the soluble tissue factor domain can be a tissue factor mutant, wherein the wild-type tissue factor polypeptide lacks a signal sequence, a transmembrane domain, and an intracellular domain and has been further modified at selected amino acids. In some instances, the soluble tissue factor domain can be a soluble human tissue factor domain. In some instances, the soluble tissue factor domain can be a soluble mouse tissue factor domain. In some instances, the soluble tissue factor domain can be a soluble rat tissue factor domain. Non-limiting examples of soluble human tissue factor domains, mouse soluble tissue factor domains, rat soluble tissue factor domains, and mutant soluble tissue factor domains are as follows. Exemplary soluble human tissue factor domain (SEQ ID NO: 1)
[0235] SGTTNTVAAYNLTWKSTNFKTILEWEPKPVNQVYTVQISTKSGDWKSKCF
[0236] YTTDTECDLTDEIVKDVKQTYLARVFSYPAGNVESTGSAGEPLYENSPEFTP
[0237] YLETNLGQPTIQSFEQVGTKVNVTVEDERTLVRRNNTFLSLRDVFGKDLIYT
[0238] LYYWKSSSSGKKTAKTNTNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTDS
[0239] PVECMGQEKGEFRE
[0240] Exemplary nucleic acid encoding a soluble human tissue factor domain (SEQ ID NO:2) <GCAAGAAGACAGCTAAAACCAACACAAACGAGTTTTTAATCGACGTGG
[0252] ATAAAGGCGAAAACTACTGTTTCAGCGTGCAAGCTGTGATCCCCTCCCG
[0253] GACCGTGAATAGGAAAAGCACCGATAGCCCCGTTGAGTGCATGGGCCA
[0254] AGAAAAGGGCGAGTTCCGGGAG
[0255] Exemplary mutant soluble human tissue factor domain (SEQ ID NO: 3)
[0256] SGTTNTVAAYNLTWKSTNFATALEWEPKPVNQVYTVQISTKSGDWKSKCF
[0257] YTTDTECALTDEIVKDVKQTYLARVFSYPAGNVESTGSAGEPLYENSPEFTP
[0258] YLETNLGQPTIQSFEQVGTKVNVTVEDERTLVARNNTALSLRDVFGKDLIY
[0259] TLYYWKSSSSGKKTAKTNTNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTD
[0260] SPVECMGQEKGEFRE
[0261] Exemplary mutant soluble human tissue factor domain (SEQ ID NO: 4)
[0262] SGTTNTVAAYNLTWKSTNFATALEWEPKPVNQVYTVQISTKSGDAKSKCF
[0263] YTTDTECALTDEIVKDVKQTYLARVFSYPAGNVESTGSAGEPLAENSPEFTP
[0264] YLETNLGQPTIQSFEQVGTKVNVTVEDERTLVARNNTALSLRDVFGKDLIY
[0265] TLYYWKSSSSGKKTAKTNTNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTD
[0266] SPVECMGQEKGEFRE
[0267] Exemplary soluble mouse tissue factor domain (SEQ ID NO: 5)
[0268] agipekafnltwistdfktilewqpkptnytytvqisdrsrnwknkcfsttdtecdltdeivkdvtwayeakvlsvprr
[0269] nsvhgdgdqlvihgeeppftnapkflpyrdtnlgqpviqqfeqdgrklnvvvkdsltlvrkngtfltlrqvfgkdlgyi
[0270] ityrkgsstgkktnitntnefsidveegvsycffvqamifsrktnqnspgsstvcteqwksflge
[0271] Exemplary soluble rat tissue factor domain (SEQ ID NO: 6)
[0272] Agtppgkafnltwistdfktilewqpkptnytytvqisdrsrnwkykctgttdtecdltdeivkdvnwtyearvlsvp
[0273] wrnsthgketlfgthgeeppftnarkflpyrdtkigqpviqkyeqggtklkvtvkdsftlvrkngtfltlrqvfgndlgy
[0274] iltyrkdsstgrktntthtneflidvekgvsycffaqavifsrktnhkspesitkcteqwksvlge
[0275] In some embodiments, the soluble tissue factor domain can comprise a sequence that is at least 70% identical, at least 72% identical, at least 74% identical, at least 76% identical, at least 78% identical, at least 80% identical, at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical to SEQ ID NO: 1, 3, 4, 5, or 6. In some embodiments, the soluble tissue factor domain can comprise the sequence of SEQ ID NO: 1, 3, 4, 5, or 6, wherein one to twenty amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) amino acids are removed from its N-terminus and / or one to twenty amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) amino acids are removed from its C-terminus.
[0276] As understood in the art, those skilled in the art understand that mutations in amino acids that are conserved between different mammalian species are more likely to reduce the activity and / or structural stability of a protein, while mutations in amino acids that are not conserved between different mammalian species are less likely to reduce the activity and / or structural stability of a protein.
[0277] In some embodiments of any multi-chain chimeric polypeptides described herein, the soluble tissue factor domain is unable to bind to Factor VIIa. In some embodiments of any multi-chain chimeric polypeptides described herein, the soluble tissue factor domain does not convert inactive Factor X into Factor Xa. In some embodiments of any multi-chain chimeric polypeptides described herein, the multi-chain chimeric polypeptide does not stimulate blood coagulation in mammals. In some embodiments of any single-chain chimeric polypeptides provided herein, the human soluble tissue factor domain does not initiate blood coagulation.
[0278] In some instances, the soluble tissue factor domain can be a soluble human tissue factor domain. In some embodiments, the soluble tissue factor domain can be a soluble mouse tissue factor domain. In some embodiments, the soluble tissue factor domain can be a soluble rat tissue factor domain.
[0279] In some examples, the soluble tissue factor domain does not include one or more (e.g., two, three, four, five, six, or seven) of the following: a lysine at an amino acid position corresponding to amino acid position 20 of a mature wild-type human tissue factor protein; an isoleucine at an amino acid position corresponding to amino acid position 22 of a mature wild-type human tissue factor protein; a tryptophan at an amino acid position corresponding to amino acid position 45 of a mature wild-type human tissue factor protein; an aspartic acid at an amino acid position corresponding to amino acid position 58 of a mature wild-type human tissue factor protein; a tyrosine at an amino acid position corresponding to amino acid position 94 of a mature wild-type human tissue factor protein; an arginine at an amino acid position corresponding to amino acid position 135 of a mature wild-type human tissue factor protein; and a phenylalanine at an amino acid position corresponding to amino acid position 140 of a mature wild-type human tissue factor protein. In some embodiments, the mutant soluble tissue factor has an amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4.
[0280] In some examples, the soluble tissue factor domain can be encoded by a nucleic acid comprising a sequence that is at least 70% identical, at least 72% identical, at least 74% identical, at least 76% identical, at least 78% identical, at least 80% identical, at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical to SEQ ID NO:2.
[0281] In some embodiments, the soluble tissue factor domain can have a total length of about 20 amino acids to about 220 amino acids, about 20 amino acids to about 215 amino acids, about 20 amino acids to about 210 amino acids, about 20 amino acids to about 205 amino acids, about 20 amino acids to about 200 amino acids, about 20 amino acids to about 195 amino acids, about 20 amino acids to about 190 amino acids, about 20 amino acids to about 185 amino acids, about 20 amino acids to about 180 amino acids, about 20 amino acids to about 160 amino acids, about 20 amino acids to about 140 amino acids, about 20 amino acids to about 120 amino acids, about 20 amino acids to about 100 amino acids. , about 20 amino acids to about 80 amino acids, about 20 amino acids to about 60 amino acids, about 20 amino acids to about 40 amino acids, about 40 amino acids to about 220 amino acids, about 40 amino acids to about 215 amino acids, about 40 amino acids to about 210 amino acids, about 40 amino acids to about 205 amino acids, about 40 amino acids to about 200 amino acids, about 40 amino acids to about 195 amino acids, about 40 amino acids to about 190 amino acids, about 40 amino acids to about 185 amino acids, about 40 amino acids to about 180 amino acids, about 40 amino acids to about 160 amino acids, about 40 amino acids to about 140 amino acids, about 40 amino acids to about 120 amino acids, about 40 amino acids to about 100 amino acids, about 40 amino acids to about 80 amino acids, about 40 amino acids to about 60 amino acids, about 60 amino acids to about 220 amino acids, about 60 amino acids to about 215 amino acids, about 60 amino acids to about 210 amino acids, about 60 amino acids to about 205 amino acids, about 60 amino acids to about 200 amino acids, about 60 amino acids to about 195 amino acids, about 60 amino acids to about 190 amino acids, about 60 amino acids to about 185 amino acids, about 60 amino acids to about 180 amino acids, about 60 amino acids to about 160 amino acids, about 60 amino acids to about 140 amino acids, about 60 amino acids amino acids to about 120 amino acids, about 60 amino acids to about 100 amino acids, about 60 amino acids to about 80 amino acids, about 80 amino acids to about 220 amino acids, about 80 amino acids to about 215 amino acids, about 80 amino acids to about 210 amino acids, about 80 amino acids to about 205 amino acids, about 80 amino acids to about 200 amino acids, about 80 amino acids to about 195 amino acids, about 80 amino acids to about 190 amino acids, about 80 amino acids to about 185 amino acids, about 80 amino acids to about 180 amino acids, about 80 amino acids to about 160 amino acids, about 80 amino acids to about 140 amino acids, about 80 amino acids to about 120 amino acids,about 80 amino acids to about 100 amino acids, about 100 amino acids to about 220 amino acids, about 100 amino acids to about 215 amino acids, about 100 amino acids to about 210 amino acids, about 100 amino acids to about 205 amino acids, about 100 amino acids to about 200 amino acids, about 100 amino acids to about 195 amino acids, about 100 amino acids to about 190 amino acids, about 100 amino acids to about 185 amino acids, about 100 amino acids to about 180 amino acids, about 100 amino acids to about 160 amino acids, about 100 amino acids to about 140 amino acids, about 100 amino acids to about 120 amino acids, about 120 amino acids to about 220 amino acids, about 120 amino acids to about 215 amino acids, about 120 amino acids to about 210 amino acids, about 120 amino acids to about 205 amino acids, about 120 amino acids to about 200 amino acids, about 120 amino acids to about 195 amino acids, about 120 amino acids to about 190 amino acids, about 120 amino acids to about 185 amino acids, about 120 amino acids to about 180 amino acids, about 120 amino acids to about 160 amino acids, about 120 amino acids to about 140 amino acids, about 140 amino acids to about 220 amino acids, about 140 amino acids to about 215 amino acids, about 140 amino acids to about 210 amino acids, about 140 amino acids to about 205 amino acids, about 140 amino acids to about 200 amino acids, about 140 amino acids to about 195 amino acids, about 140 amino acids to about 190 amino acids, about 140 amino acids to about 185 amino acids, about 140 amino acids to about 180 amino acids, about 140 amino acids to about 160 amino acids, about 160 amino acids to about 220 amino acids, about 160 amino acids to about 215 amino acids, about 160 amino acids to about 210 amino acids, about 160 amino acids to about 205 amino acids, about 160 amino acids to about 200 amino acids, about 160 amino acids to about 195 amino acids, about 160 amino acids to about 190 amino acids, about 160 amino acids to about 185 amino acids, about 160 amino acids to about 180 amino acids, about 180 amino acids to about 220 amino acids, about 180 amino acids to about 215 amino acids, about 180 amino acids to about 210 amino acids, about 180 amino acids to about 205 amino acids, about 180 amino acids to about 200 amino acids, about 180 amino acids to about 195 amino acids, about 180 amino acids to about 190 amino acids, about 180 amino acids to about 185 amino acids, about 185 amino acids to about 220 amino acids, about 185 amino acids to about 215 amino acids, about 185 amino acids to about 210 amino acids, about 185 amino acids to about 205 amino acids,about 185 amino acids to about 200 amino acids, about 185 amino acids to about 195 amino acids, about 185 amino acids to about 190 amino acids, about 190 amino acids to about 220 amino acids, about 190 amino acids to about 215 amino acids, about 190 amino acids to about 210 amino acids, about 190 amino acids to about 205 amino acids, about 190 amino acids to about 200 amino acids, about 190 amino acids to about 195 amino acids, about 195 amino acids to about 220 amino acids, about 195 amino acids to about 215 amino acids, about 195 amino acids to about 210 amino acids, about 195 amino acids to about 205 amino acids, about 195 amino acids to about 200 amino acids, about 200 amino acids to about 220 amino acids, about 200 amino acids to about 215 amino acids, about 200 amino acids to about 210 amino acids, about 200 amino acids to about 205 amino acids, about 205 amino acids to about 220 amino acids, about 205 amino acids to about 215 amino acids, about 205 amino acids to about 210 amino acids, about 210 amino acids to about 220 amino acids, about 210 amino acids to about 215 amino acids, or about 215 amino acids to about 220 amino acids.
[0282] Adapter sequence
[0283] In some embodiments, the linker sequence can be a flexible linker sequence. Non-limiting examples of linker sequences that can be used are described in Klein et al., Protein Engineering, Design & Selection 27(10):325–330, 2014; Priyanka et al., Protein Sci. 22(2):153–167, 2013. In some instances, the linker sequence is a synthetic linker sequence.
[0284] In some embodiments of any multi-chain chimeric polypeptides described herein, the first chimeric polypeptide can include one, two, three, four, five, six, seven, eight, nine, or ten linker sequences (e.g., the same or different linker sequences, such as any of the exemplary linker sequences described herein or known in the art). In some embodiments of any multi-chain chimeric polypeptides described herein, the second chimeric polypeptide can include one, two, three, four, five, six, seven, eight, nine, or ten linker sequences (e.g., the same or different linker sequences, such as any of the exemplary linker sequences described herein or known in the art).
[0285] In some embodiments, the linker sequence can have a total length of 1 amino acid to about 100 amino acids, 1 amino acid to about 90 amino acids, 1 amino acid to about 80 amino acids, 1 amino acid to about 70 amino acids, 1 amino acid to about 60 amino acids, 1 amino acid to about 50 amino acids, 1 amino acid to about 40 amino acids, 1 amino acid to about 30 amino acids, 1 amino acid to about 25 amino acids, 1 amino acid to about 20 amino acids, 1 amino acid to about 15 amino acids, 1 amino acid to about 10 amino acids, 1 amino acid to about 8 amino acids, 1 amino acid to about 6 amino acids, 1 amino acid to about 4 amino acids, about 2 amino acids to about 100 amino acids, about 2 amino acids to about 90 amino acids, about 2 amino acids to about 80 amino acids, about 2 amino acids to about 70 amino acids, about 2 amino acids to about 60 amino acids, about 2 amino acids to about 50 amino acids, about 2 amino acids to about 40 amino acids, about 2 amino acids to about 30 amino acids, about 2 amino acids to about 25 amino acids, about 2 amino acids to about 20 amino acids, about 2 amino acids to about 15 amino acids, about 2 amino acids to about 10 amino acids, about 2 amino acids to about 8 amino acids, about 2 amino acids to about 6 amino acids, about 2 amino acids to about 4 amino acids, about 4 amino acids to about 100 amino acids, about 4 amino acids to about 90 amino acids, about 4 amino acids to about 80 amino acids, amino acids, about 4 amino acids to about 70 amino acids, about 4 amino acids to about 60 amino acids, about 4 amino acids to about 50 amino acids, about 4 amino acids to about 40 amino acids, about 4 amino acids to about 30 amino acids, about 4 amino acids to about 25 amino acids, about 4 amino acids to about 20 amino acids, about 4 amino acids to about 15 amino acids, about 4 amino acids to about 10 amino acids, about 4 amino acids to about 8 amino acids, about 4 amino acids to about 6 amino acids, about 6 amino acids to about 100 amino acids, about 6 amino acids to about 90 amino acids, about 6 amino acids to about 80 amino acids, about 6 amino acids to about 70 amino acids, about 6 amino acids to about 60 amino acids, about 6 amino acids to about about 50 amino acids, about 6 amino acids to about 40 amino acids, about 6 amino acids to about 30 amino acids, about 6 amino acids to about 25 amino acids, about 6 amino acids to about 20 amino acids, about 6 amino acids to about 15 amino acids, about 6 amino acids to about 10 amino acids, about 6 amino acids to about 8 amino acids, about 8 amino acids to about 100 amino acids, about 8 amino acids to about 90 amino acids, about 8 amino acids to about 80 amino acids, about 8 amino acids to about 70 amino acids, about 8 amino acids to about 60 amino acids, about 8 amino acids to about 50 amino acids, about 8 amino acids to about 40 amino acids, about 8 amino acids to about 30 amino acids, about 8 amino acids to about 25 amino acids,about 8 amino acids to about 20 amino acids, about 8 amino acids to about 15 amino acids, about 8 amino acids to about 10 amino acids, about 10 amino acids to about 100 amino acids, about 10 amino acids to about 90 amino acids, about 10 amino acids to about 80 amino acids, about 10 amino acids to about 70 amino acids, about 10 amino acids to about 60 amino acids, about 10 amino acids to about 50 amino acids, about 10 amino acids to about 40 amino acids, about 10 amino acids to about 30 amino acids, about 10 amino acids to about 25 amino acids, about 10 amino acids to about 20 amino acids, about 10 amino acids to about 15 amino acids, about 15 amino acids to about 100 amino acids, about 15 amino acids to about 9 0 amino acids, about 15 amino acids to about 80 amino acids, about 15 amino acids to about 70 amino acids, about 15 amino acids to about 60 amino acids, about 15 amino acids to about 50 amino acids, about 15 amino acids to about 40 amino acids, about 15 amino acids to about 30 amino acids, about 15 amino acids to about 25 amino acids, about 15 amino acids to about 20 amino acids, about 20 amino acids to about 100 amino acids, about 20 amino acids to about 90 amino acids, about 20 amino acids to about 80 amino acids, about 20 amino acids to about 70 amino acids, about 20 amino acids to about 60 amino acids, about 20 amino acids to about 50 amino acids, about 20 amino acids to about 40 amino acids, about 2 0 amino acids to about 30 amino acids, about 20 amino acids to about 25 amino acids, about 25 amino acids to about 100 amino acids, about 25 amino acids to about 90 amino acids, about 25 amino acids to about 80 amino acids, about 25 amino acids to about 70 amino acids, about 25 amino acids to about 60 amino acids, about 25 amino acids to about 50 amino acids, about 25 amino acids to about 40 amino acids, about 25 amino acids to about 30 amino acids, about 30 amino acids to about 100 amino acids, about 30 amino acids to about 90 amino acids, about 30 amino acids to about 80 amino acids, about 30 amino acids to about 70 amino acids, about 30 amino acids to about 60 amino acids, about 30 amino acids to about 50 amino acids, about 30 amino acids to about 40 amino acids, about 40 amino acids to about 100 amino acids, about 40 amino acids to about 90 amino acids, about 40 amino acids to about 80 amino acids, about 40 amino acids to about 70 amino acids, about 40 amino acids to about 60 amino acids, about 40 amino acids to about 50 amino acids, about 50 amino acids to about 100 amino acids, about 50 amino acids to about 90 amino acids, about 50 amino acids to about 80 amino acids, about 50 amino acids to about 70 amino acids, about 50 amino acids to about 60 amino acids, about 60 amino acids to about 100 amino acids, about 60 amino acids to about 90 amino acids, about 60 amino acids to about 80 amino acids,about 60 amino acids to about 70 amino acids, about 70 amino acids to about 100 amino acids, about 70 amino acids to about 90 amino acids, about 70 amino acids to about 80 amino acids, about 80 amino acids to about 100 amino acids, about 80 amino acids to about 90 amino acids, or about 90 amino acids to about 100 amino acids.
[0286] In some embodiments, the linker is rich in glycine (Gly or G) residues. In some embodiments, the linker is rich in serine (Ser or S) residues. In some embodiments, the linker is rich in glycine and serine residues. In some embodiments, the linker has one or more glycine-serine residue pairs (GS), such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more GS pairs. In some embodiments, the linker has one or more Gly-Gly-Gly-Ser (GGGS) sequences, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more GGGS sequences. In some embodiments, the linker has one or more Gly-Gly-Gly-Gly-Ser (GGGGS) sequences, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more GGGGS sequences. In some embodiments, the linker has one or more Gly-Gly-Ser-Gly (GGSG) sequences, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more GGSG sequences.
[0287] In some embodiments, the linker sequence may comprise or consist of: GGGGSGGGGSGGGGS (SEQ ID NO: 7). In some embodiments, the linker sequence may be encoded by a nucleic acid comprising or consisting of: GGCGGTGGAGGATCCGGAGGAGGTGGCTCCGGCGGCGGAGGATCT (SEQ ID NO: 8). In some embodiments, the linker sequence may comprise or consist of: GGGSGGGS (SEQ ID NO: 9).
[0288] target binding domain
[0289] In some embodiments of any of the multi-chain chimeric polypeptides described herein, the first target binding domain, the second target binding domain, and / or the additional one or more target binding domains can be antigen binding domains (e.g., any exemplary antigen binding domains described herein or known in the art), soluble interleukin or cytokine proteins (e.g., any exemplary soluble interleukin proteins or soluble cytokine proteins described herein), and soluble interleukin or cytokine receptors (e.g., any exemplary soluble interleukin receptors or soluble cytokine receptors described herein).
[0290] In some embodiments of any of the multi-chain chimeric polypeptides described herein, one or both of the first target binding domain and the second target binding domain are antigen binding domains. In some embodiments of any of the multi-chain chimeric polypeptides described herein, one or both of the first target binding domain and the second target binding domain are soluble interleukin or cytokine receptors.
[0291] In some embodiments of any of the multi-chain chimeric polypeptides described herein, the first chimeric polypeptide further comprises one or more additional target binding domains. In some embodiments of any of the multi-chain chimeric polypeptides described herein, the second chimeric polypeptide further comprises one or more additional target binding domains.
[0292] In some embodiments of any of the multi-chain chimeric polypeptides described herein, the one or more additional target binding domains can each independently specifically bind to a target selected from the group consisting of: CD16a, CD28, CD3 (e.g., one or more of CD3α, CD3β, CD3δ, CD3ε, and CD3γ), CD33, CD20, CD19, CD22, CD123, IL-1R, IL-1, VEGF, IL-6R, IL-4, IL-10, PDL-1, TIGIT, PD-1, TIM3, CTLA4, MICA, MICB, IL-6, IL-8, TNFα, CD26a, CD36, ULBP2, CD30, CD20, 0, IGF-1R, MUC4AC, MUC5AC, Trop-2, CMET, EGFR, HER1, HER2, HER3, PSMA, CEA, B7H3, EPCAM, BCMA, P-cadherin, CEACAM5, UL16 binding proteins (e.g., ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, and ULBP6), HLA-DR, DLL4, TYRO3, AXL, MER, CD122, CD155, PDGF-DD, ligands of TGF-β receptor II (TGF-βRII), ligands of TGF-βRIII, ligands of DNAM-1, ligands of NKp46, ligands of NKp44, ligands of NKG2D, NK P30 ligand, scMHCI ligand, scMHCII ligand, scTCR ligand, IL-1 receptor, IL-2 receptor, IL-3 receptor, IL-7 receptor, IL-8 receptor, IL-10 receptor, IL-12 receptor, IL-15 receptor, IL-17 receptor, IL-18 receptor, IL-21 receptor, PDGF-DD receptor, stem cell factor (SCF) receptor, stem cell-like tyrosine kinase 3 ligand (FLT3L) receptor, MICA receptor, MICB receptor, ULP16 binding protein receptor, CD155 receptor, CD122 receptor and CD28 receptor.
[0293] In some embodiments of any of the multi-chain chimeric polypeptides described herein, the first target binding domain, the second target binding domain, and / or the one or more additional target binding domains can each independently have the following total number of amino acids: about 5 amino acids to about 1000 amino acids, about 5 amino acids to about 900 amino acids, about 5 amino acids to about 800 amino acids, about 5 amino acids to about 700 amino acids, about 5 amino acids to about 600 amino acids, about 5 amino acids to about 500 amino acids, about 5 amino acids to about 400 amino acids, about 5 amino acids to about 300 amino acids, about 5 amino acids to about 280 amino acids, about 5 amino acids to about 260 amino acids, about 5 amino acids to about 240 amino acids. , about 5 amino acids to about 220 amino acids, about 5 amino acids to about 200 amino acids, about 5 amino acids to about 180 amino acids, about 5 amino acids to about 160 amino acids, about 5 amino acids to about 140 amino acids, about 5 amino acids to about 120 amino acids, about 5 amino acids to about 100 amino acids, about 5 amino acids to about 80 amino acids, about 5 amino acids to about 60 amino acids, about 5 amino acids to about 40 amino acids, about 5 amino acids to about 20 amino acids, about 5 amino acids to about 10 amino acids, about 10 amino acids to about 1000 amino acids, about 10 amino acids to about 900 amino acids, about 10 amino acids to about 800 amino acids, about 10 amino acids to about 700 amino acids, about 10 amino acids to about 600 amino acids, about 10 amino acids to about 500 amino acids, about 10 amino acids to about 400 amino acids, about 10 amino acids to about 300 amino acids, about 10 amino acids to about 280 amino acids, about 10 amino acids to about 260 amino acids, about 10 amino acids to about 240 amino acids, about 10 amino acids to about 220 amino acids, about 10 amino acids to about 200 amino acids, about 10 amino acids to about 180 amino acids, about 10 amino acids to about 160 amino acids, about 10 amino acids to about 140 amino acids, about 10 amino acids to about 120 amino acids, about 10 amino acids to about 100 amino acids, about 10 about 20 amino acids to about 500 amino acids, about 20 amino acids to about 400 amino acids, about 20 amino acids to about 300 amino acids, about 20 amino acids to about 280 amino acids, about 20 amino acids to about 260 amino acids, about 20 amino acids to about 240 amino acids, about 20 amino acids to about 360 amino acids, about 20 amino acids to about 370 amino acids, about 20 amino acids to about 400 amino acids, about 20 amino acids to about 500 amino acids, about 20 amino acids to about 600 amino acids, about 20 amino acids to about 700 amino acids, about 20 amino acids to about 800 amino acids, about 20 amino acids to about 900 amino acids, about 20 amino acids to about 800 amino acids, about 20 amino acids to about 700 amino acids, about 20 amino acids to about 600 amino acids, about 20 amino acids to about 500 amino acids, about 20 amino acids to about 400 amino acids, about 20 amino acids to about 300 amino acids, about 20 amino acids to about 280 amino acids, about 20 amino acids to about 260 amino acids, about 20 amino acids to about 240 amino acids,about 20 amino acids to about 220 amino acids, about 20 amino acids to about 200 amino acids, about 20 amino acids to about 180 amino acids, about 20 amino acids to about 160 amino acids, about 20 amino acids to about 140 amino acids, about 20 amino acids to about 120 amino acids, about 20 amino acids to about 100 amino acids, about 20 amino acids to about 80 amino acids, about 20 amino acids to about 60 amino acids, about 20 amino acids to about 40 amino acids, about 40 amino acids to about 1000 amino acids, about 40 amino acids to about 900 amino acids, about 40 amino acids to about 800 amino acids, about 40 amino acids to about 700 amino acids, about 40 amino acids to about 600 amino acids, about 20 amino acids to about 400 amino acids, about 40 amino acids to about 800 amino acids, about 40 amino acids to about 900 amino acids, about 40 amino acids to about 10 ... amino acids, about 40 amino acids to about 500 amino acids, about 40 amino acids to about 400 amino acids, about 40 amino acids to about 300 amino acids, about 40 amino acids to about 280 amino acids, about 40 amino acids to about 260 amino acids, about 40 amino acids to about 240 amino acids, about 40 amino acids to about 220 amino acids, about 40 amino acids to about 200 amino acids, about 40 amino acids to about 180 amino acids, about 40 amino acids to about 160 amino acids, about 40 amino acids to about 140 amino acids, about 40 amino acids to about 120 amino acids, about 40 amino acids to about 100 amino acids, about 40 amino acids to about 80 amino acids, about 40 amino acids to about 6 0 amino acids, about 60 amino acids to about 1000 amino acids, about 60 amino acids to about 900 amino acids, about 60 amino acids to about 800 amino acids, about 60 amino acids to about 700 amino acids, about 60 amino acids to about 600 amino acids, about 60 amino acids to about 500 amino acids, about 60 amino acids to about 400 amino acids, about 60 amino acids to about 300 amino acids, about 60 amino acids to about 280 amino acids, about 60 amino acids to about 260 amino acids, about 60 amino acids to about 240 amino acids, about 60 amino acids to about 220 amino acids, about 60 amino acids to about 200 amino acids, about 60 amino acids to about 180 amino acids, about 60 amino acids to about 260 amino acids, about 60 amino acids to about 240 amino acids, about 60 amino acids to about 220 amino acids, about 60 amino acids to about 200 amino acids, about 60 amino acids to about 180 amino acids, about 60 amino acids to about 80 amino acids to about 500 amino acids, about 80 amino acids to about 400 amino acids, about 80 amino acids to about 300 amino acids, about 80 amino acids to about 280 amino acids, about 80 amino acids to about 260 amino acids, about 80 amino acids to about 150 amino acids, about 80 amino acids to about 260 amino acids, about 80 amino acids to about 300 amino acids, about 80 amino acids to about 400 amino acids, about 80 amino acids to about 500 amino acids, about 80 amino acids to about 600 amino acids, about 80 amino acids to about 700 amino acids, about 80 amino acids to about 800 amino acids, about 80 amino acids to about 800 amino acids, about 80 amino acids to about 900 amino acids, about 80 amino acids to about 800 amino acids, about 80 amino acids to about 900 amino acids, about 80 amino acids to about 800 amino acids, about 80 amino acids to about 800 amino acids, about 80 amino acids to about 800 amino acids,about 80 amino acids to about 240 amino acids, about 80 amino acids to about 220 amino acids, about 80 amino acids to about 200 amino acids, about 80 amino acids to about 180 amino acids, about 80 amino acids to about 160 amino acids, about 80 amino acids to about 140 amino acids, about 80 amino acids to about 120 amino acids, about 80 amino acids to about 100 amino acids, about 100 amino acids to about 1000 amino acids, about 100 amino acids to about 900 amino acids, about 100 amino acids to about 800 amino acids, about 100 amino acids to about 700 amino acids, about 100 amino acids to about 600 amino acids, about 100 amino acids to about 500 amino acids, about 100 amino acids to about 400 amino acids, about 100 amino acids to about 300 amino acids, about 100 amino acids to about 280 amino acids, about 100 amino acids to about 260 amino acids, about 100 amino acids to about 240 amino acids, about 100 amino acids to about 220 amino acids, about 100 amino acids to about 200 amino acids, about 100 amino acids to about 180 amino acids, about 100 amino acids to about 160 amino acids, about 100 amino acids to about 140 amino acids, about 100 amino acids to about 120 amino acids, about 120 amino acids to about 1000 amino acids, about 120 amino acids to about 900 amino acids, about 120 amino acids to about 80 0 amino acids, about 120 amino acids to about 700 amino acids, about 120 amino acids to about 600 amino acids, about 120 amino acids to about 500 amino acids, about 120 amino acids to about 400 amino acids, about 120 amino acids to about 300 amino acids, about 120 amino acids to about 280 amino acids, about 120 amino acids to about 260 amino acids, about 120 amino acids to about 240 amino acids, about 120 amino acids to about 220 amino acids, about 120 amino acids to about 200 amino acids, about 120 amino acids to about 180 amino acids, about 120 amino acids to about 160 amino acids, about 120 amino acids to about 140 amino acids, about 120 amino acids to about 140 amino acids, about 120 amino acids to about 160 amino acids, about 120 amino acids to about 170 amino acids, about 120 amino acids to about 170 amino acids, about 120 amino acids to about 180 amino acids, about 120 amino acids to about 190 amino acids, about 19 ... 140 amino acids to about 1000 amino acids, about 140 amino acids to about 900 amino acids, about 140 amino acids to about 800 amino acids, about 140 amino acids to about 700 amino acids, about 140 amino acids to about 600 amino acids, about 140 amino acids to about 500 amino acids, about 140 amino acids to about 400 amino acids, about 140 amino acids to about 300 amino acids, about 140 amino acids to about 280 amino acids, about 140 amino acids to about 260 amino acids, about 140 amino acids to about 240 amino acids, about 140 amino acids to about 220 amino acids, about 140 amino acids to about 200 amino acids, about 140 amino acids to about 180 amino acids,about 140 amino acids to about 160 amino acids, about 160 amino acids to about 1000 amino acids, about 160 amino acids to about 900 amino acids, about 160 amino acids to about 800 amino acids, about 160 amino acids to about 700 amino acids, about 160 amino acids to about 600 amino acids, about 160 amino acids to about 500 amino acids, about 160 amino acids to about 400 amino acids, about 160 amino acids to about 300 amino acids, about 160 amino acids to about 280 amino acids, about 160 amino acids to about 260 amino acids, about 160 amino acids to about 240 amino acids, about 160 amino acids to about 220 amino acids, about 160 amino acids to about 200 amino acids, about 160 amino acids to about 180 amino acids, about 180 amino acids to about 1000 amino acids, about 180 amino acids to about 900 amino acids, about 180 amino acids to about 800 amino acids, about 180 amino acids to about 700 amino acids, about 180 amino acids to about 600 amino acids, about 180 amino acids to about 500 amino acids, about 180 amino acids to about 400 amino acids, about 180 amino acids to about 300 amino acids, about 180 amino acids to about 280 amino acids, about 180 amino acids to about 260 amino acids, about 180 amino acids to about 240 amino acids, about 180 amino acids to about 220 amino acids, about 180 amino acids to about 2 about 200 amino acids, about 200 amino acids to about 1000 amino acids, about 200 amino acids to about 900 amino acids, about 200 amino acids to about 800 amino acids, about 200 amino acids to about 700 amino acids, about 200 amino acids to about 600 amino acids, about 200 amino acids to about 500 amino acids, about 200 amino acids to about 400 amino acids, about 200 amino acids to about 300 amino acids, about 200 amino acids to about 280 amino acids, about 200 amino acids to about 260 amino acids, about 200 amino acids to about 240 amino acids, about 200 amino acids to about 220 amino acids, about 220 amino acids to about 1000 amino acids, about 220 amino acids to about 900 amino acids, about 220 amino acids to about 800 amino acids, about 220 amino acids to about 700 amino acids, about 220 amino acids to about 600 amino acids, about 220 amino acids to about 500 amino acids, about 220 amino acids to about 400 amino acids, about 220 amino acids to about 300 amino acids, about 220 amino acids to about 280 amino acids, about 220 amino acids to about 260 amino acids, about 220 amino acids to about 240 amino acids, about 240 amino acids to about 1000 amino acids, about 240 amino acids to about 900 amino acids, about 240 amino acids to about 800 amino acids, about 240 amino acids to about 700 amino acids,about 240 amino acids to about 600 amino acids, about 240 amino acids to about 500 amino acids, about 240 amino acids to about 400 amino acids, about 240 amino acids to about 300 amino acids, about 240 amino acids to about 280 amino acids, about 240 amino acids to about 260 amino acids, about 260 amino acids to about 1000 amino acids, about 260 amino acids to about 900 amino acids, about 260 amino acids to about 800 amino acids, about 260 amino acids to about 700 amino acids, about 260 amino acids to about 600 amino acids, about 260 amino acids to about 500 amino acids, about 260 amino acids to about 400 amino acids, about 260 amino acids to about 280 amino acids, about 240 amino acids to about 260 amino acids, about 1000 amino acids, about 260 amino acids to about 900 amino acids, about 260 amino acids to about 800 amino acids, about 260 amino acids to about 700 amino acids, about 260 amino acids to about 600 amino acids, about 260 amino acids to about 500 amino acids, about 260 amino acids to about 400 amino acids, about amino acids, about 260 amino acids to about 300 amino acids, about 260 amino acids to about 280 amino acids, about 280 amino acids to about 1000 amino acids, about 280 amino acids to about 900 amino acids, about 280 amino acids to about 800 amino acids, about 280 amino acids to about 700 amino acids, about 280 amino acids to about 600 amino acids, about 280 amino acids to about 500 amino acids, about 280 amino acids to about 400 amino acids, about 280 amino acids to about 300 amino acids, about 300 amino acids to about 1000 amino acids, about 300 amino acids to about 900 amino acids, about 300 amino acids to about 8 00 amino acids, about 300 amino acids to about 700 amino acids, about 300 amino acids to about 600 amino acids, about 300 amino acids to about 500 amino acids, about 300 amino acids to about 400 amino acids, about 400 amino acids to about 1000 amino acids, about 400 amino acids to about 900 amino acids, about 400 amino acids to about 800 amino acids, about 400 amino acids to about 700 amino acids, about 400 amino acids to about 600 amino acids, about 400 amino acids to about 500 amino acids, about 500 amino acids to about 1000 amino acids, about 500 amino acids to about 900 amino acids, about 500 amino acids to about 1 amino acids to about 800 amino acids, about 500 amino acids to about 700 amino acids, about 500 amino acids to about 600 amino acids, about 600 amino acids to about 1000 amino acids, about 600 amino acids to about 900 amino acids, about 600 amino acids to about 800 amino acids, about 600 amino acids to about 700 amino acids, about 700 amino acids to about 1000 amino acids, about 700 amino acids to about 900 amino acids, about 700 amino acids to about 800 amino acids, about 800 amino acids to about 1000 amino acids, about 800 amino acids to about 900 amino acids, or about 900 amino acids to about 1000 amino acids.
[0294] Any target binding domain described herein can dissociate with an equilibrium constant (K D) binds to its target: less than 1x 10 - 7 M, less than 1x 10 -8 M, less than 1x 10 -9 M, less than 1x 10 -10 M, less than 1x 10 -11 M, less than 1x 10 -12 M, or less than 1x10 -13 M. In some embodiments, the antigen binding protein constructs provided herein can be expressed as follows: D Binding to identified antigen: approximately 1x 10 -3 M to about 1x 10 -5 M, about 1x 10 -4 M to about 1x 10 -6 M, about 1x 10 -5 M to about 1x 10 -7 M, about 1x 10 -6 M to about 1x 10 -8 M, about 1x 10 -7 M to about 1x 10 -9 M, about 1x 10 -8 M to about 1x 10 -10 M, or about 1x 10 -9 M to about 1x 10 -11 M (inclusive).
[0295] Any target binding domain described herein can be expressed as follows: DBinds to its target: about 1 pM to about 30 nM (e.g., about 1 pM to about 25 nM, about 1 pM to about 20 nM, about 1 pM to about 15 nM, about 1 pM to about 10 nM, about 1 pM to about 5 nM, about 1 pM to about 2 nM, about 1 pM to about 1 nM, about 1 pM to about 950 pM, about 1 pM to about 900 pM, about 1 pM to about 850 pM, about 1 pM to about 800 pM, about 1 pM to about 750 pM, about 1 pM to about 700 pM, about 1 pM to about 650 pM, about 1 pM to about 600 pM, about 1 pM to about 550 pM, about 1 pM to about 500 pM, about 1 pM to about 450 pM, about 1 pM to about 400 pM, about 1 pM to about 350 pM, about 1 pM to about 300 pM, about 1 pM to about 250 pM, about 1 pM to about 200 pM, about 1 pM to about 150 pM, about 1 pM to about 100 pM, about 1 pM to about 90 pM, about 1 pM to about 80 pM, about 1 pM to about 70 pM, about 1 pM to about 60 pM, about 1 pM to about 50 pM, about 1 pM to about 40 pM, about 1 pM to about 30 pM, about 1 pM to about 20 pM, about 1 pM to about 10 pM, about 1 pM to about 5 pM, about 1 pM to about 4 pM, about 1 pM to about 3 pM, about 1 pM to about 2 pM, about 2 pM to about 30 nM, about 2 pM to about 25 nM, about 2 pM to about 20 nM, about 2 pM to about 15 nM, about 2 pM to about 1 pM, about 2pM to about 500pM, about 2pM to about 400pM, about 2pM to about 100pM, about 2pM to about 150pM, about 2pM to about 200pM, about 2pM to about 150pM, about 2pM to about 100pM, about 2pM to about 250pM, about 2pM to about 200pM, about 2pM to about 150pM, about 2pM to about 1 ...150pM, about 2pM to about 100pM, about 2pM to about 150pM, about 2pM to about 150pM, about 2pM to about 100pM, about 2pM to about 150pM, about 2pM to about 150pM, about 2pM to about 150pM, about 2pM to about 100pM, about 2pM to about 150pM, about 2pM to about 150pM, about 2p about 2pM to about 90pM, about 2pM to about 80pM, about 2pM to about 70pM, about 2pM to about 60pM, about 2pM to about 50pM, about 2pM to about 40pM, about 2pM to about 30pM, about 2pM to about 20pM, about 2pM to about 10pM, about 2pM to about 5pM, about 2pM to about 4pM, about 2pM to about 3pM, about 5pM to about 30nM, about 5pM to about 25nM, about 5pM to about 20nM, about 5pM to about 15nM, about 5pM to about 10nM, about 5pM to about 5nM, about 5pM to about 2nM, about 5pM to about 1nM, about 5pM to about 950pM, about 5pM to about 900pM, about 5pM to about 850pM,From about 5 pM to about 800 pM, from about 5 pM to about 750 pM, from about 5 pM to about 700 pM, from about 5 pM to about 650 pM, from about 5 pM to about 600 pM, from about 5 pM to about 550 pM, from about 5 pM to about 500 pM, from about 5 pM to about 450 pM, from about 5 pM to about 400 pM, from about 5 pM to about 350 pM, from about 5 pM to about 300 pM, from about 5 pM to about 250 pM, from about 5 pM to about 200 pM, from about 5 pM to about 150 pM, from about 5 pM to about 100 pM, from about 5 pM to about 90 pM, from about 5 pM to about 80 pM, from about 5 pM to about 70 pM, from about 5 pM to about 60 pM, from about 5 pM to about 50 pM, from about 5 pM to about 40 pM, from about 5pM to about 30pM, about 5pM to about 20pM, about 5pM to about 10pM, about 10pM to about 30nM, about 10pM to about 25nM, about 10pM to about 20nM, about 10pM to about 15nM, about 10pM to about 10nM, about 10pM to about 5nM, about 10pM to about 2nM, about 10pM to about 1nM, about 10pM to about 950pM, about 10pM to about 900pM, about 10pM to about 850pM, about 10pM to about 800pM, about 10pM to about 750pM, about 10pM to about 700pM, about 10pM to about 650pM, about 10pM to about 600pM, about 10pM to about 550pM, about 10pM to about about 500 pM, about 10 pM to about 450 pM, about 10 pM to about 400 pM, about 10 pM to about 350 pM, about 10 pM to about 300 pM, about 10 pM to about 250 pM, about 10 pM to about 200 pM, about 10 pM to about 150 pM, about 10 pM to about 100 pM, about 10 pM to about 90 pM, about 10 pM to about 80 pM, about 10 pM to about 70 pM, about 10 pM to about 60 pM, about 10 pM to about 50 pM, about 10 pM to about 40 pM, about 10 pM to about 30 pM, about 10 pM to about 20 pM, about 15 pM to about 30 nM, about 15 pM to about 25 nM, about 15 pM to about 20 nM, about 15 pM to about pM, about 15pM to about 500pM, about 15pM to about 400pM, about 15pM to about 550pM, about 15pM to about 500pM, about 15pM to about 450pM, about 15pM to about 400pM, about 15pM to about 350pM, about 15pM to about 300pM, about 15pM to about 250pM,about 15 pM to about 200 pM, about 15 pM to about 150 pM, about 15 pM to about 100 pM, about 15 pM to about 90 pM, about 15 pM to about 80 pM, about 15 pM to about 70 pM, about 15 pM to about 60 pM, about 15 pM to about 50 pM, about 15 pM to about 40 pM, about 15 pM to about 30 pM, about 15 pM to about 20 pM, about 20 pM to about 30 nM, about 20 pM to about 25 nM, about 20 pM to about 20 nM, about 20 pM to about 15 nM, about 20 pM to about 10 nM, about 20 pM to about 5 nM, about 20 pM to about 2 nM, about 20 pM to about 1 nM, about 20 pM to about 950 pM, about 20 pM to about pM, about 20 pM to about 900 pM, about 20 pM to about 850 pM, about 20 pM to about 800 pM, about 20 pM to about 750 pM, about 20 pM to about 700 pM, about 20 pM to about 650 pM, about 20 pM to about 600 pM, about 20 pM to about 550 pM, about 20 pM to about 500 pM, about 20 pM to about 450 pM, about 20 pM to about 400 pM, about 20 pM to about 350 pM, about 20 pM to about 300 pM, about 20 pM to about 250 pM, about 20 pM to about 20 pM, about 200 pM to about 150 pM, about 20 pM to about 100 pM, about 20 pM to about 90 pM, about 20 pM to about 80 pM, about 20 pM to about 70 pM pM to about 5 nM, about 30 pM to about 2 nM, about 30 pM to about 10 nM, about 30 pM to about 5 nM, about 30 pM to about 2 nM, about 30 pM to about 1 nM, about 30 pM to about 950 pM, about 30 pM to about 900 pM, about 30 pM to about 850 pM, about 30 pM to about 800 pM, about 30 pM to about 750 pM, about 30 pM to about 700 pM, about 30 pM to about 650 pM, about 30 pM to about 600 pM, about pM to about 50 pM, about 30 pM to about 40 pM, about 30 pM to about 30 nM, about 30 pM to about 25 nM, about 30 pM to about 200 pM, about 30 pM to about 150 pM, about 30 pM to about 100 pM, about 30 pM to about 90 pM, about 30 pM to about 80 pM, about 30 pM to about 70 pM, about 30 pM to about 60 pM, about 30 pM to about 50 pM, about 30 pM to about 40 pM, about 40 pM to about 30 nM, about 40 pM to about 25 nM, about 40 pM to about 30 nM, about 40 pM to about 15 nM,about 40 pM to about 10 nM, about 40 pM to about 5 nM, about 40 pM to about 2 nM, about 40 pM to about 1 nM, about 40 pM to about 950 pM, about 40 pM to about 900 pM, about 40 pM to about 850 pM, about 40 pM to about 800 pM, about 40 pM to about 750 pM, about 40 pM to about 700 pM, about 40 pM to about 650 pM, about 40 pM to about 600 pM, about 40 pM to about 550 pM, about 40 pM to about 500 pM, about 40 pM to about 450 pM, about 40 pM to about 400 pM, about 40 pM to about 350 pM, about 40 pM to about 300 pM, about 40 pM to about 250 pM, about 40 pM to about 200 pM, about 40 pM to about 150 pM, about 40 pM to about 100 pM, about 40 pM to about 90 pM, about 40 pM to about 80 pM, about 40 pM to about 70 pM, about 40 pM to about 60 pM, about 40 pM to about 50 pM, about 50 pM to about 30 nM, about 50 pM to about 25 nM, about 50 pM to about 30 nM, about 50 pM to about 15 nM, about 50 pM to about 10 nM, about 50 pM to about 5 nM, about 50 pM to about 2 nM, about 50 pM to about 1 nM, about 50 pM to about 950 pM, about 50 pM to about 900 pM, about 50 pM to about 850 pM, about 50 pM to about 800 pM, about 50 pM to about 750 pM, about 50 pM to about 700 pM, about 50 pM to about 650 pM, about 50 pM to about 600 pM, about 50 pM to about 550 pM, about 50 pM to about 500 pM, about 50 pM to about 450 pM, about 50 pM to about 400 pM, about 50 pM to about 350 pM, about 50 pM to about 300 pM, about 50 pM to about 250 pM, about 50 pM to about 200 pM, about 50 pM to about 150 pM, about 50 pM to about 100 pM, about 50 pM to about 90 pM, about 50 pM to about 80 pM, about 50 pM to about 70 pM, about 50 pM to about 60 pM, about 60 pM to about 30 nM, about 60 pM to about 25 nM, about 60 pM to about 30nM, about 60pM to about 15nM, about 60pM to about 10nM, about 60pM to about 5nM, about 60pM to about 2nM, about 60pM to about 1nM, about 60pM to about 950pM, about 60pM to about 900pM, about 60pM to about 850pM, about 60pM to about 800pM, about 60pM to about 750pM, about 60pM to about 700pM, about 60pM to about 650pM, about 60pM to about 600pM, about 60pM to about 550pM, about 60pM to about 500pM, about 60pM to about 450pM, about 60pM to about 400pM, about 60pM to about 350pM, about 60pM to about 300pM,about 60 pM to about 250 pM, about 60 pM to about 200 pM, about 60 pM to about 150 pM, about 60 pM to about 100 pM, about 60 pM to about 90 pM, about 60 pM to about 80 pM, about 60 pM to about 70 pM, about 70 pM to about 30 nM, about 70 pM to about 25 nM, about 70 pM to about 30 nM, about 70 pM to about 15 nM, about 70 pM to about 10 nM, about 70 pM to about 5 nM, about 70 pM to about 2 nM, about 70 pM to about 1 nM, about 70 pM to about 950 pM, about 70 pM to about 900 pM, about 70 pM to about 850 pM, about 70 pM to about 800 pM, about 70 pM to about 750 pM, about 70 pM to about pM to about 700 pM, about 70 pM to about 650 pM, about 70 pM to about 600 pM, about 70 pM to about 550 pM, about 70 pM to about 500 pM, about 70 pM to about 450 pM, about 70 pM to about 400 pM, about 70 pM to about 350 pM, about 70 pM to about 300 pM, about 70 pM to about 250 pM, about 70 pM to about 200 pM, about 70 pM to about 150 pM, about 70 pM to about 100 pM, about 70 pM to about 90 pM, about 70 pM to about 80 pM, about 80 pM to about 30 nM, about 80 pM to about 25 nM, about 80 pM to about 30 nM, about 80 pM to about 15 nM, about 80 pM to about 10 nM, about pM to about 5nM, about 80pM to about 2nM, about 80pM to about 1nM, about 80pM to about 950pM, about 80pM to about 900pM, about 80pM to about 850pM, about 80pM to about 800pM, about 80pM to about 750pM, about 80pM to about 700pM, about 80pM to about 650pM, about 80pM to about 600pM, about 80pM to about 550pM, about 80pM to about 500pM, about 80pM to about 450pM, about 80pM to about 400pM, about 80pM to about 350pM, about 80pM to about 300pM, about 80pM to about 250pM, about 80pM to about 200pM, about 80pM to about 150 pM, about 80 pM to about 100 pM, about 80 pM to about 90 pM, about 90 pM to about 30 nM, about 90 pM to about 25 nM, about 90 pM to about 30 nM, about 90 pM to about 15 nM, about 90 pM to about 10 nM, about 90 pM to about 5 nM, about 90 pM to about 2 nM, about 90 pM to about 1 nM, about 90 pM to about 950 pM, about 90 pM to about 900 pM, about 90 pM to about 850 pM, about 90 pM to about 800 pM, about 90 pM to about 750 pM, about 90 pM to about 700 pM, about 90 pM to about 650 pM, about 90 pM to about 600 pM, about 90 pM to about 550 pM, about 90 pM to about 500 pM,about 90 pM to about 450 pM, about 90 pM to about 400 pM, about 90 pM to about 350 pM, about 90 pM to about 300 pM, about 90 pM to about 250 pM, about 90 pM to about 200 pM, about 90 pM to about 150 pM, about 90 pM to about 100 pM, about 100 pM to about 30 nM, about 100 pM to about 25 nM, about 100 pM to about 30 nM, about 100 pM to about 15 nM, about 100 pM to about 10 nM, about 100 pM to about 5 nM, about 100 pM to about 2 nM, about 100 pM to about 1 nM, about 100 pM to about 950 pM, about 100 pM to about 900 pM, about 100 pM to about 850 pM, about 100 pM to about 800 pM, about 100 pM to about 750 pM, about 100 pM to about 700 pM, about 100 pM to about 650 pM, about 100 pM to about 600 pM, about 100 pM to about 550 pM, about 100 pM to about 500 pM, about 100 pM to about 450 pM, about 100 pM to about 400 pM, about 100 pM to about 350 pM, about 100 pM to about 300 pM, about 100 pM to about 250 pM, about 100 pM to about 200 pM, about 100 pM to about 150 pM, about 150 pM to about 30 nM, about 150 pM to about 25 nM, about 150 pM to about 30 nM, about 150 pM to about 15 nM, about 1 pM to about 10 nM, about 150 pM to about 5 nM, about 150 pM to about 2 nM, about 150 pM to about 1 nM, about 150 pM to about 950 pM, about 150 pM to about 900 pM, about 150 pM to about 850 pM, about 150 pM to about 800 pM, about 150 pM to about 750 pM, about 150 pM to about 700 pM, about 150 pM to about 650 pM, about 150 pM to about 600 pM, about 150 pM to about 550 pM, about 150 pM to about 500 pM, about 150 pM to about 450 pM, about 150 pM to about 400 pM, about 150 pM to about 350 pM, about 150 pM to about 300 pM, about 150 pM pM to about 850 pM, about 200 pM to about 800 pM, about 200 pM to about 750 pM, about 200 pM to about 700 pM, about 200 pM to about 650 pM, about 200 pM to about 600 pM, about 200 pM to about 550 pM, about 200 pM to about 100 pM, about 200 pM to about 500 pM, about 200 pM to about 200 pM, about 200 pM to about 100 pM, about 200 pM to about 500 pM, about 200 pM to about 200 pM, about 200 pM to about 100 pM, about 200 pM to about 500 pM, about 200 pM to about 200 pM, about 200 pM to about 100 pM, about 200 pM to about 500 pM, about 200 pM to about 200 pMabout 200 pM to about 500 pM, about 200 pM to about 450 pM, about 200 pM to about 400 pM, about 200 pM to about 350 pM, about 200 pM to about 300 pM, about 200 pM to about 250 pM, about 300 pM to about 30 nM, about 300 pM to about 25 nM, about 300 pM to about 30 nM, about 300 pM to about 15 nM, about 300 pM to about 10 nM, about 300 pM to about 5 nM, about 300 pM to about 2 nM, about 300 pM to about 1 nM, about 300 pM to about 950 pM, about 300 pM to about 900 pM, about 300 pM to about 850 pM, about 300 pM to about 800 pM, about 300 pM to about about 750 pM, about 300 pM to about 700 pM, about 300 pM to about 650 pM, about 300 pM to about 600 pM, about 300 pM to about 550 pM, about 300 pM to about 500 pM, about 300 pM to about 450 pM, about 300 pM to about 400 pM, about 300 pM to about 350 pM, about 400 pM to about 30 nM, about 400 pM to about 25 nM, about 400 pM to about 30 nM, about 400 pM to about 15 nM, about 400 pM to about 10 nM, about 400 pM to about 5 nM, about 400 pM to about 2 nM, about 400 pM to about 1 nM, about 400 pM to about 950 pM, about 400 pM to about 900 pM, about 400 pM to about 850 pM, about 400 pM to about 800 pM, about 400 pM to about 750 pM, about 400 pM to about 700 pM, about 400 pM to about 650 pM, about 400 pM to about 600 pM, about 400 pM to about 550 pM, about 400 pM to about 500 pM, about 500 pM to about 30 nM, about 500 pM to about 25 nM, about 500 pM to about 30 nM, about 500 pM to about 15 nM, about 500 pM to about 10 nM, about 500 pM to about 5 nM, about 500 pM to about 2 nM, about 500 pM to about 1 nM, about 500 pM to about 950 pM, about 500 pM to about 900 pM, about 500 pM to about about 850 pM, about 500 pM to about 800 pM, about 500 pM to about 750 pM, about 500 pM to about 700 pM, about 500 pM to about 650 pM, about 500 pM to about 600 pM, about 500 pM to about 550 pM, about 600 pM to about 30 nM, about 600 pM to about 25 nM, about 600 pM to about 30 nM, about 600 pM to about 15 nM, about 600 pM to about 10 nM, about 600 pM to about 5 nM, about 600 pM to about 2 nM, about 600 pM to about 1 nM, about 600 pM to about 950 pM, about 600 pM to about 900 pM, about 600 pM to about 850 pM, about 600 pM to about 800 pM,about 600 pM to about 750 pM, about 600 pM to about 700 pM, about 600 pM to about 650 pM, about 700 pM to about 30 nM, about 700 pM to about 25 nM, about 700 pM to about 30 nM, about 700 pM to about 15 nM, about 700 pM to about 10 nM, about 700 pM to about 5 nM, about 700 pM to about 2 nM, about 700 pM to about 1 nM, about 700 pM to about 950 pM, about 700 pM to about 900 pM, about 700 pM to about 850 pM, about 700 pM to about 800 pM, about 700 pM to about 7 50pM, about 800pM to about 30nM, about 800pM to about 25nM, about 800pM to about 30nM, about 800pM to about 15nM, about 800pM to about 10nM, about 800pM to about 5nM, about 800pM to about 2nM, about 800pM to about 1nM, about 800pM to about 950pM, about 800pM to about 900pM, about 800pM to about 850pM, about 900pM to about 30nM, about 900pM to about 25nM, about 900pM to about 30nM, about 900pM to about 15nM, about 900pM to about 10 nM, about 900 pM to about 5 nM, about 900 pM to about 2 nM, about 900 pM to about 1 nM, about 900 pM to about 950 pM, about 1 nM to about 30 nM, about 1 nM to about 25 nM, about 1 nM to about 20 nM, about 1 nM to about 15 nM, about 1 nM to about 10 nM, about 1 nM to about 5 nM, about 2 nM to about 30 nM, about 2 nM to about 25 nM, about 2 nM to about 20 nM, about 2 nM to about 15 nM, about 2 nM to about 10 nM, about 2 nM to about 5 nM, about 4 nM to about 30 nM, about 4 nM to about 25 nM, about about 4 nM to about 20 nM, about 4 nM to about 15 nM, about 4 nM to about 10 nM, about 4 nM to about 5 nM, about 5 nM to about 30 nM, about 5 nM to about 25 nM, about 5 nM to about 20 nM, about 5 nM to about 15 nM, about 5 nM to about 10 nM, about 10 nM to about 30 nM, about 10 nM to about 25 nM, about 10 nM to about 20 nM, about 10 nM to about 15 nM, about 15 nM to about 30 nM, about 15 nM to about 25 nM, about 15 nM to about 20 nM, about 20 nM to about 30 nM, and about 20 nM to about 25 nM).
[0296] Any target binding domain described herein can be expressed as follows: DBinds to its target: about 1 nM to about 10 nM (e.g., about 1 nM to about 9 nM, about 1 nM to about 8 nM, about 1 nM to about 7 nM, about 1 nM to about 6 nM, about 1 nM to about 5 nM, about 1 nM to about 4 nM, about 1 nM to about 3 nM, about 1 nM to about 2 nM, about 2 nM to about 10 nM, about 2 nM to about 9 nM, about 2 nM to about 8 nM, about 2 nM to about 7 nM, about 2 nM to about 6 nM, about 2 nM to about 5 nM, about 2 nM to about 4 nM, about 2 nM to about 3 nM, about 1 nM to about 2 nM, about 2 nM to about 10 nM, about 2 nM to about 9 nM, about 2 nM to about 8 nM, about 2 nM to about 7 nM, about 2 nM to about 6 nM, about 2 nM to about 5 nM, about 2 nM to about 4 nM, about 2 nM to about 3 nM, about 3 nM to about 10 nM, about 3 nM to about 9 nM, about 3 nM to about 8 nM, about 3 nM to about 7 nM, about 3 nM to about 6 nM, about 3 nM to about 7nM, about 7nM to about 10nM, about 7nM to about 9nM, about 7nM to about 8nM, about 8nM to about 10nM, about 8nM to about 9nM, and about 9nM to about 10nM).
[0297] The K of any of the antigen binding protein constructs described herein can be determined using a variety of different methods known in the art (e.g., electrophoretic mobility shift assays, membrane filtration binding assays, surface plasmon resonance, and biomolecular binding kinetics assays, etc.). D value.
[0298] Antigen binding domain
[0299] In some embodiments of any of the multi-chain chimeric polypeptides described herein, the first target binding domain and the second target binding domain specifically bind to the same antigen. In some embodiments of these multi-chain chimeric polypeptides, the first target binding domain and the second target binding domain specifically bind to the same epitope. In some embodiments of these multi-chain chimeric polypeptides, the first target binding domain and the second target binding domain comprise the same amino acid sequence.
[0300] In some embodiments of any of the multi-chain chimeric polypeptides described herein, the first target binding domain and the second target binding domain specifically bind different antigens.
[0301] In some embodiments of any multi-chain chimeric polypeptide described herein, one or both of the first target binding domain and the second target binding domain are antigen binding domains. In some embodiments of any multi-chain chimeric polypeptide described herein, each of the first target binding domain and the second target binding domain is an antigen binding domain.
[0302] In some embodiments of any of the multi-chain chimeric polypeptides described herein, the antigen binding domain comprises or is a scFv or a single domain antibody (eg, a VHH or VNAR domain).
[0303] In some examples, the first and / or second target binding domain is an antigen binding domain. Non-limiting examples of antigen binding domains that can specifically bind to a ligand of a TGF-βRII ligand include antigen binding domains of SAR-439459, NIS793, SRK-181, and GC1008 (sumetumomab).
[0304] In some instances, one or more additional target-binding domains can be antigen-binding domains (e.g., any of the antigen-binding domains described herein) that specifically bind to any of the following: CD16a (see, e.g., those described in U.S. Patent No. 9,035,026), CD28 (see, e.g., those described in U.S. Patent No. 7,723,482), CD3 (see, e.g., those described in U.S. Patent No. 9,226,962), CD33 (see, e.g., those described in U.S. Patent No. 8,759,494), CD20 (see, e.g., those described in WO 2014 / 026054), CD19 (see, e.g., those described in U.S. Patent No. 9,701,758), CD22 (see, e.g., those described in WO 2003 / 104425), CD123 (see, e.g., those described in WO 2014 / 130635), IL-1R (see, e.g., those described in U.S. Patent No. 8,741,604), IL-1 (see, e.g., those described in WO 2014 / 095808), VEGF (see, e.g., those described in U.S. Patent No. 9,090,684), IL-6R (see, e.g., those described in U.S. Patent No. 7,482,436), IL-4 (see, e.g., those described in U.S. Patent Application Publication No. 2012 / 0171197), IL-10 (see, e.g., those described in U.S. Patent Application Publication No. 2016 / 0340413), PDL-1 (see, e.g., those described in Drees et al., Protein Express. Purif. [Protein Expression and Purification] 94:60-66, 2014), TIGIT (see, e.g., those described in U.S. Patent Application Publication No. 2017 / 0198042), PD-1 (see, e.g., those described in U.S. Patent No. 7,488,802), TIM3 (see, e.g., those described in U.S. Patent No. 8,552,156), CTLA4 (see, e.g., those described in WO2012 / 120125), MICA (see, e.g., those described in WO 2016 / 154585), MICB (see, e.g., those described in U.S. Patent No. 8,753,640), IL-6 (see, e.g., those described in Gejima et al., Human Antibodies [Human Antibodies] 11(4):121-129, 2002), IL-8 (see, e.g., those described in U.S. Patent No. 6,117,980), TNFα (see, e.g., those described in Geng et al., Immunol. Res.[Immunol.] 62(3):377-385, 2015), CD26a (see, e.g., those described in WO 2017 / 189526), CD36 (see, e.g., those described in U.S. Patent Application Publication No. 2015 / 0259429), ULBP2 (see, e.g., those described in U.S. Patent No. 9,273,136), CD30 (see, e.g., those described in Homach et al., Scand. J. Immunol. 48(5):497-501, 1998), CD200 (see, e.g., those described in U.S. Patent No. 9,085,623), IGF-1R (see, e.g., those described in U.S. Patent Application Publication No. 2017 / 0051063), MUC4AC (see, e.g., those described in WO 2012 / 170470), MUC5AC (see, e.g., those described in U.S. Patent No. 9,238,084), Trop-2 (see, e.g., those described in WO 2013 / 068946), CMET (see, e.g., those described in Edwardraja et al., Biotechnol. Bioeng. [Biotechnology and Bioengineering] 106(3):367-375, 2010), EGFR (see, e.g., Akbari et al., Protein [Protein Expression and Purification] 127:8-15, 2016), HER1 (see, e.g., those described in U.S. Patent Application Publication No. 2013 / 0274446), HER2 (see, e.g., those described in Cao et al., Biotechnol. Lett. 37(7):1347-1354, 2015), HER3 (see, e.g., those described in U.S. Patent No. 9,505,843), PSMA (see, e.g., those described in Parker et al., Protein Expr. Purif. 89(2):136-145, 2013), CEA (see, e.g., those described in WO 1995 / 015341), B7H3 (see, e.g., those described in U.S. Patent No. 9,371,395), EPCAM (see, e.g., those described in WO 1995 / 015341). 2014 / 159531), BCMA (see, e.g., Smith et al., Mol. Ther.[Molecular Therapy] 26(6):1447-1456, 2018), P-cadherin (see, e.g., those described in U.S. Patent No. 7,452,537), CEACAM5 (see, e.g., those described in U.S. Patent No. 9,617,345), UL16 binding protein (see, e.g., those described in WO 2017 / 083612), HLA-DR (see, e.g., Pistillo et al., Exp. Clin. Immunogenet. [Experimental and Clinical Immunogenet.] 14(2):123-130, 1997), DLL4 (see, e.g., those described in WO 2014 / 007513), TYRO3 (see, e.g., those described in WO 2016 / 166348), AXL (see, e.g., those described in WO 2012 / 175692), MER (see, e.g., those described in WO 2016 / 106221), CD122 (see, e.g., those described in U.S. Patent Application Publication No. 2016 / 0367664), CD155 (see, e.g., those described in WO 2017 / 149538), or PDGF-DD (see, e.g., those described in U.S. Patent No. 9,441,034).
[0305] The antigen binding domains present in any multi-chain chimeric polypeptide described herein are each independently selected from: a VHH domain, a VNAR domain, and a scFv. In some embodiments, any antigen binding domain described herein is a BiTe, (scFv)2, a nanobody, a nanobody-HSA, a DART, a TandAb, a scdiabody, a scdiabody-CH3, a scFv-CH-CL-scFv, an HSA body, a scdiabody-HSA, or a tandem-scFv. Other examples of antigen binding domains that can be used in any multi-chain chimeric polypeptide are known in the art.
[0306] The VHH domain is a single monomeric variable antibody domain found in camelids. The VNAR domain is a single monomeric variable antibody domain found in cartilaginous fish. NARNon-limiting aspects of domains are described in, for example, Cromie et al., Curr. Top. Med. Chem. [Current Topics in Medicinal Chemistry] 15:2543-2557, 2016; De Genst et al., Dev. Comp. Immunol. [Development and Comparative Immunology] 30:187-198, 2006; De Meyer et al., Trends Biotechnol. 32:263-270, 2014; Kijanka et al., Nanomedicine 10:161-174, 2015; Kovaleva et al., Expert. Opin. Biol. Ther. 14:1527-1539, 2014; Krah et al., Immunopharmacol. Immunotoxicol. 38:21-28, 2016; Mujic-Delic et al., Trends Pharmacol. Sci. 35:247-255, 2014; Muyldermans, J. Biotechnol. 74:277-302, 2001; Muyldermans et al., Trends Biochem. Sci. 26:230–235, 2001; Muyldermans, Ann. Rev. Biochem. 82:775–797, 2013; Rahbarizadeh et al., Immunol. Invest. 40:299–338, 2011; Van Audenhove et al., EBioMedicine 8:40–48, 2016; Van Bockstaele et al., Curr. Opin. Investig. Drugs 10:1212–1224, 2009; Vincke et al., Methods Mol. Biol. 911:15-26, 2012; and Wesolowski et al., Med. Microbiol. Immunol. 198:157-174, 2009.
[0307] In some embodiments, each antigen binding domain in the multi-chain chimeric polypeptides described herein is a VHH domain, or at least one antigen binding domain is a VHH domain. In some embodiments, each antigen binding domain in the multi-chain chimeric polypeptides described herein is a VNAR domain, or at least one antigen binding domain is a VNAR domain. In some embodiments, each antigen binding domain in the multi-chain chimeric polypeptides described herein is a scFv domain, or at least one antigen binding domain is a scFv domain.
[0308] In some embodiments, two or more polypeptides present in the multi-chain chimeric polypeptide can be assembled (e.g., non-covalently assembled) to form any antigen-binding domain described herein, such as an antigen-binding fragment of an antibody (e.g., any antigen-binding fragment of an antibody described herein), VHH-scAb, VHH-Fab, bi-scFab, F(ab')2, diabody, crossover Mab, DAF (two-in-one), DAF (four-in-one), DutaMab, DT-IgG, knobs-in-holes common light chain, knobs-in-holes assembly, charge pair, Fab arm exchange, SEED body, LUZ-Y, Fcab, kappa lambda-body, orthogonal Fab, DVD-IgG, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, Zybody, DVI-IgG, diabody-CH3, trio, minibody, minibody, TriBi minibody, scFv-CH3 KIH, Fab-scFv, F(ab')2-scFv2, scFv-KIH, Fab-scFv-Fc, tetravalent HCAb, scdiabody-Fc, diabody-Fc, tandem scFv-Fc, intrabody, dock and lock, lmmTAC, IgG-IgG conjugate, Cov-X-body and scFv1-PEG-scFv2. See, e.g., Spiess et al., Mol. Immunol. 67:95-106, 2015, which is incorporated herein in its entirety, for a description of these elements. Non-limiting examples of antigen-binding fragments of antibodies include Fv fragments, Fab fragments, F(ab')2 fragments, and Fab' fragments. Additional examples of antigen-binding fragments of antibodies are antigen-binding fragments of IgG (e.g., antigen-binding fragments of IgG1, IgG2, IgG3, or IgG4) (e.g., antigen-binding fragments of human or humanized IgG, e.g., human or humanized IgG1, IgG2, IgG3, or IgG4); antigen-binding fragments of IgA (e.g., antigen-binding fragments of IgA1 or IgA2) (e.g., antigen-binding fragments of human or humanized IgA, e.g., human or humanized IgA1 or IgA2); antigen-binding fragments of IgD (e.g., antigen-binding fragments of human or humanized IgD); antigen-binding fragments of IgE (e.g., antigen-binding fragments of human or humanized IgE); or antigen-binding fragments of IgM (e.g., antigen-binding fragments of human or humanized IgM).
[0309] An "Fv" fragment comprises a non-covalently linked dimer of one heavy- and one light-chain variable domain.
[0310] The "Fab" fragment includes, in addition to the heavy and light chain variable domains of the Fv fragment, the light chain constant domain and the first constant domain of the heavy chain (C H1 ).
[0311] The "F(ab')2" fragment comprises two Fab fragments connected by a disulfide bond near the hinge region.
[0312] "Dual variable domain immunoglobulin" or "DVD-Ig" refers to multivalent and multispecific binding proteins as described, e.g., in DiGiammarino et al., Methods Mol. Biol. 899:145-156, 2012; Jakob et al., MABs 5:358-363, 2013; and U.S. Patent Nos. 7,612,181; 8,258,268; 8,586,714; 8,716,450; 8,722,855; 8,735,546; and 8,822,645, the entire contents of each of which are incorporated by reference.
[0313] DARTs are described, for example, in Garber, Nature Reviews Drug Discovery 13:799-801, 2014.
[0314] In some embodiments, any of the antigen binding domains described herein can bind to an antigen selected from the group consisting of: a protein, a carbohydrate, a lipid, and combinations thereof.
[0315] Additional examples and aspects of antigen binding domains are known in the art.
[0316] Soluble interleukin or cytokine proteins
[0317] In some embodiments of any multi-chain chimeric polypeptide described herein, one or more additional target binding domains can be a soluble interleukin protein or a soluble cytokine protein. In some embodiments, the soluble interleukin or soluble cytokine protein is selected from the group consisting of IL-2, IL-3, IL-7, IL-8, IL-10, IL-12, IL-15, IL-17, IL-18, IL-21, PDGF-DD, SCF, and FLT3L. Non-limiting examples of soluble IL-2, IL-3, IL-7, IL-8, IL-10, IL-15, IL-17, IL-18, IL-21, PDGF-DD, SCF, and FLT3L are provided below.
[0318] Human soluble IL-2 (SEQ ID NO:10)
[0319] aptssstkkt qlqlehllld lqmilnginn yknpkltrml tfkfympkka telkhlqcleeelkpleevl nlaqsknfhl rprdlisnin vivlelkgse ttfmceyade tativeflnr witfcqsiistlt
[0320] Human soluble IL-3 (SEQ ID NO:11)
[0321] apmtqttplkt swvncsnmid eiithlkqpp lplldfnnln gedqdilmen nlrrpnleafnravkslqna saiesilknl lpclplataa ptrhpihikd gdwnefrrkl tfylktlena qaqqttlslaif
[0322] Human soluble IL-7 (SEQ ID NO:12)
[0323] dcdiegkdgkqyesv lmvsidqlld smkeigsncl nnefnffkrh icdankegmflfraarklrq flkmnstgdf dlhllkvseg ttillnctgq vkgrkpaalg eaqptkslee nkslkeqkklndlcflkrll qeiktcwnki lmgtkeh
[0324] Human soluble IL-8 (SEQ ID NO:13)
[0325] egavlprsak elrcqcikty skpfhpkfik elrviesgph canteiivkl sdgrelcldpkenwvqrvve kflkraens
[0326] Human soluble IL-10 (SEQ ID NO:14)
[0327] spgqgtqsensc thfpgnlpnm lrdlrdafsr vktffqmkdq ldnlllkesl ledfkgylgcqalsemiqfy leevmpqaen qdpdikahvn slgenlktlr lrlrrchrfl pcenkskave qvknafnklqekgiykamse fdifinyiea ymtmkirn
[0328] Human soluble IL-15 (SEQ ID NO:15)
[0329] Nwvnvisdlkki edliqsmhid atlytesdvh psckvtamkc fllelqvisl esgdasihdtvenliilann slssngnvte sgckeceele eknikeflqs fvhivqmfin ts
[0330] Human soluble IL-17 (SEQ ID NO:16)
[0331] gitiprn pgcpnsedkn fprtvmvnln ihnrntntnp krssdyynrs tspwnlhrnedperypsviw eakcrhlgci nadgnvdyhm nsvpiqqeil vlrrepphcp nsfrlekilv svgctcvtpivhhva
[0332] Human soluble IL-18 (SEQ ID NO:17)
[0333] yfgklesklsvirn lndqvlfidq gnrplfedmt dsdcrdnapr tifiismykd sqprgmavtisvkcekistl scenkiisfk emnppdnikd tksdiiffqr svpghdnkmq fesssyegyf lacekerdlfklilkkedel
[0334] gdrsimftvq ned
[0335] Human soluble PDGF-DD (SEQ ID NO:18)
[0336] rdtsatpqsasi kalrnanlrr desnhltdly rrdetiqvkg ngyvqsprfp nsyprnllltwrlhsqentr
[0337] iqlvfdnqfg leeaendicr ydfvevedis etstiirgrw cghkevppri ksrtnqikitfksddyfvak
[0338] pgfkiyyslledfqpaaase tnwesvtssi sgvsynspsv tdptliadal dkkiaefdtvedllkyfnpe
[0339] swqedlenmy ldtpryrgrs yhdrkskvdl drlnddakry sctprnysvn ireelklanvvffprcllvq
[0340] rcggncgcgt vnwrsctcns gktvkkyhev lqfepghikr rgraktmalv diqldhhercdcicssrppr Human soluble SCF (SEQ ID NO:19)
[0341] egicrnrvtnnvkdv tklvanlpkd ymitlkyvpg mdvlpshcwi semvvqlsdsltdlldkfsn
[0342] iseglsnysiidklvnivdd lvecvkenss kdlkksfksp eprlftpeef frifnrsidafkdfvvaset
[0343] sdcvvsstls pekdsrvsvt kpfmlppvaa sslrndssss nrkaknppgd sslhwaamalpalfsliigf
[0344] afgalywkkr qpsltraven iqineednei smlqekeref qev
[0345] Human soluble FLT3L (SEQ ID NO:20)
[0346] tqdcsfqhspissd favkirelsd yllqdypvtv asnlqdeelc gglwrlvlaq rwmerlktvagskmqgller
[0347] vnteihfvtk cafqpppscl rfvqtnisrl lqetseqlva lkpwitrqnf srclelqcqpdsstlpppws
[0348] prpleatapt apqppllllll llpvglllla aawclhwqrt rrrtprpgeq vppvpspqdlllveh
[0349] Non-limiting examples of soluble MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, and ULBP6 are provided below.
[0350] Human soluble MICA (SEQ ID NO: 21)
[0351] ephslry nltvlswdgs vqsgfltevh ldgqpflrcd rqkcrakpqg qwaedvlgnktwdretrdlt
[0352] gngkdlrmtl ahikdqkegl hslqeirvce ihednstrss qhfyydgelf lsqnletkewtmpqssraqt
[0353] lamnvrnflk edamktkthy hamhadclqe lrrylksgvv lrrtvppmvn vtrseasegnitvtcrasgf
[0354] ypwnitlswr qdgvslshdt qqwgdvlpdg ngtyqtwvat ricqgeeqrf tcymehsgnhsthpvpsgkv
[0355] lvlqshwqtf hvsavaaaai fviiifyvrc ckkktsaaeg pelvslqvld qhpvgtsdhrdatqlgfqpl
[0356] msdlgstgst ega
[0357] Human soluble MICB (SEQ ID NO: 22)
[0358] aephslry nlmvlsqdes vqsgflaegh ldgqpflryd rqkrrakpqg qwaedvlgaktwdtetedlt
[0359] engqdlrrtl thikdqkggl hslqeirvce ihedsstrgs rhfyydgelf lsqnletqestwpqssraqt
[0360] lamnvtnfwk edamctkthy ramqadclqk lqrylksgva irrtvppmvn vtcsevsegnitwtcrassf
[0361] yprnitltwr qdgvslshnt qqwgdvlpdg ngtyqtwvat rirqgeeqrf tcymehsgnhgthpvpsgkv
[0362] lvlqsqrtdf pyvsaampcf viiiilcvpc ckktsaaeg pelvslqvld qhpvgtgdhrdaaqlgfqpl
[0363] msatgstgst ega
[0364] ULBP1(SEQ ID NO:23)
[0365] wvdthclcydfiit pxrpepqwc evqglvderp flhydcvnhk akafaslgkk vnvtktweeq
[0366] tetlrdvvdf lkgqlldiqv enlipieplt lqarmscehe ahghgrgswq flfngqkfllfdsnnrkwta
[0367] lhpgakkmte kweknrdvtm ffqkislgdc kmwleeflmy weqmldptkp pslapg
[0368] ULBP2(SEQ ID NO:24)
[0369] gradphslcyditvi pkfrpgprwc avqgqvdekt flhydcgnkt vtpvsplgkklnvttawkaq
[0370] npvlrevvdi lteqlrdiql enytpkeplt lqarmsceqk aeghssgswq fsfdgqifllfdsekrmwtt
[0371] vhpgarkmke kwendkvvam sfhyfsmgdc igwledflmg mdstlepsag aplams
[0372] Human soluble ULBP3 (SEQ ID NO:25)
[0373] dahslwynftiihlprhgqqw cevqsqvdqk nflsydcgsd kvlsmghlee qlyatdawgkqlemlrevgq
[0374] rlrleladte ledftpsgpl tlqvrmscec eadgyirgsw qfsfdgrkfl lfdsnnrkwtvvhagarrmk
[0375] ekwekdsglt tffkmvsmrd ckswlrdflm hrkkrlepta pptmapg
[0376] Human soluble ULBP4 (SEQ ID NO:26)
[0377] hslcfnftik slsrpgqpwc eaqvflnknl flqynsdnnm vkplgllgkk vyatstwgeltqtlgevgrd
[0378] lrmllcdikp qiktsdpstl qvemfcqrea erctgaswqf atngeksllf damnmtwtvinheaskiket
[0379] wkkdrgleky frklskgdcd hwlreflghw eampeptvsp vnasdihwss sslpdrwiilgafillvlmg
[0380] ivlicvwwqn gewqaglwpl rts
[0381] Human soluble ULBP5 (SEQ ID NO: 27)
[0382] gladp hslcyditvi pkfrpgprwc avqgqvdekt flhydcgskt vtpvsplgkklnvttawkaq
[0383] npvlrevvdi lteqlldiql enyipkeplt lqarmsceqk aeghgsgswq lsfdgqifllfdsenrmwtt
[0384] vhpgarkmke kwendkdmtm sfhyismgdc tgwledflmg mdstlepsag apptmssg
[0385] Human soluble ULBP6 (SEQ ID NO: 28)
[0386] rrddp hslcyditvi pkfrpgprwc avqgqvdekt flhydcgnkt vtpvsplgkklnvtmawkaq
[0387] npvlrevvdi lteqlldiql enytpkeplt lqarmsceqk aeghssgswq fsidgqtfllfdsekrmwtt
[0388] vhpgarkmke kwendkdvam sfhyismgdc igwledflmg mdstlepsag aplamssg
[0389] Additional examples of soluble interleukin proteins and soluble cytokine proteins are known in the art.
[0390] Soluble receptors
[0391] In some embodiments of any multi-chain chimeric polypeptide described herein, one or both of the first target binding domain and the second target binding domain are soluble interleukin receptors or soluble cytokine receptors or ligand receptors. In some embodiments, the first and / or second target binding domains can be soluble TGF-β receptor II (TGF-βRII) (see, e.g., Yung et al., Am. J. Resp. Crit. Care Med. [American Journal of Respiratory and Critical Care Medicine] 194(9): 1140-1151, 2016).
[0392] In some embodiments, the first target binding domain comprises a soluble TGF-β receptor (e.g., soluble TGFRβRII (e.g., soluble human TGFRβRII)). In some embodiments, the second target binding domain comprises a soluble TGF-β receptor (e.g., soluble TGFRβRII (e.g., soluble human TGFRβRII)). In some embodiments, the soluble human TGFRβRII comprises a first sequence of soluble human TGFRβRII and a second sequence of soluble human TGFRβRII. In some embodiments of these multi-chain chimeric polypeptides, the soluble human TGFRβRII comprises a linker disposed between the first sequence of soluble human TGFRβRII and the second sequence of soluble human TGFRβRII. In some examples of these multi-chain chimeric polypeptides, the linker comprises the sequence GGGGSGGGGSGGGGS (SEQ ID NO: 7).
[0393] In some embodiments, the first sequence of soluble human TGFRβRII comprises a sequence at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEK KKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD (SEQ ID NO: 66).
[0394] In some embodiments, the second sequence of soluble human TGFRβRII comprises a sequence at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSIT SICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEK KKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD (SEQ ID NO: 66).
[0395] In some embodiments, the first sequence of soluble human TGFRβRII is encoded by a sequence at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to: ATTCCTCCCCACGTGCAGAAGAGCGTGAATAATGACATGATCGTGACCGATAACAATGGCGCCGTGAAATTTCCCCAGCTGTGCAAATTCTGCGATGTGAGGTTTTCCACCTGCGACAACCAGAAGTCCTGT ATGAGCAACTGCACAATCACCTCCATCTGTGAGAAGCCTCAGGAGGTGTGCGTGGCTGTCTGGCGGAAGAATGACGAGAATATCACCCTGGAAACCGTCTGCCACGATCCCAAGCTGCCCTACCACGATTTCATCCTGGA AGACGCCGCCAGCCCTAAGTGCATCATGAAAGAGAAAAAGAAGCCTGGCGAGACCTTTTTCATGTGCTCCTGCAGCAGCGACGAATGCAACGACAATATCATCTTTAGCGAGGAATACAAATACCAGCAACCCCGAC(SEQ ID NO:67).
[0396] In some embodiments, the second sequence of soluble human TGFRβRII is encoded by a sequence at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to: ATTCCTCCCCACGTGCAGAAGAGCGTGAATAATGACATGATCGTGACCGATAACAATGGCGCCGTGAAATTTCCCCAGCTGTGCAAATTCTGCGATGTGAGGTTTTCCACCTGCGACAACCAGAAGTCCTGT ATGAGCAACTGCACAATCACCTCCATCTGTGAGAAGCCTCAGGAGGTGTGCGTGGCTGTCTGGCGGAAGAATGACGAGAATATCACCCTGGAAACCGTCTGCCACGATCCCAAGCTGCCCTACCACGATTTCATCCTGGA AGACGCCGCCAGCCCTAAGTGCATCATGAAAGAGAAAAAGAAGCCTGGCGAGACCTTTTTCATGTGCTCCTGCAGCAGCGACGAATGCAACGACAATATCATCTTTAGCGAGGAATACAAATACCAGCAACCCCGAC(SEQ ID NO:67).
[0397] In some embodiments, the soluble human TGFRβRII is composed of a human TGFRβRII having at least 80% identity to (e.g.,Sequences encoding at least 82% identity, at least 84% identity, at least 86% identity, at least 88% identity, at least 90% identity, at least 92% identity, at least 94% identity, at least 96% identity, at least 98% identity, at least 99% identity or 100% identity): ATCCCCCCCCATGTGCAAAAGAGCGTGAACAACGATATGATCGTGACCGACAACAACGGCGCCGTGAAGTTTCCCCAGCTCTGCAAGTTCTGCGATGTCAGGTTCAGCACCTGCGATAATCAGAAGTCCTGCATGTCCAACTGCACGATCACCTCCATCTGCGAGAAGCCCCAAGAAGTGTGCGTGGCCGTGTGGCGGAAAAATGACGAGAACATCACCCTGGAGACCGTGTGTCACGACCCCAAGCTCCCTTATCACGACTTCATTCTGGAGGACGCTGCCTCCCCCAAATGCATCATGAAGGAGAAGAAGAAGCCCGGAGAGACCTTCTTTATGTGTTCCTGTAGCAGCGACGAGTGTAACGACAACATCATCTTCAGCGAAGAGTACAACACCAGCAACCCTGATGGAGGTGGCGGATCCGGAGGTGGAGGTTCTGGTGGAGGTGGGAGTATTCCTCCCCACGTGCAGAAGAGCGTGAATAATGACATGATCGTGACCGATAACAATGGCGCCGTGAAATTTCCCCAGCTGTGCAAATTCTGCGATGTGAGGTTTTCCACCTGCGACAACCAGAAGTCCTGTATGAGCAACTGCACAATCACCTCCATCTGTGAGAAGCCTCAGGAGGTGTGCGTGGCTGTCTGGCGGAAGAATGACGAGAATATCACCCTGGAAACCGTCTGCCACGATCCCAAGCTGCCCTACCACGATTTCATCCTGGAAGACGCCGCCAGCCCTAAGTGCATCATGAAAGAGAAAAAGAAGCCTGGCGAGACCTTTTTCATGTGCTCCTGCAGCAGCGACGAATGCAACGACAATATCATCTTTAGCGAGGAATACAATACCAGCAACCCCGAC(SEQ ID NO:68).
[0398] In some embodiments, the soluble human TGFβRII comprises a sequence that is at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to: IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLET VCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSGGGGSGGGGSIPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(SEQID NO:69).
[0399] In some embodiments, the one or more additional target binding domains can be soluble TGF-β receptor II (TGF-βRII) (see, e.g., those described in Yung et al., Am. J. Resp. Crit. Care Med. 194(9): 1140-1151, 2016), soluble TGF-βRIII (see, e.g., those described in Heng et al., Placenta 57:320, 2017), soluble NKG2D (see, e.g., Cosman et al., Immunity 14(2): 123-133, 2001; Costa et al., Front. Immunol. ol., vol. 9, chap. 1150, May 29, 2018; doi:10.3389 / fimmu.2018.01150), soluble NKp30 (see, e.g., Costa et al., Front. Immunol., vol. 9, chap. 1150, May 29, 2018; doi:10.3389 / fimmu.2018.01150), soluble NKp44 (see, e.g., Costa et al., Front. Immunol., vol. 9, chap. 1150, May 29, 2018; doi:10.3389 / fimmu.2018.01150), a et al., Front. Immunol., vol. 9, no. 1150, May 29, 2018; doi: 10.3389 / fimmu.2018.01150), soluble NKp46 (see, e.g., Mandelboim et al., Nature 409: 1055-1060, 2001; Costa ... 150, May 29, 2018; doi:10.3389 / fimmu.2018.01150), soluble DNAM-1 (see, e.g., those described in Costa et al., Front. Immunol., vol. 9, no. 1150, May 29, 2018; doi:10.3389 / fimmu.2018.01150), scMHCI (see, e.g., Washburn et al., PLoS One [Public Library of Science · One] 6 (3): e18439, 2011), scMHCII (see, for example, those described in Bishwajit et al., Cellular Immunol. [Cellular Immunology] 170 (1): 25-33, 1996), scTCR (see, for example, those described in Weber et al., Nature [Nature] 356 (6372): 793-796, 1992), soluble CD155 (see, for example, Tahara-Hanaoka et al., Int.Immunol. [International Immunology] 16(4): 533-538, 2004), or soluble CD28 (see, for example, those described in Hebbar et al., Clin. Exp. Immunol. [Clinical and Experimental Immunology] 136: 388-392, 2004).
[0400] Other examples of soluble interleukin receptors and soluble cytokine receptors are known in the art.
[0401] Additional target binding domains
[0402] In some embodiments of any of the multi-chain chimeric polypeptides, the first chimeric polypeptide further comprises one or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art), wherein at least one of the one or more additional antigen binding domains is positioned between the soluble tissue factor domain (e.g., any exemplary soluble tissue factor domain described herein or known in the art) and the first domain of the affinity domain pair (e.g., any exemplary first domain of any exemplary affinity domain pair described herein). In some embodiments, the first chimeric polypeptide can further include a linker sequence (e.g., any exemplary linker sequence described herein or known in the art) between the soluble tissue factor domain (e.g., any exemplary soluble tissue factor domain described herein) and at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art), and / or a linker sequence (e.g., any exemplary linker sequence described herein or known in the art) between at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) and the first domain of an affinity domain pair (e.g., any exemplary first domain described herein of any exemplary affinity domain pair described herein).
[0403] In some embodiments of any multi-chain chimeric polypeptides described herein, the first chimeric polypeptide further comprises one or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) additional target binding domains located at the N-terminus and / or C-terminus of the first chimeric polypeptide. In some embodiments, at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) is directly adjacent to the first domain of the affinity domain pair in the first chimeric polypeptide (e.g., any exemplary first domain described herein of any exemplary affinity domain pair described herein). In some embodiments, the first chimeric polypeptide further comprises a linker sequence (e.g., any exemplary linker sequence described herein or known in the art) between at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) and the first domain of the affinity domain pair (e.g., any exemplary first domain described herein of any exemplary affinity domain pair described herein). In some embodiments, at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) is directly adjacent to the first target binding domain (e.g., any exemplary target binding domain described herein or known in the art) in the first chimeric polypeptide. In some embodiments, the first chimeric polypeptide further comprises a linker sequence (e.g., any exemplary linker sequence described herein or known in the art) between at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) and the first target binding domain (e.g., any exemplary target binding domain described herein or known in the art).
[0404] In some embodiments of any of the multi-chain chimeric polypeptides described herein, at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) is disposed at the N-terminus and / or C-terminus of the first chimeric polypeptide, and at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) is located between the soluble tissue factor domain (e.g., any exemplary soluble tissue factor domain described herein or known in the art) and the first domain of the affinity domain pair (e.g., any exemplary first domain of any exemplary affinity domain pair described herein) in the first chimeric polypeptide. In some embodiments, at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) disposed at the N-terminus is directly adjacent to the first target binding domain (e.g., any exemplary target binding domain described herein or known in the art) or the first domain of the affinity domain pair (e.g., any exemplary first domain of any exemplary affinity domain pair described herein) in the first chimeric polypeptide. In some embodiments, the first chimeric polypeptide further comprises a linker sequence (e.g., any linker sequence described herein or known in the art) disposed between at least one additional target binding domain (e.g., any exemplary target binding domain described herein or known in the art) and the first target binding domain (e.g., any exemplary target binding domain described herein or known in the art) or the first domain of an affinity domain pair (e.g., any exemplary first domain described herein of any exemplary affinity domain pair described herein). In some embodiments, at least one additional target binding domain (e.g., any exemplary target binding domain described herein or known in the art) of the one or more additional target binding domains disposed at the C-terminus is directly adjacent to the first target binding domain (e.g., any exemplary target binding domain described herein or known in the art) or the first domain of an affinity domain pair (e.g., any exemplary first domain of any exemplary affinity domain pair described herein) in the first chimeric polypeptide. In some embodiments, the first chimeric polypeptide further comprises a linker sequence (e.g., any exemplary linker sequence described herein or known in the art) disposed between at least one additional target binding domain (e.g., any exemplary target binding domain described herein or known in the art) and the first target binding domain (e.g., any exemplary target binding domain described herein or known in the art) or the first domain of an affinity domain pair (e.g., any exemplary first domain described herein of any exemplary affinity domain pair described herein).In some embodiments, at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) positioned between a soluble tissue factor domain (e.g., any exemplary soluble tissue factor domain described herein) and a first domain of an affinity domain pair (e.g., any first domain described herein or any exemplary affinity domain pair described herein) is directly adjacent to the soluble tissue factor domain and / or the first domain of the affinity domain pair. In some embodiments, the first chimeric polypeptide further comprises a linker sequence (e.g., any exemplary linker sequence described herein or known in the art) disposed between: (i) the soluble tissue factor domain (e.g., any exemplary soluble tissue factor described herein) and at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art), which is positioned between the soluble tissue factor domain (e.g., any exemplary soluble tissue factor domain described herein) and the first domain of an affinity domain pair (e.g., any exemplary first domain of any exemplary affinity domain pair described herein), and / or (ii) the first domain of an affinity domain pair and at least one of the one or more additional target binding domains, which is positioned between the soluble tissue factor domain and the first domain of an affinity domain pair.
[0405] In some embodiments of any multi-chain chimeric polypeptides described herein, the second chimeric polypeptide further comprises one or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) at the N-terminal end and / or C-terminal end of the second chimeric polypeptide. In some embodiments, at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) is directly adjacent to the second domain of the affinity domain pair in the second chimeric polypeptide (e.g., any exemplary second domain of any exemplary affinity domain pair described herein). In some embodiments, the second chimeric polypeptide further comprises a linker sequence (e.g., any exemplary linker sequence described herein or known in the art) between at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) and the second domain of the affinity domain pair (e.g., any second domain of any exemplary affinity domain pair described herein) in the second chimeric polypeptide. In some embodiments, at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) is directly adjacent to the second target binding domain (e.g., any target binding domain described herein or known in the art) in the second chimeric polypeptide. In some embodiments, the second chimeric polypeptide further comprises a linker sequence (e.g., any exemplary linker sequence described herein or known in the art) between at least one of the one or more additional target binding domains (e.g., any exemplary target binding domains described herein or known in the art) and the second target binding domain (e.g., any exemplary target binding domain described herein or known in the art) in the second chimeric polypeptide.
[0406] In some embodiments of any multi-chain chimeric polypeptide described herein, two or more (e.g., three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more) first target binding domains, second target binding domains, and one or more additional target binding domains specifically bind to the same antigen. In some embodiments, two or more (e.g., three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more) first target binding domains, second target binding domains, and one or more additional target binding domains specifically bind to the same epitope. In some embodiments, two or more (e.g., three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more) first target binding domains, second target binding domains, and one or more additional target binding domains comprise the same amino acid sequence. In some embodiments, the first target binding domain, the second target binding domain, and the one or more additional target binding domains each specifically bind to the same antigen. In some embodiments, the first target binding domain, the second target binding domain, and the one or more additional target binding domains each specifically bind to the same epitope. In some embodiments, the first target binding domain, the second target binding domain, and the one or more additional target binding domains each comprise the same amino acid sequence.
[0407] In some embodiments of any multi-chain chimeric polypeptides described herein, the first target binding domain, the second target binding domain, and one or more additional target binding domains specifically bind to different antigens. In some embodiments of any multi-chain chimeric polypeptides described herein, one or more (e.g., two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more) first target binding domains, second target binding domains, and one or more target binding domains are antigen binding domains. In some embodiments, the first target binding domain, the second target binding domain, and one or more additional target binding domains are each an antigen binding domain (e.g., scFv or single domain antibody).
[0408] Affinity domain pairs
[0409] In some embodiments, the multi-chain chimeric polypeptide comprises: 1) a first chimeric polypeptide comprising a first domain of an affinity domain pair, and 2) a second chimeric polypeptide comprising a second domain of the affinity domain pair, such that the first chimeric polypeptide and the second chimeric polypeptide are associated through the binding of the first and second domains of the affinity domain pair. In some embodiments, the affinity domain pair is a sushi domain from the α chain of the human IL-15 receptor (IL15Rα) and soluble IL-15. Sushi domains, also known as short consensus repeats or type 1 glycoprotein motifs, are common motifs in protein-protein interactions. Sushi domains have been found on many protein-binding molecules, including complement components C1r, C1s, factor H, and C2m, as well as non-immune molecules factor XIII and β2-glycoprotein. A typical sushi domain has approximately 60 amino acid residues and contains four cysteines (Ranganathan, Pac. Symp Biocomput. 2000: 155-67). The first cysteine can form a disulfide bond with the third cysteine, and the second cysteine can form a disulfide bridge with the fourth cysteine. In some embodiments where one member of the affinity domain pair is soluble IL-15, the soluble IL15 has a D8N or D8A amino acid substitution. In some embodiments where one member of the affinity domain pair is the α chain of the human IL-15 receptor (IL15Rα), the human IL15Rα is mature, full-length IL15Rα. In some embodiments, the affinity domain pair is barnase and barnstar. In some embodiments, the affinity domain pair is PKA and AKAP. In some embodiments, the affinity domain pairs are adaptor / docking tag modules based on mutant RNase I fragments (Rossi, Proc Natl Acad Sci USA. 103:6841-6846, 2006; Sharkey et al., Cancer Res. 68:5282-5290, 2008; Rossi et al., Trends Pharmacol Sci. 33:474-481, 2012) or SNARE modules based on the interaction between syntaxin, synaptotagmin, synaptobrevin, and SNAP25 (Deyev et al., Nat Biotechnol. 1486-1492, 2003).
[0410] In some embodiments, a first chimeric polypeptide of the multi-chain chimeric polypeptide comprises a first domain of an affinity domain pair, and a second chimeric polypeptide of the multi-chain chimeric polypeptide comprises a second domain of an affinity domain pair, wherein the first domain of the affinity domain pair and the second domain of the affinity domain pair are at a distance of less than 1 x 10-7 M, less than 1x 10 -8 M, less than 1x 10 - 9 M, less than 1x 10 -10 M, less than 1x 10 -11 M, less than 1x 10 -12 M, or less than 1x 10 -13 In some embodiments, the first domain of the affinity domain pair and the second domain of the affinity domain pair bind to each other with a dissociation equilibrium constant (KD) of D Mutual binding: about 1x 10 -4 M to about 1x 10 -6 M, about 1x 10 -5 M to about 1x 10 -7 M, about 1x 10 -6 M to about 1x 10 - 8 M, about 1x 10 -7 M to about 1x 10 -9 M, about 1x 10 -8 M to about 1x 10 -10 M, about 1x 10 -9 M to about 1x 10 -11 M, about 1x 10 -10 M to about 1x 10 -12 M, about 1x 10 -11 M to about 1x 10 -13 M, about 1x 10 -4 M to about 1x 10 -5 M, about 1x 10 -5 M is about 1x10 -6 M, about 1x 10 -6 M to about 1x 10 -7 M, about 1x 10 -7 M to about 1x 10 -8 M, about 1x 10 -8 M is about 1x10 -9 M, about 1x 10 -9 M to about 1x 10 -10 M, about 1x 10 -10 M to about 1x 10 -11 M, about 1x 10 -11 M to about 1x 10 -12 M, or about 1x 10 -12 M to about 1x 10 -13Any of a variety of different methods known in the art (e.g., electrophoretic mobility shift assays, membrane filtration binding assays, surface plasmon resonance, and biomolecule binding kinetics assays, etc.) can be used to determine the K for binding of the first domain of an affinity domain pair to the second domain of the affinity domain pair. D value.
[0411] In some embodiments, a first chimeric polypeptide of the multi-chain chimeric polypeptide comprises a first domain of an affinity domain pair, and a second chimeric polypeptide of the multi-chain chimeric polypeptide comprises a second domain of an affinity domain pair, wherein the first domain of the affinity domain pair, the second domain of the affinity domain pair, or both are about 10 to 100 amino acids long. For example, the first domain of the affinity domain pair, the second domain of the affinity domain pair, or both can be about 10 to 100 amino acids long, about 15 to 100 amino acids long, about 20 to 100 amino acids long, about 25 to 100 amino acids long, about 30 to 100 amino acids long, about 35 to 100 amino acids long, about 40 to 100 amino acids long, about 45 to 100 amino acids long, about 50 to 100 amino acids long, about 55 to 100 amino acids long, or about 60 to 100 amino acids long. 100 amino acids long, about 60 to 100 amino acids long, about 65 to 100 amino acids long, about 70 to 100 amino acids long, about 75 to 100 amino acids long, about 80 to 100 amino acids long, about 85 to 100 amino acids long, about 90 to 100 amino acids long, about 95 to 100 amino acids long, about 10 to 95 amino acids long, about 10 to 90 amino acids long, about 10 to 85 amino acids long, about 10 to 80 amino acids long amino acids long, about 10 to 75 amino acids long, about 10 to 70 amino acids long, about 10 to 65 amino acids long, about 10 to 60 amino acids long, about 10 to 55 amino acids long, about 10 to 50 amino acids long, about 10 to 45 amino acids long, about 10 to 40 amino acids long, about 10 to 35 amino acids long, about 10 to 30 amino acids long, about 10 to 25 amino acids long, about 10 to 20 amino acids long, about 10 to 15 amino acids long In some embodiments, the first domain of the affinity domain pair, the second domain of the affinity domain pair, or both, is about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids in length.
[0412] In some embodiments, any of the first and / or second domains of the affinity domain pairs disclosed herein may include one or more additional amino acids (e.g., 1, 2, 3, 5, 6, 7, 8, 9, 10, or more amino acids) at their N-terminus and / or C-terminus, as long as the function of the first and / or second domains of the affinity domain pair remains intact. For example, the sushi domain of the α chain from the human IL-15 receptor (IL15Rα) may include one or more additional amino acids at the N-terminus and / or C-terminus while still retaining the ability to bind to soluble IL-15. Additionally or alternatively, soluble IL-15 may include one or more additional amino acids at the N-terminus and / or C-terminus while still retaining the ability to bind to the sushi domain of the α chain from the human IL-15 receptor (IL15Rα).
[0413] Non-limiting examples of sushi domains from the alpha chain of IL-15 receptor alpha (IL15Rα) can include sequences that are at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 99% identical, or 100% identical to ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECV LNKATNVAHWTTPSLKCIR (SEQ ID NO: 29). In some embodiments, the sushi domain from the alpha chain of IL15Rα can be encoded by a nucleic acid comprising ATTACATGCCCCCCTCCCATGAGCGTGGAGCACGCCGACATCTGGGTGAAGAGCTATAGCCTCTACAGCCGGGAGAGGTATATCTGTAACAGCGGCTTCAAGAGGAAGGCCGGCACCAGCAGCCTCACCGAGTGCGTGCTGAATAAGGCTACCAACGTGGCTCACTGGACAACACCCTCTTTAAAGTGCATCCGG (SEQ ID NO: 30).
[0414] In some embodiments, the soluble IL-15 may comprise a sequence that is at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 99% identical, or 100% identical to NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESSGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS (SEQ ID NO: 15). In some embodiments, soluble IL-15 can be encoded by a nucleic acid comprising the sequence: AACTGGGTGAACGTCATCAGCGATTTAAAGAAGAT CGAAGATTTAATTCAGTCCATGCATATCGACGCCACTTTATACACAGAATCCGACGTGCACCCCTCTTGTAAGGTGACCGCCATGAAATGTTTTTTACTGGAGCTGCAAGTTATCTCTTTAGAGAGCGGAGACGCTAGCATCCACGACACCGTGGAGAATTTAATCATTTTAGCCAATAACTCTTTATCCAGCAACGGCAACGTGACAGAGTCCGGCTGCAAGGAGTGCGAAGAGCTGGAGGAGAAGAACATCAAGGAGTTTCTGCAATCCTTTGTGCACATTGTCCAGATGTTCATCAATACCTCC (SEQ ID NO: 31).
[0415] signal sequence
[0416] In some embodiments, the multi-chain chimeric polypeptide includes a first chimeric polypeptide comprising a signal sequence at its N-terminus. In some embodiments, the multi-chain chimeric polypeptide includes a second chimeric polypeptide comprising a signal sequence at its N-terminus. In some embodiments, the first chimeric polypeptide of the multi-chain chimeric polypeptide and the second chimeric polypeptide of the multi-chain chimeric polypeptide both comprise a signal sequence. One of ordinary skill in the art will appreciate that a signal sequence is an amino acid sequence present at the N-terminus of many endogenously produced proteins that guides the protein into the secretory pathway (e.g., guiding the protein to reside in certain intracellular organelles, reside in the cell membrane, or be secreted from the cell). Signal sequences are heterogeneous and their primary amino acid sequences vary greatly. However, signal sequences are typically 16 to 30 amino acids in length and include a hydrophilic, generally positively charged N-terminal region, a central hydrophobic domain, and a C-terminal region comprising a signal peptidase cleavage site.
[0417] In some embodiments, the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both comprise a signal sequence having the amino acid sequence MKWVTFISLLFLFSSAYS (SEQ ID NO: 32). In some embodiments, the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both comprise a signal sequence encoded by the nucleic acid sequence ATGAAATGGGTGACCTTTATTTCTTTACTGTTCCTCTTTAGCAGCGCCTA CTCC (SEQ ID NO: 33), ATGAAGTGGGTCACATTTATCTCTTTACTGTTC CTCTTCTCCAGCGCCTACAGC (SEQ ID NO: 34), or ATGAAATGGGTGAC CTTTATTTCTTTACTGTTCCTCTTTAGCAGCGCCTACTCC (SEQ ID NO: 35).
[0418] In some embodiments, the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both comprise a signal sequence having the amino acid sequence MKCLLYLAFLFLGVNC (SEQ ID NO: 36). In some embodiments, the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both comprise a signal sequence having the amino acid sequence MGQIVTMFEALPHIIDEVINIVIIVLIIITSIKAVYNFATCGILALVSFLFLAGRSCG (SEQ ID NO: 37). In some embodiments, the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both comprise a signal sequence having the amino acid sequence MPNHQSGSPTGSSDLLLSGKKQRPHLALRRKRRREMRKINRKVRRMNLAPIKEKTAWQHLQALISEAEEVLKTSQTPQNSLTLFLALLSVLGPPVTG (SEQ ID NO: 38). In some embodiments, the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both comprise a signal sequence having the amino acid sequence MDSKGSSQKGSRLLLLLVVSNLLLCQGVVS (SEQ ID NO: 39). One of ordinary skill in the art will appreciate other suitable signal sequences that can be used in the first chimeric polypeptide and / or the second chimeric polypeptide of the multi-chain chimeric polypeptide described herein.
[0419] In some embodiments, the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both comprise a signal sequence that is about 10 to 100 amino acids in length. For example, the signal sequence can be about 10 to 100 amino acids long, about 15 to 100 amino acids long, about 20 to 100 amino acids long, about 25 to 100 amino acids long, about 30 to 100 amino acids long, about 35 to 100 amino acids long, about 40 to 100 amino acids long, about 45 to 100 amino acids long, about 50 to 100 amino acids long, about 55 to 100 amino acids long, about 60 to 100 amino acids long, or about 70 to 100 amino acids long. amino acids long, about 65 to 100 amino acids long, about 70 to 100 amino acids long, about 75 to 100 amino acids long, about 80 to 100 amino acids long, about 85 to 100 amino acids long, about 90 to 100 amino acids long, about 95 to 100 amino acids long, about 10 to 95 amino acids long, about 10 to 90 amino acids long, about 10 to 85 amino acids long, about 10 to 80 amino acids long, about 10 to 75 amino acids long amino acids long, about 10 to 70 amino acids long, about 10 to 65 amino acids long, about 10 to 60 amino acids long, about 10 to 55 amino acids long, about 10 to 50 amino acids long, about 10 to 45 amino acids long, about 10 to 40 amino acids long, about 10 to 35 amino acids long, about 10 to 30 amino acids long, about 10 to 25 amino acids long, about 10 to 20 amino acids long, about 10 to 15 amino acids long, about 20 In some embodiments, the signal sequence is about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids in length.
[0420] In some embodiments, any of the signal sequences disclosed herein may comprise one or more additional amino acids (e.g., 1, 2, 3, 5, 6, 7, 8, 9, 10 or more amino acids) at its N-terminus and / or C-terminus, as long as the function of the signal sequence remains intact. For example, a signal sequence having the amino acid sequence MKCLLYLAFLFLGVNC (SEQ ID NO: 36) may comprise one or more additional amino acids at the N-terminus or C-terminus while still retaining the ability to direct the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both, to the secretory pathway.
[0421] In some embodiments, the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both comprise a signal sequence that directs the multi-chain chimeric polypeptide into the extracellular space. Such embodiments can be used to produce multi-chain chimeric polypeptides that are relatively easy to isolate and / or purify.
[0422] Peptide tags
[0423] In some embodiments, the multi-chain chimeric polypeptide comprises a first chimeric polypeptide comprising a peptide tag (e.g., at the N-terminus or C-terminus of the first chimeric polypeptide). In some embodiments, the multi-chain chimeric polypeptide comprises a second chimeric polypeptide comprising a peptide tag (e.g., at the N-terminus or C-terminus of the second chimeric polypeptide). In some embodiments, both the first chimeric polypeptide of the multi-chain chimeric polypeptide and the second chimeric polypeptide of the multi-chain chimeric polypeptide comprise a peptide tag. In some embodiments, the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both comprise two or more peptide tags.
[0424] Exemplary peptide tags that can be included in the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both include, but are not limited to, an Avi tag (GLNDIFEAQKIEWHE; SEQ ID NO:40), a calmodulin tag (KRRWKKNFIAVSAANRFKKISSSGAL; SEQ ID NO:41), a polyglutamate tag (EEEEEE; SEQ ID NO:42), an E-tag (GAPVPYPDPLEPR; SEQ ID NO:43), a FLAG-tag (DYKDDDDK; SEQ ID NO:44), an HA-tag (peptide from hemagglutinin) (YPYDVPDYA; SEQ ID NO:45), a his-tag (HHHHH (SEQ ID NO:46); HHHHHH (SEQ ID NO:47); HHHHHHH (SEQ ID NO:48); HHHHHHHH (SEQ ID NO:49); HHHHHHHHH (SEQ ID NO:50). NO:50; or HHHHHHHHHHH (SEQ ID NO:51)), myc-tag (EQKLISEEDL; SEQ ID NO:52), NE-tag (TKENPRSNQEESYDDNES; SEQ ID NO:53), S-tag (KETAAAKFERQHMDS; SEQ ID NO:54), SBP-tag (MDEKTTGWRGGHVVEGLAGELEQLRARLEHHPQGQREP; SEQ ID NO:55), Sof tag 1 (SLAELLNAGLGGS; SEQ ID NO:56), Sof tag 3 (TQDPSRVG; SEQ ID NO:57), Spot-tag (PDRVRAVSHWSS; SEQ ID NO:58), Strep-tag (WSHPQFEK; SEQ ID NO:59), TC tag (CCPGCC; SEQ ID NO:60), Ty tag (EVHTNQDPLD; SEQ ID NO:61). NO:61), V5 tag (GKPIPNPLLGLDST; SEQ ID NO:62), VSV-tag (YTDIEMNRLGK; SEQ ID NO:63), and Xpress tag (DLYDDDDK; SEQ ID NO:64). In some embodiments, the tissue factor protein is a peptide tag.
[0425] The peptide tag that can be included in the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both can be used in any of a variety of applications related to multi-chain chimeric polypeptides. For example, the peptide tag can be used to purify the multi-chain chimeric polypeptide. As a non-limiting example, the first chimeric polypeptide of the multi-chain chimeric polypeptide (e.g., the recombinantly expressed first chimeric polypeptide), the second chimeric polypeptide of the multi-chain chimeric polypeptide (e.g., the recombinantly expressed second chimeric polypeptide), or both can include a myc tag; antibodies that recognize one or more myc tags can be used to purify the multi-chain chimeric polypeptide including the first chimeric polypeptide with a myc tag, the second chimeric polypeptide with a myc tag, or both. A non-limiting example of an antibody that recognizes a myc tag is 9E10, which is available from the non-commercial Developmental Research Hybridoma Bank. As another non-limiting example, the first chimeric polypeptide of the multi-chain chimeric polypeptide (e.g., the recombinantly expressed first chimeric polypeptide), the second chimeric polypeptide of the multi-chain chimeric polypeptide (e.g., the recombinantly expressed second chimeric polypeptide), or both can comprise a histidine tag; the multi-chain chimeric polypeptide comprising the first chimeric polypeptide with the histidine tag, the second chimeric polypeptide with the histidine tag, or both can be purified using nickel or cobalt chelates. One of ordinary skill in the art will recognize other suitable tags and agents that bind to these tags for purification of multi-chain chimeric polypeptides. In some embodiments, the peptide tag is removed from the first chimeric polypeptide and / or the second chimeric polypeptide of the multi-chain chimeric polypeptide after purification. In some embodiments, the peptide tag is not removed from the first chimeric polypeptide and / or the second chimeric polypeptide of the multi-chain chimeric polypeptide after purification.
[0426] The peptide tag that can be contained in the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both can be used, for example, in immunoprecipitation of the multi-chain chimeric polypeptide, imaging of the multi-chain chimeric polypeptide (e.g., via Western blot, ELISA, flow cytometry, and / or immunocytochemistry), and / or solubilization of the multi-chain chimeric polypeptide.
[0427] In some embodiments, the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both comprise a peptide tag that is about 10 to 100 amino acids in length. For example, the peptide tag can be about 10 to 100 amino acids long, about 15 to 100 amino acids long, about 20 to 100 amino acids long, about 25 to 100 amino acids long, about 30 to 100 amino acids long, about 35 to 100 amino acids long, about 40 to 100 amino acids long, about 45 to 100 amino acids long, about 50 to 100 amino acids long, about 55 to 100 amino acids long, about 60 to 100 amino acids long, or about 70 to 100 amino acids long. long, about 65 to 100 amino acids long, about 70 to 100 amino acids long, about 75 to 100 amino acids long, about 80 to 100 amino acids long, about 85 to 100 amino acids long, about 90 to 100 amino acids long, about 95 to 100 amino acids long, about 10 to 95 amino acids long, about 10 to 90 amino acids long, about 10 to 85 amino acids long, about 10 to 80 amino acids long, about 10 to 75 amino acids long amino acids long, about 10 to 70 amino acids long, about 10 to 65 amino acids long, about 10 to 60 amino acids long, about 10 to 55 amino acids long, about 10 to 50 amino acids long, about 10 to 45 amino acids long, about 10 to 40 amino acids long, about 10 to 35 amino acids long, about 10 to 30 amino acids long, about 10 to 25 amino acids long, about 10 to 20 amino acids long, about 10 to 15 amino acids long, about 20 In some embodiments, the peptide tag is about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids in length.
[0428] The peptide tag included in the first chimeric polypeptide of the multi-chain chimeric polypeptide, the second chimeric polypeptide of the multi-chain chimeric polypeptide, or both can have any suitable length. For example, the length of the peptide tag can be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acids. In embodiments where the multi-chain chimeric polypeptide comprises two or more peptide tags, the two or more peptide tags can have the same or different lengths. In some embodiments, any peptide tag disclosed herein can include one or more additional amino acids (e.g., 1, 2, 3, 5, 6, 7, 8, 9, 10 or more amino acids) at the N-terminus and / or the C-terminus, as long as the function of the peptide tag remains intact. For example, a myc tag having the amino acid sequence EQKLISEEDL (SEQ ID NO: 65) can include one or more additional amino acids (e.g., at the N-terminus and / or the C-terminus of the peptide tag) while still retaining the ability to be bound by an antibody (e.g., 9E10).
[0429] Exemplary multi-chain chimeric polypeptides
[0430] In some examples of multi-chain chimeric polypeptides, the first target binding domain and the soluble tissue factor domain are directly adjacent to each other in the first chimeric polypeptide. In some embodiments of multi-chain chimeric polypeptides, the soluble tissue factor domain and the first domain of the affinity domain pair are directly adjacent to each other in the first chimeric polypeptide.
[0431] In some embodiments of these multi-chain chimeric polypeptides, the second domain of the affinity domain pair and the second target binding domain are directly adjacent to each other in the second chimeric polypeptide.
[0432] In some embodiments of these multi-chain chimeric polypeptides, the soluble tissue factor domain can be any exemplary soluble tissue factor domain described herein. In some embodiments of these multi-chain chimeric polypeptides, the affinity domain pair can be any exemplary affinity domain pair described herein.
[0433] In some embodiments of these multi-chain chimeric polypeptides, one or both of the first target binding domain and the second target binding domain is a soluble TGF-β receptor (e.g., soluble TGFRβRII, e.g., soluble human TGFRβRII).
[0434] In some embodiments of the multi-chain chimeric polypeptide, the soluble human TGFRβRII comprises a first sequence of soluble human TGFRβRII and a second sequence of soluble human TGFRβRII. In some embodiments of these multi-chain chimeric polypeptides, the soluble human TGFRβRII comprises a linker disposed between the first sequence of soluble human TGFRβRII and the second sequence of soluble human TGFRβRII. In some examples of these multi-chain chimeric polypeptides, the linker comprises the sequence GGGGSGGGGSGGGGS (SEQ ID NO: 7).
[0435] In some embodiments of these multi-chain chimeric polypeptides, the first sequence of the soluble human TGFRβRII receptor comprises a sequence that is at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to:
[0436] IPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD (SEQ ID NO: 66).
[0437] In some embodiments of these multi-chain chimeric polypeptides, the second sequence of the soluble human TGFRβRII receptor comprises a sequence that is at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to:
[0438] IPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD (SEQ ID NO: 66).
[0439] In some embodiments of these multi-chain chimeric polypeptides, the first sequence of the soluble human TGFRβRII receptor is encoded by a sequence that is at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to:
[0440] ATTCCTCCCCACGTGCAGAAGAGCGTGAATAATGACATGATCGTGACCGATAACAATGGCGCCGTGAAATTTCCCCAGCTGTGCAAATTCTGCGATGTGAGGTTTTCCACCTGCGACAACCAGAAGTCCTGTATGAGCAACTGCACAATCACCTCCATCTGTGAGAAGCCTCAGGAGGTGTGCGTGGCTGTCTGGCGGAAGAATGA CGAGAATATCACCCTGGAAACCGTCTGCCACGATCCCAAGCTGCCCTACCACGATTTCATCCTGGAAGACGCCGCCAGCCCTAAGTGCATCATGAAAGAAAAAGAAGCCTGGCGAGACCTTTTTCATGTGCTCCTGCAGCAGCGACGAATGCAACGACAATATCATCTTTAGCGAGGAATACAATACCAGCAACCCCGAC(SEQ ID NO:67).
[0441] In some embodiments of these multi-chain chimeric polypeptides, the second sequence of the soluble human TGFRβRII receptor is encoded by a sequence that is at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to:
[0442] ATTCCTCCCCACGTGCAGAAGAGCGTGAATAATGACATGATCGTGACCGATAACAATGGCGCCGTGAAATTTCCCCAGCTGTGCAAATTCTGCGATGTGAGGTTTTCCACCTGCGACAACCAGAAGTCCTGTATGAGCAACTGCACAATCACCTCCATCTGTGAGAAGCCTCAGGAGGTGTGCGTGGCTGTCTGGCGGAAGAATGA CGAGAATATCACCCTGGAAACCGTCTGCCACGATCCCAAGCTGCCCTACCACGATTTCATCCTGGAAGACGCCGCCAGCCCTAAGTGCATCATGAAAGAAAAAGAAGCCTGGCGAGACCTTTTTCATGTGCTCCTGCAGCAGCGACGAATGCAACGACAATATCATCTTTAGCGAGGAATACAATACCAGCAACCCCGAC(SEQ ID NO:67).
[0443] In some embodiments of these multi-chain chimeric polypeptides, the soluble human TGFRβRII receptor is encoded by a sequence that is at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to:
[0444] ATCCCCCCCCATGTGCAAAAGAGCGTGAACAACGATATGATCGTGACCGACAACAACGGCGCCGTGAAGTTTCCCCAGCTCTGCAAGTTCTGCGATGTCAGGTTCAGCACCTGCGATAATCAGAAGTCCTGCATGTCCAACTGCACGATCACCTCCATCTGCGAGAAGCCCCAAGAAGTGTGCGTGGCCGTGTGGCGGAAAAATGACGAGAACATCACCCTGGAGACCGTGTGTCACGACCCCAAGCTCCCTTATCACGACTTCATTCTGGAGGACGCTGCCTCCCCCAAATGCATCATGAAGGAGAAGAAGAAGCCCGGAGAGACCTTCTTTATGTGTTCCTGTAGCAGCGACGAGTGTAACGACAACATCATCTTCAGCGAAGAGTACAACACCAGCAACCCTGATGGAGGTGGCGGATCCGGAGGTGGAGGTTCTGGTGGAGGTGGGAGTATTCCTCCCCACGTGCAGAAGAGCGTGAATAATGACATGATCGTGACCGATAACAATGGCGCCGTGAAATTTCCCCAGCTGTGCAAATTCTGCGATGTGAGGTTTTCCACCTGCGACAACCAGAAGTCCTGTATGAGCAACTGCACAATCACCTCCATCTGTGAGAAGCCTCAGGAGGTGTGCGTGGCTGTCTGGCGGAAGAATGACGAGAATATCACCCTGGAAACCGTCTGCCACGATCCCAAGCTGCCCTACCACGATTTCATCCTGGAAGACGCCGCCAGCCCTAAGTGCATCATGAAAGAGAAAAAGAAGCCTGGCGAGACCTTTTTCATGTGCTCCTGCAGCAGCGACGAATGCAACGACAATATCATCTTTAGCGAGGAATACAATACCAGCAACCCCGAC(SEQ ID NO:68)。
[0445] In some embodiments of these multi-chain chimeric polypeptides, the human TGFβRII receptor comprises a sequence that is at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to:
[0446] IPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSGGGG SGGGGSIPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(SEQ IDNO:69).
[0447] In some embodiments, the first chimeric polypeptide can comprise a sequence that is at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to (SEQ ID NO: 70).
[0448]
[0449] In some embodiments, the first chimeric polypeptide can comprise a sequence that is at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to (SEQ ID NO: 72).
[0450]
[0451] In some embodiments, the second chimeric polypeptide can comprise a sequence at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to IPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGET FFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSGGGGSGGGGSIPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDP KLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIR(SEQ ID NO:74).
[0452]
[0453] In some embodiments, the second chimeric polypeptide can comprise a sequence at least 80% identical (e.g., at least 82% identical, at least 84% identical, at least 86% identical, at least 88% identical, at least 90% identical, at least 92% identical, at least 94% identical, at least 96% identical, at least 98% identical, at least 99% identical, or 100% identical) to: MKWVTFISLLFLFSSAYSIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIM KEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSGGGGSGGGGSIPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIR(SEQ ID NO:76).
[0454]
[0455] Nucleic acid / vector
[0456] Also provided herein are nucleic acids encoding any of the multi-chain chimeric polypeptides described herein. In some embodiments, a first nucleic acid can encode a first chimeric polypeptide and a second nucleic acid can encode a second chimeric polypeptide. In some embodiments, a single nucleic acid can encode both the first chimeric polypeptide and the second chimeric polypeptide.
[0457] Also provided herein are vectors comprising any nucleic acid encoding any of the multi-chain chimeric polypeptides described herein. In some embodiments, a first vector may comprise a nucleic acid encoding a first chimeric polypeptide, and a second vector may comprise a nucleic acid encoding a second chimeric polypeptide. In some embodiments, a single vector may comprise a first nucleic acid encoding a first chimeric polypeptide and a second nucleic acid encoding a second chimeric polypeptide.
[0458] Any vector described herein can be an expression vector. For example, the expression vector can include a promoter sequence operably linked to the sequence encoding the first chimeric polypeptide and the second chimeric polypeptide.
[0459] Non-limiting examples of vectors include plasmids, transposons, cosmids, and viral vectors (e.g., any adenoviral vector (e.g., pSV or pCMV vector), adeno-associated virus (AAV) vector, lentiviral vector, and retroviral vector), as well as any Vectors. The vectors may, for example, include sufficient cis-acting elements for expression; other elements for expression may be provided by the host mammalian cells or in an in vitro expression system. A skilled artisan will be able to select appropriate vectors and mammalian cells to produce any of the multi-chain chimeric polypeptides described herein.
[0460] cell
[0461] Also provided herein are cells (e.g., any of the exemplary cells described herein or known in the art) comprising any of the nucleic acids described herein encoding any of the multi-chain chimeric polypeptides described herein (e.g., encoding both a first and a second chimeric polypeptide). Also provided herein are cells (e.g., any of the exemplary cells described herein or known in the art) comprising any of the nucleic acids described herein encoding any of the first chimeric polypeptides described herein. Also provided herein are cells (e.g., any of the exemplary cells described herein or known in the art) comprising any of the nucleic acids described herein encoding any of the second chimeric polypeptides described herein.
[0462] Also provided herein are cells (e.g., any of the exemplary cells described herein or known in the art) comprising any of the vectors described herein encoding any of the multi-chain chimeric polypeptides described herein (e.g., encoding both a first and a second chimeric polypeptide). Also provided herein are cells (e.g., any of the exemplary cells described herein or known in the art) comprising any of the vectors described herein encoding any of the first chimeric polypeptides described herein. Also provided herein are cells (e.g., any of the exemplary cells described herein or known in the art) comprising any of the vectors described herein encoding any of the second chimeric polypeptides described herein.
[0463] In some embodiments of any of the methods described herein, the cell can be a eukaryotic cell. As used herein, the term "eukaryotic cell" refers to a cell with a unique membrane-bound nucleus. Such cells may include, for example, mammalian (e.g., rodent, non-human primate, or human), insect, fungal, or plant cells. In certain embodiments, the eukaryotic cell is a yeast cell, such as Saccharomyces cerevisiae. In certain embodiments, the eukaryotic cell is a higher eukaryotic organism, such as a mammalian, avian, plant, or insect cell. Non-limiting examples of mammalian cells include Chinese hamster ovary cells and human embryonic kidney cells (e.g., HEK293 cells).
[0464] Methods for introducing nucleic acids and expression vectors into cells (e.g., eukaryotic cells) are known in the art. Non-limiting examples of methods that can be used to introduce nucleic acids into cells include lipofection, transfection, electroporation, microinjection, calcium phosphate transfection, dendrimer-based transfection, cationic polymer transfection, cell squeezing, sonoporation, optical transfection, transfection by penetration, hydrodynamic delivery, magnetofection, viral transduction (e.g., adenoviral and lentiviral transduction), and nanoparticle transfection.
[0465] Methods for producing multi-chain chimeric polypeptides
[0466] Also provided herein are methods of producing any of the multi-chain chimeric polypeptides described herein, the methods comprising: culturing any of the cells described herein in a culture medium under conditions sufficient to cause production of the multi-chain chimeric polypeptide; and recovering the multi-chain chimeric polypeptide from the cells and / or the culture medium.
[0467] Also provided herein are methods of producing any of the multi-chain chimeric polypeptides described herein, the methods comprising: culturing any of the cells described herein in a first culture medium under conditions sufficient to result in production of a first chimeric polypeptide; recovering the first chimeric polypeptide from the cells and / or the first culture medium; culturing any of the cells described herein in a second culture medium under conditions sufficient to result in production of a second chimeric polypeptide; recovering the second chimeric polypeptide from the cells and / or the second culture medium; and combining (e.g., mixing) the recovered first chimeric polypeptide and the recovered second chimeric polypeptide to form a multi-chain chimeric polypeptide (e.g., any multi-chain chimeric polypeptide described herein).
[0468] Recovery of the multi-chain chimeric polypeptide, the first chimeric polypeptide, or the second chimeric polypeptide from cells (e.g., eukaryotic cells) can be performed using techniques well known in the art (e.g., ammonium sulfate precipitation, polyethylene glycol precipitation, ion exchange chromatography (anionic or cationic), hydrophobic interaction-based chromatography, metal affinity chromatography, ligand affinity chromatography, and size exclusion chromatography).
[0469] Methods for culturing cells are well known in the art. Cells can be maintained in vitro under conditions that are conducive to proliferation, differentiation, and growth. In short, cells can be cultured by contacting cells (e.g., any cells) with a cell culture medium containing necessary growth factors and supplements to support cell viability and growth.
[0470] Also provided herein are multi-chain chimeric polypeptides (e.g., any of the multi-chain chimeric polypeptides described herein), first chimeric polypeptides (e.g., any first chimeric polypeptide of the first chimeric polypeptides), or second chimeric polypeptides (e.g., any second chimeric polypeptide of the second chimeric polypeptides described herein) produced by any of the methods described herein.
[0471] Treatment
[0472] Provided herein are methods for treating unresectable advanced / metastatic pancreatic cancer in a subject (e.g., any of the exemplary subjects described herein or known in the art), comprising administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; and (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds to a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds to a ligand of TGF-βRII. Any of the exemplary multi-chain chimeric polypeptides described herein can be used in these methods.
[0473] In some embodiments, the methods described herein can result in a decrease in the size and / or volume of a tumor in a subject or population of subjects (e.g., at least a 1% decrease, at least a 5% decrease, at least a 10% decrease, at least a 15% decrease, at least a 20% decrease, at least a 25% decrease, at least a 30% decrease, at least a 35% decrease, at least a 40% decrease, at least a 45% decrease, at least a 50% decrease, at least a 55% decrease, at least a 60% decrease, at least a 65% decrease, at least a 70% decrease, at least a 75% decrease, at least a 80% decrease, at least a 85% decrease, at least a 90% decrease, at least a 95% decrease, or at least a 99% decrease, or about a 1% decrease to about a 95% decrease, about a 1% decrease to about a 90% decrease). reduction, about 1% reduction to about 85% reduction, about 1% reduction to about 80% reduction, about 1% reduction to about 75% reduction, about 1% reduction to about 70% reduction, about 1% reduction to about 65% reduction, about 1% reduction to about 60% reduction, about 1% reduction to about 55% reduction, about 1% reduction to about 50% reduction, about 1% reduction to about 45% reduction, about 1% reduction to about 40% reduction, about 1% reduction to about 35% reduction, about 1% reduction to about 30% reduction, about 1% reduction to about 25% reduction, about 1% reduction to about 20% reduction, about 1% reduction to about 15% reduction, about 1% reduction to about 10% reduction, about 1% reduction to about 5% reduction, about 5% reduction to about 99% reduction, about 5% reduction to about 95% reduction, about 5% reduction to about 90% reduction, about 5% reduction to about 85% reduction, about 5% reduction to about 80% reduction, about 5% reduction to about 75% reduction, about 5% reduction to about 70% reduction, about 5% reduction to about 65% reduction, about 5% reduction to about 60% reduction, about 5% reduction to about 55% reduction, about 5% reduction to about 50% reduction, about 5% reduction to about 45% reduction, about 5% reduction to about 40% reduction, about 5% reduction to about 35% reduction, about 5% reduction to about 30% reduction, about 5% reduction to about 25% reduction, about 5% reduction to about 20% reduction, about 5% reduction to about 15% reduction, about 5% reduction to about 10% reduction, about 10% reduction to about 99% reduction, about 10% reduction to about 95% reduction, about 1 0% reduction to about 90% reduction, about 10% reduction to about 85% reduction, about 10% reduction to about 80% reduction, about 10% reduction to about 75% reduction, about 10% reduction to about 70% reduction, about 10% reduction to about 65% reduction, about 10% reduction to about 60% reduction, about 10% reduction to about 55% reduction, about 10% reduction to about 50% reduction, about 10% reduction to about 45% reduction, about 10% reduction to about 40% reduction, about 10% reduction to about 35% reduction, about 10% reduction to about 30% reduction, about 10% reduction to about 25% reduction, about 10% reduction to about 20% reduction, about 10% reduction to about 15% reduction, about 15% reduction to about 99% reduction, about 15% reduction to about 95% reduction,about 15% reduction to about 90% reduction, about 15% reduction to about 85% reduction, about 15% reduction to about 80% reduction, about 15% reduction to about 75% reduction, about 15% reduction to about 70% reduction, about 15% reduction to about 65% reduction, about 15% reduction to about 60% reduction, about 15% reduction to about 55% reduction, about 15% reduction to about 50% reduction, about 15% reduction to about 45% reduction, about 15% reduction to about 40% reduction, about 15% reduction to about 35% reduction, about 15% reduction to about 30% reduction, about 15% reduction to about 25% reduction, about 15% reduction to about 20% reduction, about 20% reduction to about 99% reduction, about 20% reduction to about 95% reduction, about 20% reduction to about 90 % reduction, about 20% reduction to about 85% reduction, about 20% reduction to about 80% reduction, about 20% reduction to about 75% reduction, about 20% reduction to about 70% reduction, about 20% reduction to about 65% reduction, about 20% reduction to about 60% reduction, about 20% reduction to about 55% reduction, about 20% reduction to about 50% reduction, about 20% reduction to about 45% reduction, about 20% reduction to about 40% reduction, about 20% reduction to about 35% reduction, about 20% reduction to about 30% reduction, about 20% reduction to about 25% reduction, about 25% reduction to about 99% reduction, about 25% reduction to about 95% reduction, about 25% reduction to about 90% reduction, about 25% reduction to about 85% reduction, about 25% reduction to about 80% reduction, about 25% reduction to about 75% reduction, about 25% reduction to about 70% reduction, about 25% reduction to about 65% reduction, about 25% reduction to about 60% reduction, about 25% reduction to about 55% reduction, about 25% reduction to about 50% reduction, about 25% reduction to about 45% reduction, about 25% reduction to about 40% reduction, about 25% reduction to about 35% reduction, about 25% reduction to about 30% reduction, about 30% reduction to about 99% reduction, about 30% reduction to about 95% reduction, about 30% reduction to about 90% reduction, about 30% reduction to about 85% reduction, about 30% reduction to about 80% reduction, about 30% reduction to about 75% reduction, about 30% reduction to about 70% reduction, about 30 % reduction to about 65% reduction, about 30% reduction to about 60% reduction, about 30% reduction to about 55% reduction, about 30% reduction to about 50% reduction, about 30% reduction to about 45% reduction, about 30% reduction to about 40% reduction, about 30% reduction to about 35% reduction, about 35% reduction to about 99% reduction, about 35% reduction to about 95% reduction, about 35% reduction to about 90% reduction, about 35% reduction to about 85% reduction, about 35% reduction to about 80% reduction, about 35% reduction to about 75% reduction, about 35% reduction to about 70% reduction, about 35% reduction to about 65% reduction, about 35% reduction to about 60% reduction, about 35% reduction to about 55% reduction, about 35% reduction to about 50% reduction,about 35% reduction to about 45% reduction, about 35% reduction to about 40% reduction, about 40% reduction to about 99% reduction, about 40% reduction to about 95% reduction, about 40% reduction to about 90% reduction, about 40% reduction to about 85% reduction, about 40% reduction to about 80% reduction, about 40% reduction to about 75% reduction, about 40% reduction to about 70% reduction, about 40% reduction to about 65% reduction, about 40% reduction to about 60% reduction, about 40% reduction to about 55% reduction, about 40% reduction to about 50% reduction, about 40% reduction to about 45% reduction, about 45% reduction to about 99% reduction, about 45% reduction to about 95% reduction, about 45% reduction to about 90% reduction, about 45% reduction to about 85 % reduction, about 45% reduction to about 80% reduction, about 45% reduction to about 75% reduction, about 45% reduction to about 70% reduction, about 45% reduction to about 65% reduction, about 45% reduction to about 60% reduction, about 45% reduction to about 55% reduction, about 45% reduction to about 50% reduction, about 50% reduction to about 99% reduction, about 50% reduction to about 95% reduction, about 50% reduction to about 90% reduction, about 50% reduction to about 85% reduction, about 50% reduction to about 80% reduction, about 50% reduction to about 75% reduction, about 50% reduction to about 70% reduction, about 50% reduction to about 65% reduction, about 50% reduction to about 60% reduction, about 50% reduction to about 55% reduction, about 55% reduction to about 99% reduction, about 55% reduction to about 95% reduction, about 55% reduction to about 90% reduction, about 55% reduction to about 85% reduction, about 55% reduction to about 80% reduction, about 55% reduction to about 75% reduction, about 55% reduction to about 70% reduction, about 55% reduction to about 65% reduction, about 55% reduction to about 60% reduction, about 60% reduction to about 99% reduction, about 60% reduction to about 95% reduction, about 60% reduction to about 90% reduction, about 60% reduction to about 85% reduction, about 60% reduction to about 80% reduction, about 60% reduction to about 75% reduction, about 60% reduction to about 70% reduction, about 60% reduction to about 65% reduction, about 65% reduction to about 99% reduction, about 65 % reduction to about 95% reduction, about 65% reduction to about 90% reduction, about 65% reduction to about 85% reduction, about 65% reduction to about 80% reduction, about 65% reduction to about 75% reduction, about 65% reduction to about 70% reduction, about 70% reduction to about 99% reduction, about 70% reduction to about 95% reduction, about 70% reduction to about 90% reduction, about 70% reduction to about 85% reduction, about 70% reduction to about 80% reduction, about 70% reduction to about 75% reduction, about 75% reduction to about 99% reduction, about 75% reduction to about 95% reduction, about 75% reduction to about 90% reduction, about 75% reduction to about 85% reduction, about 75% reduction to about 80% reduction, about 80% reduction to about 99% reduction,
[0013] The present invention relates to a method for evaluating the size and / or volume of a tumor in a subject, e.g., from about 80% to about 95% reduction, from about 80% to about 90% reduction, from about 80% to about 85% reduction, from about 85% to about 99% reduction, from about 85% to about 95% reduction, from about 85% to about 90% reduction, from about 90% to about 99% reduction, from about 90% to about 95% reduction, or from about 95% to about 99% reduction), for example, compared to the size and / or volume of the tumor before administration, or compared to a similar subject not receiving treatment or receiving a different treatment. In some embodiments, the size and / or volume of a subject's tumor can be assessed by X-ray, ultrasound, computed tomography (CT) scan, magnetic resonance imaging (MRI), and positron emission tomography (PET).
[0474] In some embodiments, the methods described herein can result in a decrease in tumor growth rate in a subject or population of subjects (e.g., at least a 1% decrease, at least a 5% decrease, at least a 10% decrease, at least a 15% decrease, at least a 20% decrease, at least a 25% decrease, at least a 30% decrease, at least a 35% decrease, at least a 40% decrease, at least a 45% decrease, at least a 50% decrease, at least a 55% decrease, at least a 60% decrease, at least a 65% decrease, at least a 70% decrease, at least a 75% decrease, at least a 80% decrease, at least a 85% decrease, at least a 90% decrease, at least a 95% decrease, or at least a 99% decrease, or about a 1% decrease to about a 99% decrease (or any subrange within that range described herein)), e.g., as compared to the subject's tumor growth rate prior to administration, or compared to a similar subject not receiving treatment or receiving a different treatment). In some embodiments, the subject's tumor growth rate can be determined by imaging the subject over time (e.g., using X-rays, ultrasound, computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET)).
[0475] Also provided herein are methods of improving the objective response rate in a subject (e.g., any of the exemplary subjects described herein) with unresectable advanced / metastatic pancreatic cancer, the methods comprising administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; and (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds to a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds to a ligand of TGF-βRII. Any of the exemplary multi-chain chimeric polypeptides described herein can be used in these methods.
[0476] As used herein, the term "objective response rate" refers to the international criteria proposed by the Response Evaluation Criteria in Solid Tumors Committee (RECIST) v1.1 (as described in Eisenhauer et al., Eur. J. Cancer 45:228-247, 2009).
[0477] In some embodiments, the methods can result in an increase in the objective response rate (e.g., at least a 1% increase, at least a 5% increase, at least a 10% increase, at least a 15% increase, at least a 20% increase, at least a 25% increase, at least a 30% increase, at least a 35% increase, at least a 40% increase, at least a 45% increase, at least a 50% increase, at least a 55% increase, at least a 60% increase, at least a 65% increase, at least a 70% increase, at least a 75% increase, at least a 80% increase, at least a 85% increase, at least a 90% increase, at least a 95% increase, at least a 100% increase, at least a 110% increase, at least a 120% increase, at least a 130% increase, at least a 140% increase, at least a 150% increase, or at least a 150% increase) in a subject or population of subjects. At least a 160% increase, at least a 170% increase, at least a 180% increase, at least a 190% increase, at least a 200% increase, at least a 210% increase, at least a 220% increase, at least a 230% increase, at least a 240% increase, at least a 250% increase, at least a 260% increase, at least a 270% increase, at least a 280% increase, at least a 290% increase, or at least a 300% increase, or about a 1% increase to about a 300% increase, about a 1% increase to about a 280% increase, about a 1% increase to about a 260% increase, about a 1% increase to about a 240% increase, about a 1% increase to about a 220% increase, about a 1% increase to about a 200% increase, about a 1% increase to about a 180% increase, about a 1% increase to about a 160% increase , about 1% increase to about 140% increase, about 1% increase to about 120% increase, about 1% increase to about 100% increase, about 1% increase to about 95% increase, about 1% increase to about 90% increase, about 1% increase to about 85% increase, about 1% increase to about 80% increase, about 1% increase to about 75% increase, about 1% increase to about 70% increase, about 1% increase to about 65% increase, about 1% increase to about 60% increase, about 1% increase to about 55% increase, about 1% increase to about 50% increase, about 1% increase to about 45% increase, about 1% increase to about 40% increase, about 1% increase to about 35% increase, about 1% increase to about 30% increase, about 1% increase to about 25% increase, about 1% increase to about 20 % increase, about 1% increase to about 15% increase, about 1% increase to about 10% increase, about 1% increase to about 5% increase, about 5% increase to about 300% increase, about 5% increase to about 280% increase, about 5% increase to about 260% increase, about 5% increase to about 240% increase, about 5% increase to about 220% increase, about 5% increase to about 200% increase, about 5% increase to about 180% increase, about 5% increase to about 160% increase, about 5% increase to about 140% increase, about 5% increase to about 120% increase, about 5% increase to about 100% increase, about 5% increase to about 95% increase, about 5% increase to about 90% increase, about 5% increase to about 85% increase, about 5% increase to about 80% increase,about 5% increase to about 75% increase, about 5% increase to about 70% increase, about 5% increase to about 65% increase, about 5% increase to about 60% increase, about 5% increase to about 55% increase, about 5% increase to about 50% increase, about 5% increase to about 45% increase, about 5% increase to about 40% increase, about 5% increase to about 35% increase, about 5% increase to about 30% increase, about 5% increase to about 25% increase, about 5% increase to about 20% increase, about 5% increase to about 15% increase, about 5% increase to about 10% increase, about 10% increase to about 300% increase, about 10% increase to about 280% increase, about 10% increase to about 260% increase, about 10% increase to about 240% increase, about 10% increase about 10% increase to about 95% increase, about 10% increase to about 90% increase, about 10% increase to about 85% increase, about 10% increase to about 80% increase, about 10% increase to about 75% increase, about 10% increase to about 70% increase, about 10% increase to about 65% increase, about 10% increase to about 60% increase, about 10% increase to about 55% increase, about 10% increase to about 50% increase, about 10% increase to about 60% increase about 45% increase, about 10% increase to about 40% increase, about 10% increase to about 35% increase, about 10% increase to about 30% increase, about 10% increase to about 25% increase, about 10% increase to about 20% increase, about 10% increase to about 15% increase, about 15% increase to about 300% increase, about 15% increase to about 280% increase, about 15% increase to about 260% increase, about 15% increase to about 240% increase, about 15% increase to about 220% increase, about 15% increase to about 200% increase, about 15% increase to about 180% increase, about 15% increase to about 160% increase, about 15% increase to about 140% increase, about 15% increase to about 120% increase, about 15% increase to about 100% increase, about 15% increase to about 95% increase, about 15% increase to about 90% increase, about 15% increase to about 85% increase, about 15% increase to about 80% increase, about 15% increase to about 75% increase, about 15% increase to about 70% increase, about 15% increase to about 65% increase, about 15% increase to about 60% increase, about 15% increase to about 55% increase, about 15% increase to about 50% increase, about 15% increase to about 45% increase, about 15% increase to about 40% increase, about 15% increase to about 35% increase, about 15% increase to about 30% increase, about 15% increase to about 25% increase, about 15% increase to about 20% increase, about 20% increase to about 300% increase,about 20% increase to about 280% increase, about 20% increase to about 260% increase, about 20% increase to about 240% increase, about 20% increase to about 220% increase, about 20% increase to about 200% increase, about 20% increase to about 180% increase, about 20% increase to about 160% increase, about 20% increase to about 140% increase, about 20% increase to about 120% increase, about 20% increase to about 100% increase, about 20% increase to about 95% increase, about 20% increase to about 90% increase, about 20% increase to about 85% increase, about 20% increase to about 80% increase, about 20% increase to about 75% increase, about 20% increase to about 70% increase, about 20% increase to about 65% increase, about 20% increase to about 60% increase, about 20% increase to about 55% increase, about 20% increase to about 50% increase, about 20% increase to about 45% increase, about 20% increase to about 40% increase, about 20% increase to about 35% increase, about 20% increase to about 30% increase, about 20% increase to about 25% increase, about 25% increase to about 300% increase, about 25% increase to about 280% increase, about 25% increase to about 260% increase, about 25% increase to about 240% increase, about 25% increase to about 220% increase, about 25% increase to about 200% increase, about 25% increase to about 180% increase, about 25% increase to about 160% increase, about 25% increase to about 140% increase, about 25% increase to about 2 an increase to about 120% increase, an increase to about 100% increase, an increase to about 25% to about 95% increase, an increase to about 90% increase, an increase to about 85% increase, an increase to about 80% increase, an increase to about 75% increase, an increase to about 70% increase, an increase to about 65% increase, an increase to about 60% increase, an increase to about 55% increase, an increase to about 50% increase, an increase to about 45% increase, an increase to about 40% increase, an increase to about 35% increase, an increase to about 30% increase, an increase to about 30% increase, an increase to about 300% increase, an increase to about 280% increase increase, about 30% increase to about 260% increase, about 30% increase to about 240% increase, about 30% increase to about 220% increase, about 30% increase to about 200% increase, about 30% increase to about 180% increase, about 30% increase to about 160% increase, about 30% increase to about 140% increase, about 30% increase to about 120% increase, about 30% increase to about 100% increase, about 30% increase to about 95% increase, about 30% increase to about 90% increase, about 30% increase to about 85% increase, about 30% increase to about 80% increase, about 30% increase to about 75% increase, about 30% increase to about 70% increase, about 30% increase to about 65% increase, about 30% increase to about 60% increase,about 30% increase to about 55% increase, about 30% increase to about 50% increase, about 30% increase to about 45% increase, about 30% increase to about 40% increase, about 30% increase to about 35% increase, about 35% increase to about 300% increase, about 35% increase to about 280% increase, about 35% increase to about 260% increase, about 35% increase to about 240% increase, about 35% increase to about 220% increase, about 35% increase to about 200% increase, about 35% increase to about 180% increase, about 35% increase to about 160% increase, about 35% increase to about 140% increase, about 35% increase to about 120% increase, about 35% increase to about 100% increase, about 35% increase to about 95% increase, about 35% increase to about 90% increase, about 35% increase to about 85% increase, about 35% increase to about 80% increase, about 35% increase to about 75% increase, about 35% increase to about 70% increase, about 35% increase to about 65% increase, about 35% increase to about 60% increase, about 35% increase to about 55% increase, about 35% increase to about 50% increase, about 35% increase to about 45% increase, about 35% increase to about 40% increase, about 40% increase to about 300% increase, about 40% increase to about 280% increase, about 40% increase to about 260% increase, about 40% increase to about 240% increase, about 40% increase to about 220% increase, about 40% increase to about 200% increase, about 40% increase to about 180% increase, about 40% increase to about 160% increase, about 40% increase to about 140% increase, about 40% increase to about 120% increase, about 40% increase to about 100% increase, about 40% increase to about 95% increase, about 40% increase to about 90% increase, about 40% increase to about 85% increase, about 40% increase to about 80% increase, about 40% increase to about 75% increase, about 40% increase to about 70% increase, about 40% increase to about 65% increase, about 40% increase to about 60% increase, about 40% increase to about 55% increase, about 40% increase to about 50% increase, about 40% increase to about 45% increase, about 45% increase to about 300% increase, about 45% increase to about 280% increase increase, about 45% increase to about 260% increase, about 45% increase to about 240% increase, about 45% increase to about 220% increase, about 45% increase to about 200% increase, about 45% increase to about 180% increase, about 45% increase to about 160% increase, about 45% increase to about 140% increase, about 45% increase to about 120% increase, about 45% increase to about 100% increase, about 45% increase to about 95% increase, about 45% increase to about 90% increase, about 45% increase to about 85% increase, about 45% increase to about 80% increase, about 45% increase to about 75% increase, about 45% increase to about 70% increase, about 45% increase to about 65% increase, about 45% increase to about 60% increase,about 45% increase to about 55% increase, about 45% increase to about 50% increase, about 50% increase to about 300% increase, about 50% increase to about 280% increase, about 50% increase to about 260% increase, about 50% increase to about 240% increase, about 50% increase to about 220% increase, about 50% increase to about 200% increase, about 50% increase to about 180% increase, about 50% increase to about 160% increase, about 50% increase to about 140% increase, about 50% increase to about 120% increase, about 50% increase to about 100% increase, about 50% increase to about 95% increase, about 50% increase to about 90% increase, about 50% increase to about 85% increase, about 50% increase to about 80% increase , about 50% increase to about 75% increase, about 50% increase to about 70% increase, about 50% increase to about 65% increase, about 50% increase to about 60% increase, about 50% increase to about 55% increase, about 55% increase to about 300% increase, about 55% increase to about 280% increase, about 55% increase to about 260% increase, about 55% increase to about 240% increase, about 55% increase to about 220% increase, about 55% increase to about 200% increase, about 55% increase to about 180% increase, about 55% increase to about 160% increase, about 55% increase to about 140% increase, about 55% increase to about 120% increase, about 55% increase to about 100% increase, about 55% increase to about 95% increase , about 55% increase to about 90% increase, about 55% increase to about 85% increase, about 55% increase to about 80% increase, about 55% increase to about 75% increase, about 55% increase to about 70% increase, about 55% increase to about 65% increase, about 55% increase to about 60% increase, about 60% increase to about 300% increase, about 60% increase to about 280% increase, about 60% increase to about 260% increase, about 60% increase to about 240% increase, about 60% increase to about 220% increase, about 60% increase to about 200% increase, about 60% increase to about 180% increase, about 60% increase to about 160% increase, about 60% increase to about 140% increase, about 60% increase to about 120% increase , about 60% increase to about 100% increase, about 60% increase to about 95% increase, about 60% increase to about 90% increase, about 60% increase to about 85% increase, about 60% increase to about 80% increase, about 60% increase to about 75% increase, about 60% increase to about 70% increase, about 60% increase to about 65% increase, about 65% increase to about 300% increase, about 65% increase to about 280% increase, about 65% increase to about 260% increase, about 65% increase to about 240% increase, about 65% increase to about 220% increase, about 65% increase to about 200% increase, about 65% increase to about 180% increase, about 65% increase to about 160% increase, about 65% increase to about 140% increase,about 65% increase to about 120% increase, about 65% increase to about 100% increase, about 65% increase to about 95% increase, about 65% increase to about 90% increase, about 65% increase to about 85% increase, about 65% increase to about 80% increase, about 65% increase to about 75% increase, about 65% increase to about 70% increase, about 70% increase to about 300% increase, about 70% increase to about 280% increase, about 70% increase to about 260% increase, about 70% increase to about 240% increase, about 70% increase to about 220% increase, about 70% increase to about 200% increase, about 70% increase to about 180% increase, about 70% increase to about 160% increase, about 70% increase to about 140% increase, about 70% increase to about 120% increase, about 70% increase to about 100% increase, about 70% increase to about 95% increase, about 70% increase to about 90% increase, about 70% increase to about 85% increase, about 70% increase to about 80% increase, about 70% increase to about 75% increase, about 75% increase to about 300% increase, about 75% increase to about 280% increase, about 75% increase to about 260% increase, about 75% increase to about 240% increase, about 75% increase to about 220% increase, about 75% increase to about 200% increase, about 75% increase to about 180% increase, about 75% increase to about 160% increase, about 75% increase to about 140% increase, about 75% increase to about 120% increase, about 75% increase to about 100% increase, about 75% increase to about 95% increase, about 75% increase to about 90% increase, about 75% increase to about 85% increase, about 75% increase to about 80% increase, about 80% increase to about 300% increase, about 80% increase to about 280% increase, about 80% increase to about 260% increase, about 80% increase to about 240% increase, about 80% increase to about 220% increase, about 80% increase to about 200% increase, about 80% increase to about 180% increase, about 80% increase to about 160% increase, about 80% increase to about 140% increase, about 80% increase to about 120% increase, about 80% increase to about 100% increase, about 80% increase to about 95% increase, about 80% increase to about 90% increase, about 80% increase to about 85% increase, about 85% increase to about 300% increase, about 85% increase to about 280% increase, about 85% increase to about 260% increase, about 85% increase to about 240% increase, about 85% increase to about 220% increase, about 85% increase to about 200% increase, about 85% increase to about 180% increase, about 85% increase to about 160% increase, about 85% increase to about 140% increase, about 85% increase to about 120% increase, about 85% increase to about 100% increase, about 85% increase to about 95% increase, about 85% increase to about 90% increase, about 90% increase to about 300% increase, about 90% increase to about 280% increase,about 90% increase to about 260% increase, about 90% increase to about 240% increase, about 90% increase to about 220% increase, about 90% increase to about 200% increase, about 90% increase to about 180% increase, about 90% increase to about 160% increase, about 90% increase to about 140% increase, about 90% increase to about 120% increase, about 90% increase to about 100% increase, about 90% increase to about 95% increase, about 95% increase to about 300% increase, about 95% increase to about 280% increase, about 95% increase to about 260% increase, about 95% increase to about 240% increase, about 95% increase to about 220% increase, about 95% increase to about 200% increase, about 95% increase to about 180% increase, about 95% increase to about 160% increase, about 95% increase to about 140% increase, about 95% increase to about 120% increase, about 95% increase to about 100% increase, about 100% increase to about 300% increase, about 100% increase to about 280% increase, about 100% increase to about 260% increase, about 100% increase to about 240% increase, about 100% increase to about 220% increase, about 100% increase to about 200% increase, about 100% increase to about 180% increase, about 100% increase to about 160% increase, about 100% increase to about 140% increase, about 100% increase to about 120% increase, about 120% increase to about 300% increase, about 120% increase to about 400% increase. 0% increase to about 280% increase, about 120% increase to about 260% increase, about 120% increase to about 240% increase, about 120% increase to about 220% increase, about 120% increase to about 200% increase, about 120% increase to about 180% increase, about 120% increase to about 160% increase, about 120% increase to about 140% increase, about 140% increase to about 300% increase, about 140% increase to about 280% increase, about 140% increase to about 260% increase, about 140% increase to about 240% increase, about 140% increase to about 220% increase, about 140% increase to about 200% increase, about 140% increase to about 180% increase, about 140% increase to about 160% increase, about 160% increase to about 300% increase, about 160% increase to about 280% increase, about 160% increase to about 260% increase, about 160% increase to about 240% increase, about 160% increase to about 220% increase, about 160% increase to about 200% increase, about 160% increase to about 180% increase, about 180% increase to about 300% increase, about 180% increase to about 280% increase, about 180% increase to about 260% increase, about 180% increase to about 240% increase, about 180% increase to about 220% increase, about 180% increase to about 200% increase, about 200% increase to about 300% increase, about 200% increase to about 280% increase,About 200% increase to about 260% increase, about 200% increase to about 240% increase, about 200% increase to about 220% increase, about 220% increase to about 300% increase, about 220% increase to about 280% increase, about 220% increase to about 260% increase, about 220% increase to about 240% increase, about 240% increase to about 300% increase, about 240% increase to about 280% increase, about 240% increase to about 260% increase, about 260% increase to about 300% increase, about 260% increase to about 280% increase, or about 280% increase to about 300% increase), e.g., compared to a similar subject not receiving treatment or receiving a different treatment.
[0478] Also provided herein are methods of increasing progression-free survival or progression-free survival in a subject or population of subjects (e.g., any of the exemplary subjects described herein) with unresectable advanced / metastatic pancreatic cancer, the methods comprising administering to one or more subjects a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; and (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds to a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds to a ligand of TGF-βRII. Any of the exemplary multi-chain chimeric polypeptides described herein can be used in these methods.
[0479] As used herein, the term "progression-free survival" refers to the length of time that a subject survives without cancer progression during and / or after treatment. Progression-free survival can be based on, for example, anatomical measurements of tumor size or volume (e.g., as determined using X-rays, ultrasound, computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET)). The term "progression-free survival rate" refers to the percentage of subjects who survive without cancer progression at a defined time (e.g., 6 months, 1 year, etc.) since initiating treatment.
[0480] In some embodiments, the methods described herein provide an increase in progression-free survival or progression-free survival rate in a subject or population of subjects (e.g., at least a 1% increase, at least a 5% increase, at least a 10% increase, at least a 15% increase, at least a 20% increase, at least a 25% increase, at least a 30% increase, at least a 35% increase, at least a 40% increase, at least a 45% increase, at least a 50% increase, at least a 55% increase, at least a 60% increase, at least a 65% increase, at least a 70% increase, at least a 75% increase, at least a 80% increase, at least a 85% increase, at least a 90% increase, at least a 95% increase, at least a 100% increase, at least a 110% increase, at least a 120% increase, at least a 130% increase, at least a 140% increase, at least a 150% increase, at least a 150% increase, at least a 160% increase, at least a 170% increase, at least a 180% increase, at least a 190% increase, at least a 200% increase, at least a 210% increase, at least a 220% increase, at least a 230% increase, at least a 240% increase, at least a 250% increase, at least a 260% increase, at least a 270% increase, at least a 280% increase, at least a 290% increase, at least a 300% increase, at least a 310% increase, at least a 320% increase, at least a 330% increase, at least a 340% increase, at least a 350% increase, at least a 360% increase, at least a 370% increase, at least a 380%
[00135] The present invention relates to an increase in the amount of pancreatic cancer that is administered to a subject comprising the multi-chain chimeric polypeptide or a combination of the above-described polypeptides. The invention also relates to an increase in the amount of pancreatic cancer that is administered to a subject comprising the above-described polypeptides or a combination of the above-described polypeptides. The invention also relates to an increase in the amount of pancreatic cancer that is administered to a subject comprising the above-described polypeptides or a combination of the above-described polypeptides.
[0481] Also provided herein are methods of increasing the time to progression of a subject or population of subjects (e.g., any of the exemplary subjects described herein) with unresectable advanced / metastatic pancreatic cancer, the methods comprising administering to one or more subjects a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; and (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds to a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds to a ligand of TGF-βRII. Any of the exemplary multi-chain chimeric polypeptides described herein can be used in these methods.
[0482] As used herein, the term "time to progression" can refer to the length of time from the start of treatment until cancer progresses and / or metastasizes to other parts of the subject's body. Cancer progression and / or metastasis can be determined, for example, by imaging the subject using X-rays, ultrasound, computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET).
[0483] In some embodiments, the methods described herein result in an increase in time to progression (e.g., at least a 1% increase, at least a 5% increase, at least a 10% increase, at least a 15% increase, at least a 20% increase, at least a 25% increase, at least a 30% increase, at least a 35% increase, at least a 40% increase, at least a 45% increase, at least a 50% increase, at least a 55% increase, at least a 60% increase, at least a 65% increase, at least a 70% increase, at least a 75% increase, at least a 80% increase, at least a 85% increase, at least a 90% increase, at least a 95% increase, at least a 100% increase, at least a 110% increase, at least a 120% increase, at least a 130% increase, at least a 140% increase, at least a 150% increase, at least a 160% increase, at least a 170% increase, at least a 180% increase, at least a 190% increase, at least a 200% increase, at least a 210% increase, at least a 220% increase, at least a 230% increase, at least a 240% increase, at least a 250% increase, at least a 260% increase, at least a 270% increase, at least a 280% increase, at least a 290% increase, at least a 300% increase, at least a 310% increase, at least a 320% increase, at least a 330% increase, at least a 340% increase, at least a 350% increase, at least a 360% increase, at least a 370% increase
[00135] In some embodiments, the time to progression of the subject is as follows: a 1:1 increase in the amount of the multi-chain chimeric polypeptide administered to the subject prior to administration of the multi-chain chimeric polypeptide; ...
[0484] Also provided herein are methods of increasing the duration of remission in a subject or population of subjects (e.g., any of the exemplary subjects described herein) with unresectable advanced / metastatic pancreatic cancer, the methods comprising administering to one or more subjects a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; and (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds to a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds to a ligand of TGF-βRII. Any of the exemplary multi-chain chimeric polypeptides described herein can be used in these methods.
[0485] As used herein, the term "duration of remission" can refer to the length of time from response to treatment until cancer progression in a subject. For example, duration of remission can measure the length of time a tumor continues to respond to treatment without the cancer growing or metastasizing. In some instances, the growth or metastasis of pancreatic cancer in a subject can be determined by imaging the subject (e.g., using X-rays, ultrasound, computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET)).
[0486] In some embodiments, the methods described herein can result in an increase in the duration of remission in a subject or population of subjects (e.g., at least a 1% increase, at least a 5% increase, at least a 10% increase, at least a 15% increase, at least a 20% increase, at least a 25% increase, at least a 30% increase, at least a 35% increase, at least a 40% increase, at least a 45% increase, at least a 50% increase, at least a 55% increase, at least a 60% increase, at least a 65% increase, at least a 70% increase, at least a 75% increase, at least a 80% increase, at least a 85% increase, at least a 90% increase, at least a 95% increase, at least a 100% increase, at least a 110% increase, at least a 120% increase, at least a 130% increase, at least a 140% increase, at least a 150% increase, at least a 160% increase, at least a 170% increase, at least a 180% increase, at least a 190% increase, at least a 200% increase, at least a 210% increase, at least a 220% increase, at least a 230% increase, at least a 240% increase, at least a 250% increase, at least a 260% increase, at least a 270% increase, at least a 280% increase, at least a 290% increase, at least a 300% increase, at least a 310% increase, at least a 320% increase, at least a 330% increase, at least a 340% increase, at least a 350% increase, at least a 360% increase, at least a 370% increase, at least a 380% increase, at least a 390% increase, at
[00135] In some embodiments, the multi-chain chimeric polypeptide may be administered to a subject for at least 150% of the total dose, or to a subject for at least 170% of the total dose, or to a subject for at least 180% of the total dose, or to a subject for at least 190% of the total dose, or to a subject for at least 200% of the total dose, or to a subject for at least 210% of the total dose, or to a subject for at least 220% of the total dose, or to a subject for at least 230% of the total dose, or to a subject for at least 240% of the total dose, or to a subject for at least 250% of the total dose, or to a subject for at least 260% of the total dose, or to a subject for at least 270% of the total dose, or to a subject for at least 280% of the total dose, or to a subject for at least 290% of the total dose, or to a subject for at least 30 ...
[0487] Also provided herein are methods of increasing overall survival in a population of subjects with unresectable advanced / metastatic pancreatic cancer (e.g., any of the exemplary subjects described herein), comprising administering to each subject in the population a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; and (b) a second chimeric polypeptide comprising: (i) a second domain of an affinity domain pair; and (ii) a second target binding domain, wherein: the first chimeric polypeptide and the second chimeric polypeptide are associated through binding of the first and second domains of the affinity domain pair; and the first target binding domain specifically binds to a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds to a ligand of TGF-βRII. Any of the exemplary multi-chain chimeric polypeptides described herein can be used in these methods.
[0488] As used herein, the term "overall survival" can refer to the length of time that a subject population is still alive from the date of diagnosis or the start of treatment. Overall survival can measure how long a subject population undergoing a certain cancer treatment regimen survives compared to another similar subject population in a control group (e.g., receiving a different treatment, e.g., a first-line and / or second-line treatment for pancreatic cancer, e.g., any of the exemplary first-line and / or second-line treatments for pancreatic cancer described herein).
[0489] In some embodiments, the methods described herein result in an increase in overall survival of a subject (e.g., at least a 1% increase, at least a 5% increase, at least a 10% increase, at least a 15% increase, at least a 20% increase, at least a 25% increase, at least a 30% increase, at least a 35% increase, at least a 40% increase, at least a 45% increase, at least a 50% increase, at least a 55% increase, at least a 60% increase, at least a 65% increase, at least a 70% increase, at least a 75% increase, at least an 80% increase, at least an 85% increase, at least a 90% increase, at least a 95% increase, at least a 100% increase, at least a 110% increase, at least a 120% increase, at least a 130% increase, at least a 140% increase, at least a 150% increase). , at least 160% increase, at least 170% increase, at least 180% increase, at least 190% increase, at least 200% increase, at least 210% increase, at least 220% increase, at least 230% increase, at least 240% increase, at least 250% increase, at least 260% increase, at least 270% increase, at least 280% increase, at least 290% increase, or at least 300% increase, or about 1% increase to about 300% increase (or any subrange of ranges described herein)), for example, compared to another similar population of subjects in a control group (e.g., receiving a different treatment, such as a first-line and / or second-line treatment for pancreatic cancer, such as any exemplary first-line and / or second-line treatment for pancreatic cancer described herein).
[0490] As used herein, the term "subject" can refer to an organism, typically a mammal (eg, a human). In some embodiments, the subject is a patient.
[0491] In some embodiments, one or more subjects are 18 years of age or older (e.g., 19 years of age or older, 20 years of age or older, 25 years of age or older, 30 years of age or older, 35 years of age or older, 40 years of age or older, 45 years of age or older, 50 years of age or older, 55 years of age or older, 60 years of age or older, 65 years of age or older, 70 years of age or older, 75 years of age or older, 80 years of age or older, 85 years of age or older, 90 years of age or older, 95 years of age or older, or 100 years of age or older).
[0492] In some embodiments, one or more subjects have received prior treatment with standard first-line systemic therapy for pancreatic cancer, and one or more subjects' pancreatic cancer has progressed with and / or is intolerant to the prior treatment. In some embodiments, one or more subjects have received prior treatment with standard first-line systemic therapy for pancreatic cancer, and one or more subjects are intolerant to the first-line systemic therapy.
[0493] In some embodiments, standard first-line systemic therapy includes one or more of the following: FOLFIRINOX, modified FOLFINIROX, gemcitabine, nab-paclitaxel, cisplatin, erlotinib, capecitabine, docetaxel, a fluoropyrimidine, and oxaliplatin.
[0494] In some embodiments, the first-line systemic therapy comprises one of the following: (i) FOLFIRINOX; (ii) modified FOLFIRINOX; (iii) gemcitabine and nab-paclitaxel; (iv) gemcitabine and erlotinib; (v) gemcitabine; (vi) gemcitabine and capecitabine; (vii) gemcitabine, docetaxel, and capecitabine; and (viii) a fluoropyrimidine and oxaliplatin.
[0495] In some embodiments, one or more subjects have been previously identified as having a BRCA1, BRCA2, or PALB2 mutation, and first-line systemic therapy includes one of: (i) FOLFIRINOX; (ii) modified FOLFIRINOX; and (iii) gemcitabine and cisplatin.
[0496] In some embodiments, one or more subjects have received prior treatment for second-line or later-line systemic therapy for pancreatic cancer, and the pancreatic cancer of one or more subjects has progressed and / or is intolerant to the prior treatment. In some embodiments, second-line or later-line systemic therapy includes one or more of the following: a different first-line systemic therapy (e.g., any exemplary first-line systemic therapy described herein), 5-fluorouracil, folinic acid, liposomal irinotecan, irinotecan, FOLFIRINOX, modified FOLFIRINOX, oxaliplatin, FOLFOX, capecitabine, gemcitabine, albumin-bound paclitaxel, cisplatin, erlotinib, pembrolizumab, larotrectinib, and entrectinib. In some embodiments, second-line or later-line systemic therapy is a different first-line systemic therapy (e.g., any exemplary first-line systemic therapy described herein).
[0497] In some embodiments, the second-line or later-line systemic therapy comprises one of: (i) 5-fluorouracil, leucovorin, and liposomal irinotecan; (ii) 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI); (iii) FOLFIRINOX or modified FOLFIRINOX; (iv) oxaliplatin, 5-fluorouracil, and leucovorin (OFF); (v) FOLFOX; (vi) capecitabine and oxaliplatin; (vii) capecitabine; and (viii) continuous infusion of 5-fluorouracil.
[0498] In some embodiments, one or more subjects have been previously treated with a fluoropyrimidine-based therapy, and the second or subsequent line of systemic therapy includes one of: (i) gemcitabine; (ii) gemcitabine and nab-paclitaxel; and (iii) gemcitabine and erlotinib.
[0499] In some embodiments, one or more subjects have been previously treated with a fluoropyrimidine-based therapy and have been previously identified as having a BRCA1, BRCA2, or PALB2 mutation, and second-line or later systemic therapy includes gemcitabine and cisplatin. In some embodiments, one or more subjects have been previously treated with a fluoropyrimidine-based therapy and have not received prior treatment with irinotecan, and second-line or later systemic therapy includes 5-fluorouracil, leucovorin, and liposomal irinotecan.
[0500] In some embodiments, one or more subjects are previously identified as having an MSI-H or dMMR tumor, and second-line or later systemic therapy includes pembrolizumab. In some embodiments, one or more subjects are previously identified as having an NTRK gene fusion, and second-line or later systemic therapy includes larotrectinib or entrectinib.
[0501] In some embodiments, one or more subjects have distant metastatic disease. In some embodiments, one or more subjects have adequate heart, lung, liver and kidney function. In some embodiments, one or more subjects have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
[0502] In some embodiments, one or more subjects have a life expectancy of at least 12 weeks (e.g., at least 14 weeks, at least 16 weeks, at least 18 weeks, at least 20 weeks, at least 22 weeks, or at least 24 weeks) prior to the administering step. In some embodiments, prior to the administering step, one or more subjects have been determined to have measurable disease as assessed by imaging studies. In some embodiments, one or more subjects have received prior radiation therapy for at least four weeks prior to the administering step. In some embodiments, prior to the administering step, any acute effect of any prior therapy in one or more subjects has been reduced to baseline or less than or equal to a grade on the NCI CTCAE v5.0.
[0503] In some embodiments, the subject has: an absolute neutrophil count greater than or equal to 1,500 / microliter; a platelet count greater than or equal to 100,000 / microliter; a hemoglobin level greater than or equal to 9 g / dL; a glomerular filtration rate (GFR) greater than 40 mL / min or a serum creatinine level less than or equal to 1.5 x upper limit of normal (ULN); a total bilirubin level less than or equal to 2.0 x ULN, or for subjects with Gilbert's syndrome, a total bilirubin level less than or equal to 3.0 x ULN; and aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) levels less than or equal to 2.5 x ULN, or less than or equal to 5.0 x ULN if liver metastases are present. In some embodiments, if there are symptoms or previously known injuries, one or more subjects have a pulmonary function test (PFT) level greater than 50% of forced expiratory volume (FEV1).
[0504] In some embodiments, the one or more subjects are female and the one or more females have tested negative for pregnancy within 14 days prior to the administering step. In some embodiments, the one or more females have been on birth control or surgically sterilized for at least 14 days prior to and during the administering step.
[0505] In some embodiments, one or more subjects are male and one or more subjects use a barrier method of contraception during the administering step and for at least 28 days after the administering step.
[0506] In some embodiments, one or more subjects do not have a history of clinically significant vascular disease. In some embodiments, one or more subjects do not have a corrected QT interval (QTc) greater than or equal to 470 milliseconds according to Fridericia correction.
[0507] In some embodiments, the one or more subjects do not have untreated CNS metastases. In some embodiments, the one or more subjects have received prior treatment for CNS metastases and the one or more subjects have been neurologically stable for at least two weeks prior to the administering step. In some embodiments, the one or more subjects are not receiving corticosteroids during the administering step. In some embodiments, the one or more subjects are receiving a stable or decreasing dose of corticosteroids less than or equal to 10 mg per day during the administering step.
[0508] In some embodiments, the subject or subjects have not received surgery, radiation therapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days prior to the administering step. In some embodiments, the subject or subjects do not have any other prior malignancies other than adequately treated basal cell or squamous cell skin cancer, cervical cancer in situ, adequately treated stage I or II cancer for which the subject or subjects are currently in complete remission, or any other cancer for which the subject or subjects are disease-free within 3 years of surgical treatment.
[0509] In some embodiments, the one or more subjects do not have a known history of hypersensitivity or allergic reaction to compounds with a similar chemical or biological composition to the multi-chain chimeric polypeptide. In some embodiments, the one or more subjects have not previously received treatment with a TGF-β antagonist or IL-15 or an analog thereof.
[0510] In some embodiments, one or more subjects are not currently taking concurrent herbal or unconventional therapies. In some embodiments, one or more subjects do not have an autoimmune disease requiring active treatment. In some embodiments, one or more subjects do not have a condition requiring systemic treatment with corticosteroids or immunosuppressive therapy within 14 days of the administering step. In some embodiments, one or more subjects do not have an active autoimmune disease and have received an inhaled or topical steroid or adrenal replacement steroid dose equal to or less than 10 mg daily prednisone equivalents.
[0511] In some embodiments, one or more subjects do not have an active systemic infection requiring parenteral antibiotic therapy. In some embodiments, one or more subjects have not previously received an organ allograft or allogeneic transplant. In some embodiments, one or more subjects have not been identified or diagnosed as HIV positive or suffering from AIDS.
[0512] In some embodiments, the one or more subjects are female and the one or more females are not pregnant or breastfeeding. In some embodiments, the one or more subjects do not have any ongoing toxicity from prior treatment. In some embodiments, the ongoing toxicity is greater than Grade 1 (using NCI CTCAE v5.0) or greater than baseline. In some embodiments, the ongoing toxicity does not include peripheral neuropathy, alopecia, and fatigue.
[0513] In some embodiments, one or more subjects do not suffer from a psychiatric disorder.
[0514] In some embodiments, the multi-chain chimeric polypeptide is administered subcutaneously to one or more subjects. In some embodiments, a single dose of the multi-chain chimeric polypeptide is administered to one or more subjects. In some embodiments, the single dose is about 0.1 mg of the multi-chain chimeric polypeptide / kg of subject body weight (mg / kg), about 0.25 mg / kg, about 0.5 mg / kg, about 0.8 mg / kg, or about 1.2 mg / kg.
[0515] In some embodiments, two or more doses of the multi-chain chimeric polypeptide are administered to one or more subjects during the treatment period. In some embodiments, at least one of the two or more doses is 0.1 mg of the multi-chain chimeric polypeptide / kg of subject body weight (mg / kg), about 0.25 mg / kg, about 0.5 mg / kg, about 0.8 mg / kg, or about 1.2 mg / kg.
[0516] In some embodiments, the treatment period is about 4 weeks.
[0517] Examples
[0518] The present invention is further illustrated in the following examples, which do not limit the scope of the invention described in the claims.
[0519] Example 1: Production and characterization of TGFRt15-TGFR fusion protein
[0520] The resulting fusion protein complex contains TGFβ receptor II / IL-15RαSu and TGFβ receptor II / TF / IL-15 fusion protein ( Figure 1 and Figure 2 ). Human TGFβ receptor II (Ile24-Asp159), tissue factor 219, and IL-15 sequences were obtained from the UniProt website, and DNA of these sequences was synthesized by Genewiz. Specifically, a construct was formed in which two TGFβ receptor II sequences were linked with a G4S(3) linker to generate a single-chain version of TGFβ receptor II, and then directly linked to the N-terminal coding region of tissue factor 219, and then to the N-terminal coding region of IL-15.
[0521] The nucleic acid and protein sequences of a construct comprising two TGFβ receptor II linked to the N-terminus of tissue factor 219, which is then linked to the N-terminus of IL-15 are shown below.
[0522] The nucleic acid sequences (including signal peptide sequences) of the two TGFβ receptor II / TF / IL-15 constructs are as follows:
[0523] (Signal peptide)
[0524] ATGAAGTGGGTGACCTTCATCAGCCTGCTGTTCCTGTTCTCCAGCGC CTACTCC
[0525] (Two human TGFβ receptor II fragments)
[0526] ATCCCCCCCCATGTGCAAAAGAGCGTGAACAACGATATGATCGTGACCGACAACAACGGCGCCGTGAAGTTTCCCCAGCTCTGCAAGTTCTGCGATGTCAGGTTCAGCACCTGCGATAATCAGAAGTCCTGCATGTCCAACTGCAGCATCACCTCCATCTGCGAGAAGCCCCAAGAAGTGTGCGTGGCCGTGTGGCGGAAAAATGACGAGAACATCACCCTGGAGACCGTGTGTCACGACCCCAAGCTCCCTTATCACGACTTCATTCTGGAGGACGCTGCCTCCCCCAAATGCATCATGAAGGAGAAGAAGAAGCCCGGAGAGACCTTCTTTATGTGTTCCTGTAGCAGCGACGAGTGTAACGACAACATCATCTTCAGCGAAGAGTACAACACCAGCAACCCTGATGGAGGTGGCGGATCCGGAGGTGGAGGTTCTGGTGGAGGTGGGAGTATTCCTCCCCACGTGCAGAAGAGCGTGAATAATGACATGATCGTGACCGATAACAATGGCGCCGTGAAATTTCCCCAGCTGTGCAAATTCTGCGATGTGAGGTTTTCCACCTGCGACAACCAGAAGTCCTGTATGAGCAACTGCTCCATCACCTCCATCTGTGAGAAGCCTCAGGAGGTGTGCGTGGCTGTCTGGCGGAAGAATGACGAGAATATCACCCTGGAAACCGTCTGCCACGATCCCAAGCTGCCCTACCACGATTTCATCCTGGAAGACGCCGCCAGCCCTAAGTGCATCATGAAAGAGAAAAAGAAGCCTGGCGAGACCTTTTTCATGTGCTCCTGCAGCAGCGACGAATGCAACGACAATATCATCTTTAGCGAGGAATACAATACCAGCAACCCCGAC
[0527] (Human Tissue Factor 219)
[0528] AGCGGCACAACCAACACAGTCGCTGCCTATAACCTCACTTGGAAGAGCACCAACTTCAAAACCATCCTCGAATGGGAACCCAAACCCGTTAACCAAGTTTACACCGTGCAGATCAGCACCAAGTCCGGCGACTGGAAGTCCAAATGTTTCTATACCACCGACACCGAGTGCGATCTCACCGATGAGATCGTGAAAGATGTGAAACAGACCTACCTCGCCCGGGTGTTTAGCTACCCCGCCGGCAATGTGGAGAGCACTGGTTCCGCTGGCGAGCCTTTATACGAGAACAGCCCCGAATTTACCCCTTACCTCGAGACCAATTTAGGACAGCCCACCATCCAAAGCTTTGAGCAAGTTGGCACAAAGGTGAATGTGACAGTGGAGGACGAGCGGACTTTAGTGCGGCGGAACAACACCTTTCTCAGCCTCCGGGATGTGTTCGGCAAAGATTTAATCTACACACTGTATTACTGGAAGTCCTCTTCCTCCGGCAAGAAGACAGCTAAAACCAACACAAACGAGTTTTTAATCGACGTGGATAAAGGCGAAAACTACTGTTTCAGCGTGCAAGCTGTGATCCCCTCCCGGACCGTGAATAGGAAAAGCACCGATAGCCCCGTTGAGTGCATGGGCCAAGAAAAGGGCGAGTTCCGGGAG
[0529] (Human IL-15)
[0530] AACTGGGTGAACGTCATCAGCGATTTAAAGAAGATCGAAGATTTAATTCAGTCCATGCATATCGACGCCACTTTATACACAGAATCCGACGTGCACCCCTCTTGTAAGGTGACCGCCATGAAATGTTTTTTACTGGAGCTGCAAGTTATCTCTTTAGAGAGCGGAGACGCT AGCATCCACGACACCGTGGAGAATTTAATCATTTTAGCCAATAACTCTTTATCCAGCAACGGCAACGTGACAGAGTCCCGGCTGCAAGGAGTGCGAAGAGCTGGAGGAGAAGAACATCAAGGAGTTTCTGCAATCCTTTGTGCACATTGTCCAGATGTTCATCAATACCTCC
[0531] The amino acid sequence of the TGFβ receptor II / TF / IL-15 fusion protein (including the leader sequence) is as follows:
[0532] (Signal peptide)
[0533] MKWVTFISLLFLFSSAYS
[0534] (human TGFβ receptor II)
[0535] IPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSGG GGSGGGGSIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
[0536] (Human Tissue Factor 219)
[0537] SGTTNTVAAYNLTWKSTNFKTILEWEPKPVNQVYTVQISTKSGDWKSKCFYTTDTECDLTDEIVKDVKQTYLARVFSYPAGNVESTGSAGEPLYENSPEFTPYLETNLG QPTIQSFEQVGTKVNVTVEDERTLVRRNNTFLSLRDVFGKDLIYTLYYWKSSSSGKKTAKTNTNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTDSPVECMGQEKGEFRE
[0538] (Human IL-15)
[0539] NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS
[0540] A construct was also prepared by directly linking two TGFβ receptor IIs to an IL-15RαSu chain synthesized by GENEWIZ Inc. The nucleic acid and protein sequences of the construct comprising the TGFβ receptor II linked to the N-terminus of IL-15RαSu are shown below.
[0541] The nucleic acid sequence of the TGFβ receptor II / IL-15RαSu construct (including the signal peptide sequence) is as follows:
[0542] (Signal peptide)
[0543] ATGAAGTGGGTGACCTTCATCAGCCTGCTGTTCCTGTTCTCCAGCGC CTACTCC
[0544] (Two human TGFβ receptor II fragments)
[0545] ATCCCCCCCCATGTGCAAAAGAGCGTGAACAACGATATGATCGTGACCGACAACAACGGCGCCGTGAAGTTTCCCCAGCTCTGCAAGTTCTGCGATGTCAGGTTCAGCACCTGCGATAATCAGAAGTCCTGCATGTCCAACTGCAGCATCACCTCCATCTGCGAGAAGCCCCAAGAAGTGTGCGTGGCCGTGTGGCGGAAAAATGACGAGAACATCACCCTGGAGACCGTGTGTCACGACCCCAAGCTCCCTTATCACGACTTCATTCTGGAGGACGCTGCCTCCCCCAAATGCATCATGAAGGAGAAGAAGAAGCCCGGAGAGACCTTCTTTATGTGTTCCTGTAGCAGCGACGAGTGTAACGACAACATCATCTTCAGCGAAGAGTACAACACCAGCAACCCTGATGGAGGTGGCGGATCCGGAGGTGGAGGTTCTGGTGGAGGTGGGAGTATTCCTCCCCACGTGCAGAAGAGCGTGAATAATGACATGATCGTGACCGATAACAATGGCGCCGTGAAATTTCCCCAGCTGTGCAAATTCTGCGATGTGAGGTTTTCCACCTGCGACAACCAGAAGTCCTGTATGAGCAACTGCTCCATCACCTCCATCTGTGAGAAGCCTCAGGAGGTGTGCGTGGCTGTCTGGCGGAAGAATGACGAGAATATCACCCTGGAAACCGTCTGCCACGATCCCAAGCTGCCCTACCACGATTTCATCCTGGAAGACGCCGCCAGCCCTAAGTGCATCATGAAAGAGAAAAAGAAGCCTGGCGAGACCTTTTTCATGTGCTCCTGCAGCAGCGACGAATGCAACGACAATATCATCTTTAGCGAGGAATACAATACCAGCAACCCCGAC
[0546] (Human IL-15Rα sushi domain)
[0547] ATTACATGCCCCCCTCCCATGAGCGTGGAGCACGCCGACATCTGGGTGAAGAGCTATAGCCTCTACAGCCGGGAGAGGTATATCTGTAACAGCGGCTTCAAGAGGAAGGCCGGCACCAGCAGCCTCACCGAGTGCGTGCTGAATAAGGCTACCAACGTGGCTCACTGGACAACACCCTCTTTAAAGTGCATCCGG
[0548] The amino acid sequences (including signal peptide sequences) of the two TGFβ receptor II / IL-15RαSu constructs are as follows:
[0549] (Signal peptide)
[0550] MKWVTFISLLFLFSSAYS
[0551] (Two human TGFβ receptor II extracellular domains)
[0552] IPPHVQKSVNNDMIVTDNNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDGGGGSGG GGSGGGGSIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD
[0553] (Human IL-15Rα sushi domain)
[0554] ITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNK ATNVAHWTTPSLKCIR
[0555] In some cases, a leader peptide is cleaved from the intact polypeptide to produce a soluble or secreted mature form.
[0556] The TGFβR / IL-15RαSu and TGFβR / TF / IL-15 constructs were cloned into modified retroviral expression vectors as previously described (Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, Li Y, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 2005;16:457–72) and the expression vectors were transfected into CHO-K1 cells. Co-expression of the two constructs in CHO-K1 cells allowed the formation and secretion of a soluble TGFβR / TF / IL-15:TGFβR / IL-15RαSu protein complex (termed TGFRt15-TGFR), which could be purified by anti-TF IgG1 affinity and other chromatography methods.
[0557] Effects of TGFRt15-TGFR on TGFβ1 activity in HEK-Blue TGFβ cells
[0558] To evaluate the activity of TGFβRII in TGFRt15-TGFR, the effect of TGFRt15-16s21 on TGFβ1 activity in HEK-Blue TGFβ cells was analyzed. HEK-Blue TGFβ cells (Invitrogen) were washed twice with preheated PBS and plated at 5×10 5 Resuspend cells / mL in assay medium (DMEM, 10% heat-inactivated FCS, 1x glutamine, 1x anti-antibody, and 2x glutamine). Add 50 μL of cells (2.5 x 10 4 Cells / well) were added, and then 50 μL of 0.1 nM TGFβ1 (R&D Systems) was added. TGFRt15-16s21 or TGFR-Fc (R&D Systems) prepared in 1:3 serial dilutions were then added to the plate to reach a total volume of 200 μL. After incubation at 37°C for 24 hours, 40 μL of induced HEK-Blue TGFβ cell supernatant was added to 160 μL of preheated QUANTI-Blue (Invitrogen) in a flat-bottom 96-well plate and incubated at 37°C for 1 to 3 hours. The OD value (OD) was then determined using a microplate reader (Multiscan Sky) at 620 nM to 655 nM. Figure 3 The IC of each protein sample was calculated using GraphPad Prism 7.04. 50 IC of TGFRt15-TGFR and TGFR-Fc 50 The results showed that the TGFβRII domain in TGFRt15-TGFR could block the activity of TGFβ1 in HEK-Blue TGFβ cells.
[0559] IL-15 in TGFRt15-TGFR promotes proliferation of 32Dβ cells containing IL-2Rβ and common γ chain
[0560] To evaluate the activity of IL-15 in TGFRt15-TGFR, 32Dβ cells expressing IL2Rβ and common γ chain were used to compare the IL-15 activity of TGFRt15-TGFR with recombinant IL-15 and evaluate their effects on promoting cell prolife...
Claims
1. A method of treating unresectable advanced / metastatic pancreatic cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of the affinity domain pair; and (ii) a second target binding domain, in: The first chimeric polypeptide and the second chimeric polypeptide are associated through the binding of the first domain and the second domain of the affinity domain pair; and The first target binding domain specifically binds a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand of TGF-βRII.
2. A method of improving the objective response rate in a subject with unresectable advanced / metastatic pancreatic cancer, the method comprising administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of the affinity domain pair; and (ii) a second target binding domain, in: The first chimeric polypeptide and the second chimeric polypeptide are associated through the binding of the first domain and the second domain of the affinity domain pair; and The first target binding domain specifically binds a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand of TGF-βRII.
3. A method of increasing progression-free survival or progression-free survival in a subject or a population of subjects with unresectable advanced / metastatic pancreatic cancer, the method comprising administering to the one or more subjects a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of the affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of the affinity domain pair; and (ii) a second target binding domain, in: The first chimeric polypeptide and the second chimeric polypeptide are associated through the binding of the first domain and the second domain of the affinity domain pair; and The first target binding domain specifically binds a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand of TGF-βRII.
4. A method of increasing the time to progression of a subject or a population of subjects with unresectable advanced / metastatic pancreatic cancer, the method comprising administering to the one or more subjects a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of the affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of the affinity domain pair; and (ii) a second target binding domain, in: The first chimeric polypeptide and the second chimeric polypeptide are associated through the binding of the first domain and the second domain of the affinity domain pair; and The first target binding domain specifically binds a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand of TGF-βRII.
5. A method of increasing the duration of remission in a subject or a population of subjects with unresectable advanced / metastatic pancreatic cancer, the method comprising administering to the one or more subjects a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of the affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of the affinity domain pair; and (ii) a second target binding domain, in: The first chimeric polypeptide and the second chimeric polypeptide are associated through the binding of the first domain and the second domain of the affinity domain pair; and The first target binding domain specifically binds a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand of TGF-βRII.
6. A method of increasing overall survival in a population of subjects with unresectable advanced / metastatic pancreatic cancer, the method comprising administering to each subject in the population a therapeutically effective amount of a multi-chain chimeric polypeptide, wherein the multi-chain chimeric polypeptide comprises: (a) a first chimeric polypeptide comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a first domain of an affinity domain pair; (b) a second chimeric polypeptide comprising: (i) a second domain of the affinity domain pair; and (ii) a second target binding domain, in: The first chimeric polypeptide and the second chimeric polypeptide are associated through the binding of the first domain and the second domain of the affinity domain pair; and The first target binding domain specifically binds a ligand of TGF-β receptor II (TGF-βRII), and the second target binding domain specifically binds a ligand of TGF-βRII.
7. The method of any one of claims 1-6, wherein the one or more subjects are 18 years of age or older.
8. The method of any one of claims 1-7, wherein the one or more subjects have received prior treatment with standard first-line systemic therapy for pancreatic cancer, and the one or more subjects' pancreatic cancer has progressed with and / or is intolerant to the prior treatment.
9. The method of any one of claims 1-7, wherein the one or more subjects have received prior treatment with a standard first-line systemic therapy for pancreatic cancer and the one or more subjects are intolerant to the first-line systemic therapy.
10. The method of claim 8 or 9, wherein the standard first-line systemic therapy comprises one or more of the following: FOLFIRINOX, modified FOLFINIROX, gemcitabine, nab-paclitaxel, cisplatin, erlotinib, capecitabine, docetaxel, a fluoropyrimidine, and oxaliplatin.
11. The method of claim 10, wherein the first-line systemic therapy comprises one of the following: (i) FOLFIRINOX; (ii) modified FOLFIRINOX; (iii) gemcitabine and nab-paclitaxel; (iv) gemcitabine and erlotinib; (v) gemcitabine; (vi) gemcitabine and capecitabine; (vii) gemcitabine, docetaxel and capecitabine; and (viii) Fluoropyrimidines and oxaliplatin.
12. The method of claim 10, wherein the one or more subjects have been previously identified as having a BRCA1, BRCA2, or PALB2 mutation, and the first-line systemic therapy comprises one of: (i) FOLFIRINOX; (ii) modified FOLFIRINOX; and (iii) Gemcitabine and cisplatin.
13. The method of any one of claims 1-12, wherein the one or more subjects have received prior treatment with second-line or later-line systemic therapy for pancreatic cancer, and the one or more subjects' pancreatic cancer has progressed with and / or is intolerant to the prior treatment.
14. The method of claim 13, wherein the second-line or later-line systemic therapy comprises one or more of the following: a different first-line systemic therapy, 5-fluorouracil, leucovorin, liposomal irinotecan, irinotecan, FOLFIRINOX, modified FOLFIRINOX, oxaliplatin, FOLFOX, capecitabine, gemcitabine, nab-paclitaxel, cisplatin, erlotinib, pembrolizumab, larotrectinib, and entrectinib.
15. The method of claim 14, wherein the second-line or later systemic therapy is different from the first-line systemic therapy.
16. The method of claim 14, wherein the second or later line systemic therapy comprises one of: (i) 5-fluorouracil, folinic acid, and liposomal irinotecan; (ii) 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI); (iii) FOLFIRINOX or modified FOLFIRINOX; (iv) oxaliplatin, 5-fluorouracil, and folinic acid (OFF); (v) FOLFOX; (vi) capecitabine and oxaliplatin; (vii) Capecitabine; and (viii) Continuous infusion of 5-fluorouracil.
17. The method of claim 14, wherein the one or more subjects have been previously treated with a fluoropyrimidine-based therapy, and the second or subsequent line of systemic therapy comprises one of: (i) gemcitabine; (ii) gemcitabine and nab-paclitaxel; and (iii) Gemcitabine and erlotinib.
18. The method of claim 14, wherein the one or more subjects were previously treated with a fluoropyrimidine-based therapy and were previously identified as having a BRCA1, BRCA2, or PALB2 mutation, and the second or subsequent line systemic therapy comprises gemcitabine and cisplatin.
19. The method of claim 14, wherein the one or more subjects were previously treated with a fluoropyrimidine-based therapy and have not received prior treatment with irinotecan, and the second-line or subsequent-line systemic therapy comprises 5-fluorouracil, folinic acid, and liposomal irinotecan.
20. The method of claim 14, wherein the one or more subjects were previously identified as having an MSI-H or dMMR tumor and the second-line or later-line systemic therapy comprises pembrolizumab.
21. The method of claim 14, wherein the one or more subjects are previously identified as having an NTRK gene fusion and the second-line or later-line systemic therapy comprises larotrectinib or entrectinib.
22. The method of any one of claims 1-21, wherein the one or more subjects have distant metastatic disease.
23. The method of any one of claims 1-22, wherein the one or more subjects have adequate cardiac, pulmonary, hepatic, and renal function.
24. The method of any one of claims 1-23, wherein the one or more subjects have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
25. The method of any one of claims 1-24, wherein the one or more subjects have a life expectancy of at least 12 weeks prior to the administering step.
26. The method of any one of claims 1-25, wherein prior to the administering step, the one or more subjects have been determined to have measurable disease as assessed by imaging studies.
27. The method of any one of claims 1-26, wherein the one or more subjects have received prior radiation therapy at least four weeks prior to the administering step.
28. The method of any one of claims 1-27, wherein prior to the administering step, any acute effect of any prior therapy in the one or more subjects has been reduced to baseline or a grade less than or equal to 1 NCITCAE v5.
0.
29. The method of any one of claims 1-28, wherein the one or more subjects have: absolute neutrophil count greater than or equal to 1,500 / μL; Platelet count greater than or equal to 100,000 / μL; Hemoglobin level greater than or equal to 9 g / dL; Glomerular filtration rate (GFR) greater than 40 mL / min or serum creatinine level less than or equal to 1.5x upper limit of normal (ULN); Total bilirubin levels less than or equal to 2.0 x ULN, or for subjects with Gilbert's syndrome, total bilirubin levels less than or equal to 3.0 x ULN; and Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) levels are less than or equal to 2.5 x ULN, or less than or equal to 5.0 x ULN if liver metastases are present.
30. The method of any one of claims 1-29, wherein the one or more subjects have a pulmonary function test (PFT) level greater than 50% forced expiratory volume (FEV1), if symptomatic or previously known injury.
31. The method of any one of claims 1-30, wherein the one or more subjects are female and the one or more females have a negative pregnancy test within 14 days prior to the administering step.
32. The method of claim 31, wherein the one or more females have been on birth control or surgically sterilized for at least 14 days prior to and during the administering step.
33. The method of any one of claims 1-30, wherein the one or more subjects are male and the one or more subjects use a barrier contraceptive method during the administering step and for at least 28 days after the administering step.
34. The method of any one of claims 1-33, wherein the one or more subjects have no history of clinically significant vascular disease.
35. The method of any one of claims 1-34, wherein the one or more subjects do not have a corrected QT interval (QTc) greater than or equal to 470 milliseconds according to Fridericia correction.
36. The method of any one of claims 1-35, wherein the one or more subjects do not have untreated CNS metastases.
37. The method of any one of claims 1-35, wherein the one or more subjects have received prior treatment for CNS metastases and the one or more subjects have been neurologically stable for at least two weeks prior to the administering step.
38. The method of any one of claims 1-37, wherein the one or more subjects are not receiving corticosteroids during the administering step.
39. The method of any one of claims 1-37, wherein the one or more subjects are receiving a stable or decreasing dose of a corticosteroid less than or equal to 10 mg per day during the administering step.
40. The method of any one of claims 1-39, wherein the one or more subjects have not received surgery, radiation therapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days prior to the administering step.
41. The method of any one of claims 1-40, wherein the one or more subjects do not have any other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, cervical cancer in situ, an adequately treated stage I or stage II cancer for which the one or more subjects are currently in complete remission, or any other cancer for which the one or more subjects are disease-free within 3 years of surgical treatment.
42. The method of any one of claims 1-41, wherein the one or more subjects do not have a known history of hypersensitivity or allergic reaction due to compounds having a similar chemical or biological composition as the multi-chain chimeric polypeptide.
43. The method of any one of claims 1-42, wherein the one or more subjects have not received prior treatment with a TGF-β antagonist or IL-15 or an analog thereof.
44. The method of any one of claims 1-43, wherein the one or more subjects are not receiving concurrent herbal or unconventional therapy.
45. The method of any one of claims 1-44, wherein the one or more subjects do not have an autoimmune disease requiring active treatment.
46. The method of any one of claims 1-45, wherein the one or more subjects do not have a condition requiring systemic treatment with corticosteroids or immunosuppressive therapy within 14 days of the administering step.
47. The method of any one of claims 1-46, wherein the one or more subjects do not have an active autoimmune disease and have received an inhaled or topical steroid or adrenal replacement steroid dose equal to or less than 10 mg daily prednisone equivalents.
48. The method of any one of claims 1-47, wherein the one or more subjects do not have an active systemic infection requiring parenteral antibiotic therapy.
49. The method of any one of claims 1-48, wherein the one or more subjects have not previously received an organ allograft or allogeneic transplant.
50. The method of any one of claims 1-49, wherein the one or more subjects have not been identified or diagnosed as HIV positive or having AIDS.
51. The method of any one of claims 1-50, wherein the one or more subjects are female and the one or more females are not pregnant or breastfeeding.
52. The method of any one of claims 1-51, wherein the one or more subjects do not have any ongoing toxicity from prior treatment.
53. The method of claim 52, wherein the persistent toxicity is greater than Grade 1 using NCI CTCAE v5.0, or greater than baseline.
54. The method of claim 52, wherein the persistent toxicity does not include peripheral neuropathy, alopecia, and fatigue.
55. The method of any one of claims 1-54, wherein the one or more subjects do not suffer from a psychiatric disorder.
56. The method of any one of claims 1-55, wherein the first target binding domain and the soluble tissue factor domain are directly adjacent to each other in the first chimeric polypeptide.
57. The method of any one of claims 1-55, wherein the first chimeric polypeptide further comprises a linker sequence between the first target binding domain and the soluble tissue factor domain in the first chimeric polypeptide.
58. The method of any one of claims 1-57, wherein the soluble tissue factor domain and the first domain of the affinity domain pair are directly adjacent to each other in the first chimeric polypeptide.
59. The method of any one of claims 1-57, wherein the first chimeric polypeptide further comprises a linker sequence between the soluble tissue factor domain in the first chimeric polypeptide and the first domain of the affinity domain pair.
60. The method of any one of claims 1-59, wherein the second domain of the affinity domain pair and the second target binding domain are directly adjacent to each other in the second chimeric polypeptide.
61. The method of any one of claims 1-59, wherein the second chimeric polypeptide further comprises a linker sequence between the second domain and the second target binding domain of the affinity domain pair in the second chimeric polypeptide.
62. The method of any one of claims 1-61, wherein one or both of the first target binding domain and the second target binding domain are antigen binding domains.
63. The method of any one of claims 1-61, wherein one or both of the first target binding domain and the second target binding domain are soluble interleukins or cytokine receptors.
64. The method of any one of claims 1-63, wherein the first chimeric polypeptide further comprises one or more additional target binding domains.
65. The method of any one of claims 1-64, wherein the second chimeric polypeptide further comprises one or more additional target binding domains.
66. The method of any one of claims 1-65, wherein the soluble tissue factor domain is a soluble human tissue factor domain.
67. The method of claim 66, wherein the soluble human tissue factor domain comprises a sequence that is at least 80% identical to SEQ ID NO:
1.
68. The method of any one of claims 1-67, wherein the affinity domain pair is a sushi domain from the alpha chain of the human IL-15 receptor (IL-15Rα) and soluble IL-15.
69. The method of any one of claims 1-68, wherein the first target binding domain comprises soluble TGF-βRII.
70. The method of claim 69, wherein the first target binding domain comprises a first sequence at least 80% identical to SEQ ID NO: 66 and a second sequence at least 80% identical to SEQ ID NO: 66, wherein the first sequence and the second sequence are separated by a linker.
71. The method of claim 70, wherein the first target binding domain comprises a first sequence that is at least 90% identical to SEQ ID NO: 66 and a second sequence that is at least 90% identical to SEQ ID NO:
66.
72. The method of claim 71, wherein the first target binding domain comprises a first sequence of SEQ ID NO: 66 and a second sequence of SEQ ID NO:
66.
73. The method of claim 70, wherein the linker comprises the sequence of SEQ ID NO:
7.
74. The method of claim 69, wherein the first target binding domain comprises a sequence that is at least 80% identical to SEQ ID NO:
69.
75. The method of claim 74, wherein the first target binding domain comprises a sequence that is at least 90% identical to SEQ ID NO:
69.
76. The method of claim 75, wherein the first target binding domain comprises the sequence of SEQ ID NO:
69.
77. The method of any one of claims 1-76, wherein the first chimeric polypeptide comprises a sequence at least 80% identical to SEQ ID NO:
70.
78. The method of claim 77, wherein the first chimeric polypeptide comprises a sequence at least 90% identical to SEQ ID NO:
70.
79. The method of claim 78, wherein the first chimeric polypeptide comprises the sequence of SEQ ID NO:
70.
80. The method of claim 79, wherein the first chimeric polypeptide comprises the sequence of SEQ ID NO:
72.
81. The method of any one of claims 1-55, wherein the second target binding domain comprises soluble TGF-βRII.
82. The method of claim 81, wherein the second target binding domain comprises a first sequence that is at least 80% identical to SEQ ID NO: 66 and a second sequence that is at least 80% identical to SEQ ID NO: 66, wherein the first sequence and the second sequence are separated by a linker.
83. The method of claim 82, wherein the second target binding domain comprises a first sequence that is at least 90% identical to SEQ ID NO: 66 and a second sequence that is at least 90% identical to SEQ ID NO:
66.
84. The method of claim 83, wherein the second target binding domain comprises a first sequence of SEQ ID NO:66 and a second sequence of SEQ ID NO:
66.
85. The method of claim 82, wherein the linker comprises the sequence of SEQ ID NO:
7.
86. The method of claim 81, wherein the second target binding domain comprises a sequence at least 80% identical to SEQ ID NO:
69.
87. The method of claim 86, wherein the second target binding domain comprises a sequence that is at least 90% identical to SEQ ID NO:
69.
88. The method of claim 87, wherein the second target binding domain comprises the sequence of SEQ ID NO:
69.
89. The method of any one of claims 1-88, wherein the second chimeric polypeptide comprises a sequence at least 80% identical to SEQ ID NO:
74.
90. The method of claim 89, wherein the first chimeric polypeptide comprises a sequence at least 80% identical to SEQ ID NO:
70.
91. The method of claim 89, wherein the second chimeric polypeptide comprises a sequence at least 90% identical to SEQ ID NO:
74.
92. The method of claim 89, wherein the first chimeric polypeptide comprises a sequence at least 90% identical to SEQ ID NO:
70.
93. The method of claim 91, wherein the second chimeric polypeptide comprises the sequence of SEQ ID NO:
74.
94. The method of claim 92, wherein the first chimeric polypeptide comprises the sequence of SEQ ID NO:
70.
95. The method of any one of claims 1-94, wherein the multi-chain chimeric polypeptide is administered subcutaneously to the one or more subjects.
96. The method of any one of claims 1-95, wherein a single dose of the multi-chain chimeric polypeptide is administered to the one or more subjects.
97. The method of claim 96, wherein the single dose is 0.1 mg of the multi-chain chimeric polypeptide / kg of the subject's body weight (mg / kg).
98. The method of claim 96, wherein the single dose is 0.25 mg / kg.
99. The method of claim 96, wherein the single dose is 0.5 mg / kg.
100. The method of claim 96, wherein the single dose is 0.8 mg / kg.
101. The method of claim 96, wherein the single dose is 1.2 mg / kg.
102. The method of any one of claims 1-95, wherein two or more doses of the multi-chain chimeric polypeptide are administered to the one or more subjects during a treatment period.
103. The method of claim 102, wherein at least one of the two or more doses is 0.1 mg of the multi-chain chimeric polypeptide / kg of the subject's body weight (mg / kg).
104. The method of claim 102, wherein at least one of the two or more doses is 0.25 mg / kg.
105. The method of claim 102, wherein at least one of the two or more doses is 0.5 mg / kg.
106. The method of claim 102, wherein at least one of the two or more doses is 0.8 mg / kg.
107. The method of claim 102, wherein at least one of the two or more doses is 1.2 mg / kg.
108. The method of any one of claims 102-107, wherein the treatment period is about 4 weeks.
